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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve
the effectiveness of care, optimize patient outcomes, and
have a favorable impact on the overall cost of care by
focusing resources on the most effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of such guidelines in the area of
cardiovascular disease since 1980. This effort is directed
by the ACC/AHA Task Force on Practice Guidelines,
whose charge is to develop and revise practice guidelines for
important cardiovascular diseases and procedures. Experts in
the subject under consideration are selected from both organi-
zations to examine subject-specific data and write guidelines.
The process includes additional representatives from other
medical practitioner and specialty groups where appropriate.
Writing groups are specifically charged to perform a formal
literature review, weigh the strength of evidence for or against
a particular treatment or procedure, and include estimates of
expected health outcomes where data exist. Patient-specific
modifiers, comorbidities and issues of patient preference that
might influence the choice of particular tests or therapies are
considered as well as frequency of follow-up and cost-
effectiveness.
The ACC/AHA Task Force on Practice Guidelines
makes every effort to avoid any actual or potential
conflicts of interest that might arise as a result of an
outside relationship or personal interest of a member of
the writing panel. Specifically, all members of the writing
panel are asked to provide disclosure statements of all
such relationships that might be perceived as real or
potential conflicts of interest. These statements are re-
viewed by the parent task force, reported orally to all
members of the writing panel at the first meeting, and
updated yearly and as changes occur.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of generally
acceptable approaches for the diagnosis, management, and
prevention of specific diseases or conditions. These guide-
lines attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment
regarding care of a particular patient must be made by the
physician and patient in light of all of the circumstances
presented by that patient.
The executive summary and recommendations are pub-
lished in the June 1, 1999 issue of Circulation. The full text is
published in the June 1999 issue of the Journal of the American
College of Cardiology. Reprints of the full text and the executive
summary are available from both organizations.
James L. Ritchie, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
I. INTRODUCTION AND OVERVIEW
A. Organization of Committee and Evidence Review
The ACC/AHA Task Force on Practice Guidelines was
formed to make recommendations regarding the diagnosis
and treatment of patients with known or suspected cardio-
vascular disease. Ischemic heart disease is the single leading
cause of death in the U.S. The most common manifestation
of this disease is chronic stable angina. Recognizing the
importance of the management of this common entity and
the absence of national clinical practice guidelines in this
area, the task force formed the current committee to develop
guidelines for the management of patients with stable angina.
Because this problem is frequently encountered in the practice
of internal medicine, the task force invited the American
College of Physicians-American Society of Internal Medicine
(ACP-ASIM) to serve as a partner in this effort by naming
four general internists to serve on the committee.
The committee reviewed and compiled published reports
(excluding abstracts) through a series of computerized
literature searches of the English language research litera-
ture since 1975 and a manual search of selected final articles.
Details of the specific searches conducted for particular
sections are provided as appropriate. Detailed evidence
tables were developed whenever necessary on the basis of
specific criteria outlined in the individual sections. The
recommendations were based primarily on these published
data. The weight of the evidence was ranked high (A) if the
data were derived from multiple randomized clinical trials
with large numbers of patients and intermediate (B) if the
data were derived from a limited number of randomized
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trials with small numbers of patients, careful analyses of
nonrandomized studies or observational registries. A low
rank (C) was given when expert consensus was the primary
basis for the recommendation.
The customary ACC/AHA classifications I, II and III
are used in tables that summarize both the evidence and
expert opinion and provide final recommendations for both
patient evaluation and therapy:
Class I Conditions for which there is evidence or
general agreement that a given procedure or
treatment is useful and effective.
Class II Conditions for which there is conflicting ev-
idence or a divergence of opinion about the
usefulness/efficacy of a procedure or treat-
ment.
Class IIa Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III Conditions for which there is evidence and/or
general agreement that the procedure/
treatment is not useful/effective and in some
cases may be harmful.
A complete list of many publications on various aspects of
this subject is beyond the scope of these guidelines; only
selected references are included. The committee consisted of
acknowledged experts in general internal medicine from the
ACP-ASIM, family medicine from the American Academy
of Family Physicians (AAFP), and general cardiology as
well as persons with recognized expertise in more special-
ized areas, including noninvasive testing, preventive cardi-
ology, coronary intervention, and cardiovascular surgery.
Both the academic and private practice sectors were repre-
sented. This document was reviewed by three outside
reviewers nominated by the ACC, three outside reviewers
nominated by the AHA, three outside reviewers nominated
by the ACP-ASIM, and two outside reviewers nominated
by the AAFP. This document was approved for publication
by the governing bodies of the ACC, AHA, and ACP-
ASIM. The task force will review these guidelines one year
after publication and yearly thereafter to determine whether
revisions are needed. These guidelines will be considered
current unless the task force revises or withdraws them from
distribution.
B. Scope of the Guidelines
These guidelines are intended to apply to adult patients
with stable chest pain syndromes and known or suspected
ischemic heart disease. Patients who have “ischemic equiv-
alents,” such as dyspnea or arm pain with exertion, are
included in these guidelines. Some patients with ischemic
heart disease may become asymptomatic with appropriate
therapy. As a result, the follow-up sections of the guidelines
may apply to patients who were previously symptomatic.
However, the diagnosis, risk stratification and treatment
sections of the guidelines are intended to apply to symp-
tomatic patients. Asymptomatic patients with “silent isch-
emia” or known coronary artery disease (CAD) that has
been detected in the absence of symptoms are beyond the
scope of these guidelines. Pediatric patients are also beyond
the scope of these guidelines because ischemic heart disease
is very unusual in such patients and is primarily related to
the presence of coronary artery anomalies. Patients with
chest pain syndromes following cardiac transplantation are
also not included in these guidelines.
Patients with nonanginal chest pain are generally at lower
risk for ischemic heart disease. Often their chest pain
syndromes have identifiable noncardiac causes. Such pa-
tients are included in these guidelines if there is sufficient
suspicion of heart disease to warrant cardiac evaluation. If
the evaluation demonstrates that ischemic heart disease is
unlikely and noncardiac causes are the primary focus of
evaluation, such patients are beyond the scope of these
guidelines. If the initial cardiac evaluation demonstrates that
ischemic heart disease is possible, subsequent management
of such patients does fall within these guidelines.
Acute ischemic syndromes are not included in these
guidelines. For patients with acute myocardial infarction
(MI), the reader is referred to the “ACC/AHA Guidelines
for the Management of Patients With Acute Myocardial
Infarction” (1). For patients with unstable angina, the reader
is referred to the Agency for Health Care Policy and
Research (AHCPR) clinical practice guideline on unstable
angina (2), which was endorsed by the ACC and the AHA.
This guideline for unstable angina did describe some low-
risk patients who should not be hospitalized but instead
evaluated as outpatients. Such patients are indistinguishable
from many patients with stable chest pain syndromes and
are therefore within the scope of the present guidelines.
Patients whose recent unstable angina was satisfactorily
treated by medical therapy and who then present with a
recurrence of symptoms with a stable pattern fall within the
scope of the present guidelines. Similarly, patients with MI
who subsequently present with stable chest pain symptoms
.30 days after the initial event are within the scope of the
present guidelines.
The present guidelines do not apply to patients with chest
pain symptoms early after revascularization by either percu-
taneous techniques or coronary artery bypass grafting. Al-
though the division between “early” and “late” symptoms is
arbitrary, the committee believed that these guidelines
should not be applied to patients who develop recurrent
symptoms within six months of revascularization.
C. Overlap With Other Guidelines
These guidelines will overlap with a large number of
recently published (or soon to be published) clinical practice
guidelines developed by the ACC/AHA Task Force on
Practice Guidelines; the National Heart, Lung, and Blood
Institute (NHLBI); and the ACP-ASIM (Table 1).
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This report includes text and recommendations from
many of these guidelines, which are clearly indicated.
Additions and revisions have been made where appropriate
to reflect more recently available evidence. This report
specifically indicates rare situations in which it deviates from
previous guidelines and presents the rationale. In some
cases, this report attempts to combine previous sets of
similar and dissimilar recommendations into one set of final
recommendations. Although this report includes a signifi-
cant amount of material from the previous guidelines, by
necessity the material was often condensed into a succinct
summary. These guidelines are not intended to provide a
comprehensive understanding of the imaging modalities,
therapeutic modalities, and clinical problems detailed in
other guidelines. For such an understanding, the reader is
referred to the original guidelines listed in the references.
D. Magnitude of the Problem
There is no question that ischemic heart disease remains
a major public health problem. Chronic stable angina is the
initial manifestation of ischemic heart disease in approxi-
mately one half of patients (3,4). It is difficult to estimate
the number of patients with chronic chest pain syndromes
in the U.S. who fall within these guidelines, but clearly it is
measured in the millions. The reported annual incidence of
angina is 213/100,000 population .30 years old (3). When
the Framingham Heart Study (4) is considered, an addi-
tional 350,000 Americans each year are covered by these
guidelines. The AHA has estimated that 6,200,000 Amer-
icans have chest pain (5); however, this may be a conserva-
tive estimate.
The prevalence of angina can also be estimated by
extrapolating from the number of MIs in the U.S. (1).
About one half of patients presenting at the hospital with
MI have preceding angina (6). The best current estimate is
that there are 1,100,000 patients with MI each year in the
U.S. (5); about one half of these (550,000) survive until
hospitalization. Two population-based studies (from Olm-
sted County, Minnesota, and Framingham, Massachusetts)
examined the annual rates of MI in patients with symptoms
of angina and reported similar rates of 3% to 3.5% per year
(4,7). On this basis, it can be estimated that there are 30
patients with stable angina for every patient with infarction
who is hospitalized. As a result, the number of patients with
stable angina can be estimated as 30 3 550,000, or
16,500,000. This estimate does not include patients who do
not seek medical attention for their chest pain or whose
chest pain has a noncardiac cause. Thus, it is likely that the
present guidelines cover at least six million Americans and
conceivably more than twice that number.
Ischemic heart disease is important not only because of its
prevalence but also because of its associated morbidity and
mortality. Despite the well-documented recent decline in
cardiovascular mortality (8), ischemic heart disease remains
the leading single cause of death in the U.S. (Table 2) and
is responsible for 1 of every 4.8 deaths (9). The morbidity
associated with this disease is also considerable: each year
.1,000,000 patients have an MI. Many more are hospital-
Table 1. Recent Clinical Practice Guidelines and Policy Statements Which Overlap With
This Guideline
Guideline Sponsor
Year of
Publication
Radionuclide imaging (12) ACC/AHA 1995
Echocardiography (13) ACC/AHA 1997
Exercise testing (14) ACC/AHA 1997
Valvular heart disease (15) ACC/AHA 1998
Ambulatory monitoring (16) ACC/AHA 1999
Coronary angiography (17) ACC/AHA 1999
Percutaneous transluminal coronary angioplasty (18) ACC/AHA 1999 or 2000
Coronary artery bypass surgery (19) ACC/AHA 1999
National cholesterol education project (20) NHLBI 1996
National hypertension education (21) NHLBI 1997
Management of hypercholesterolemia (22) ACP-ASIM 1996
Bethesda Conference on risk factor reduction (23) ACC 1996
Clinical practice guideline: cardiac rehabilitation
(24)
AHCPR 1995
Coronary artery calcification: pathophysiology,
imaging methods, and clinical implications (25)
AHA 1996
Counseling postmenopausal women about
preventive hormone therapy (26)
ACP-ASIM 1992
Bethesda Conference on insurability and
employability of the patient with ischemic heart
disease (27)
ACC 1989
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ized for unstable angina and evaluation and treatment of
stable chest pain syndromes. Beyond the need for hospital-
ization, many patients with chronic chest pain syndromes are
temporarily unable to perform normal activities for hours or
days, thereby experiencing a reduced quality of life. According
to the recently published data from the Bypass Angioplasty
Revascularization Investigation (10), about 30% of patients
never return to work following coronary revascularization, and
15% to 20% of patients rated their own health fair or poor
despite revascularization. These data confirm the widespread
clinical impression that ischemic heart disease continues to be
associated with considerable patient morbidity despite the
decline in cardiovascular mortality.
The economic costs of chronic ischemic heart disease are
enormous. Some insight into the potential cost can be
obtained by examining Medicare data for inpatient
diagnosis-related groups (DRGs) and diagnostic tests. Ta-
ble 3 shows the number of patients hospitalized under
various DRGs during 1995 and associated direct payments
by Medicare. These DRGs represent only hospitalization
of patients covered by Medicare. The table includes
estimates for the proportion of inpatient admissions for
unstable angina, MI, and revascularization for patients
with a history of stable angina. Direct costs associated
with non-Medicare patients hospitalized for the same
diagnoses are probably about the same as the covered
charges under Medicare. Thus, the direct costs of hospi-
talization are .$15 billion.
Table 4 shows the Medicare fees and volumes of com-
monly used diagnostic procedures in ischemic heart disease.
Although some of these procedures may have been per-
formed for other diagnoses and some of the cost of the
technical procedure relative value units (RVUs) may have
been for inpatients listed in Table 3, the magnitude of the
direct costs is considerable. When the 1998 Medicare
reimbursement of $36.6873 per RVU is used, the direct cost
to Medicare of these 61.2 million RVUs can be estimated at
$2.25 billion. Again, assuming that the non-Medicare
patient costs are at least as great, the estimated cost of these
diagnostic procedures alone would be about $4.5 billion.
These estimates of the direct costs associated with
chronic stable angina obviously do not take into account the
indirect costs of workdays lost, reduced productivity, long-
term medication, and associated other effects. The indirect
costs have been estimated to be almost as great as direct
costs (4). The magnitude of the problem can be succinctly
summarized: chronic stable angina affects many millions of
Americans, with associated annual costs that are measured
in tens of billions of dollars.
Given the magnitude of this problem, the need for
practice guidelines is self-evident. This need is further
reinforced by the available information, which suggests
considerable regional differences in the management of
ischemic heart disease. Figure 1 shows published informa-
tion from the Medicare database for rates of coronary
angiography in different counties of the country (11).
Three- and four-fold differences in adjusted rates for this
procedure in different counties within the same state are not
uncommon, suggesting that the clinical management of
such patients is highly variable. The reasons for such
variation in management are unknown.
Table 2. Death Rates Due to Diseases of the Heart and Cancer,
United States—1995
Death Rate per 100,000 Population
Group
Diseases of
the Heart Cancer
White males 297.9 228.1
Black males 244.2 209.1
White females 297.4 202.4
Black females 231.1 159.1
From Report of Final Mortality Statistics, 1995, Centers for Disease Control and
Prevention (8). These rates are not adjusted for age.
Table 3. Medicare Experience With Commonly Used DRGs Involving Patients With Stable Angina
DRG # Description
1995
Discharges
Covered
Charges
(million)
Medicare
Payments
(million)
% of Pts with
History of
Stable
Angina
Medicare
Payments for
Pts with
Stable Angina
125 Coronary disease/cath 62,251 $ 519.8 $ 215.9 95* 205.1
143 Chest pain 139,145 641.8 268.1 100 268.1
124 Unstable angina 145,560 1,734.8 770.6 85† 655.0
121 MI with cath 167,202 2,333.5 1,020.8 55‡ 561.4
122 MI without cath 91,569 892.0 350.8 55‡ 192.9
112 PTCA 201,066 3,897.7 1,801.9 83§ 1,495.6
106 CABG with cath 101,057 5,144.0 3,626.9 83§ 3,010.3
107 CABG without cath 64,212 2,473.2 1,280.9 83§ 1,063.1
7,451.5
*Some patients may have heart failure. †Based on TIMI III trial (28). ‡Based on Canadian Assessment of Myocardial Infarction Study (6). §Based on BARI study (10), assuming
that 85% of patients with unstable angina had preceding stable angina (see † above).
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E. Organization of the Guidelines
These guidelines are arbitrarily divided into four sec-
tions: diagnosis, risk stratification, treatment and patient
follow-up. Experienced clinicians will quickly recognize
that the distinctions between these sections may be
arbitrary and unrealistic in individual patients. However,
for most clinical decision making, these divisions are
helpful and facilitate presentation and analysis of the
available evidence.
Figure 1. Map depicting coronary angiography rates in the U.S. HRR 5 hospital referral region. From Wennberg et al. (11) with
permission.
Table 4. Medicare Fees and Volumes of Commonly Used Diagnostic Procedures for Chronic Stable Angina
Procedure
1998 CPT
Code(s)
1998 Total
(Professional
and Technical)
Medicare RVUs
Number
Performed
(1996)
Estimated %
for Stable
Angina
Estimated
Total RVUs
Echocardiogram 93307 5.96 3,935,344 20% 4,690,930
Doppler echo 93320 2.61 3,423,899 20% 1,787,233
Treadmill exercise test 93015 or
93016–93018
3.25 689,851* 80% 1,793,612
Stress echocardiography 93350, 93015 6.81 303,047 80% 1,651,000
Stress SPECT myocardial
perfusion imaging
78465, 93015 17.41 1,158,389 80% 16,134,041
Left heart catheterization with
left ventriculogram and
coronary angiography
93510, 93543,
93545, 93555,
93556
66.18 664,936† 80% 35,204,371
61,261,187
*Estimated by subtracting (93350 1 78465) from (93015 1 93018), since the total number of charges under 93015 and 93018 includes stress echo and stress SPECT. †Estimated
from Medicare data. One source (David Wennberg, personal communication) has suggested this number could be as high as 771,925.
This table does not include information on positron emission tomography (PET), or electronic beam computed tomography (EBCT) for coronary calcification. There were
no CPT codes for PET in 1996, and there are no current CPT codes for coronary calcification by EBCT.
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The three flow diagrams that follow summarize the
management of stable angina in three algorithms: clinical
assessment (Fig. 2), stress testing/angiography (Fig. 3), and
treatment (Fig. 4). The treatment mnemonic (Fig. 5) is
intended to highlight the 10 treatment elements that the
committee considered most important.
Although the evaluation of many patients will require all
three algorithms, this is not always true. Some patients may
require only clinical assessment to determine that they do
not belong within these guidelines. Others may require only
clinical assessment and treatment if the probability of CAD
is high and patient preferences and comorbidities preclude
revascularization (and therefore the need for risk stratifica-
tion). The stress testing/angiography algorithm may be
required either for diagnosis (and risk stratification) in
patients with a moderate probability of CAD or for risk
stratification only in patients with a high probability of
CAD.
II. DIAGNOSIS
A. History and Physical
Recommendations
Class I: In patients presenting with chest pain, a
detailed symptom history, focused physical
examination, and directed risk-factor assess-
ment should be performed. With this infor-
mation, the clinician should estimate the
probability of significant CAD (i.e., low, in-
termediate, high). (Level of Evidence: B)
Figure 2. Clinical assessment. AHCPR 5 Agency for Health Care Policy and Research; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty; CABG 5 coronary artery bypass graft; ACC 5 American College of Cardiology;
AHA 5 American Heart Association; LV 5 left ventricular; and ECG 5 electrocardiogram.
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Definition of Angina
Angina is a clinical syndrome characterized by discomfort
in the chest, jaw, shoulder, back or arm. It is typically
aggravated by exertion or emotional stress and relieved by
nitroglycerin. Angina usually occurs in patients with CAD
involving $1 large epicardial artery. However, angina can
also occur in persons with valvular heart disease, hypertro-
phic cardiomyopathy and uncontrolled hypertension. It can
be present in patients with normal coronary arteries and
myocardial ischemia related to spasm or endothelial dys-
function. Angina is also a symptom in patients with non-
cardiac conditions of the esophagus, chest wall or lungs.
Once cardiac causes have been excluded, the management of
patients with these noncardiac conditions is outside the
scope of these guidelines.
Clinical Evaluation of Patients With Chest Pain
History
The clinical examination is the most important step in
the evaluation of the patient with chest pain, allowing the
clinician to estimate the likelihood of clinically significant
CAD with a high degree of accuracy (29). Significant CAD
is defined angiographically as CAD with $70% diameter
stenosis of $1 major epicardial artery segment or $50%
diameter stenosis of the left main coronary artery. Although
lesions of less stenosis can cause angina, they have much less
prognostic significance (30).
The first step, a detailed description of the symptom
complex, enables the clinician to characterize the chest pain
(31). Five components are typically considered: quality,
Figure 3. Stress testing/angiography. ECG 5 electrocardiogram.
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location, duration of pain, factors that provoke the pain and
factors that relieve the pain. Various adjectives have been
used by patients to describe the quality of the anginal pain:
“squeezing,” “griplike,” “pressurelike,” “suffocating” and
“heavy” are common. Not infrequently, patients insist that
their symptom is a “discomfort” but not “pain.” Angina is
almost never sharp or stabbing, and it usually does not
change with position or respiration.
Figure 4. Treatment. CAD 5 coronary artery disease; NTG 5 nitroglycerin; MI 5 myocardial infarction; NCEP 5 National Cholesterol
Education Program; JNC 5 Joint National Committee. *Vasodilators, excessive thyroid replacement, vasoconstrictors, profound anemia,
uncontrolled hypertension, hyperthyroidism, hypoxemia, tachyarrhythmias, bradyarrhythmias, valvular heart disease (especially aortic
stenosis) and hypertrophic cardiomyopathy. **On the basis of coronary anatomy, severity of anginal symptoms, and patient preferences,
it is reasonable to consider evaluation for coronary revascularization. Unless a patient has documented left main, three-vessel, or two-vessel
CAD with significant stenosis of the proximal left anterior descending coronary artery, there is no demonstrated survival advantage
associated with revascularization in low-risk patients with chronic stable angina. Thus, medical therapy should be attempted in most
patients before considering percutaneous transluminal coronary angioplasty or coronary artery bypass graft.
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The anginal episode is typically minutes in duration.
Fleeting discomfort or a dull ache lasting for hours is rarely
angina. The location of angina is usually substernal, but
radiation to the neck, jaw, epigastrium, or arms is not
uncommon. Pain above the mandible, below the epigas-
trium, or localized to a small area over the left lateral chest
wall is rarely anginal. Angina is generally precipitated by
exertion or emotional stress and commonly relieved by rest.
Sublingual nitroglycerin also relieves angina, usually within
30 s to several minutes.
After the history of the pain is obtained, the physician
makes a global assessment of the symptom complex. One
classification scheme for chest pain in many studies uses
three groups: typical angina, atypical angina or noncardiac
chest pain (32) (Table 5).
Angina is further classified as stable or unstable (2).
Unstable angina is important in that its presence predicts a
much higher short-term risk of an acute coronary event.
Unstable angina is operationally defined as angina that
Figure 5. Treatment mnemonic: the 10 most important treatment elements of stable angina management.
Table 5. Clinical Classification of Chest Pain
Typical angina (definite)
1) Substernal chest discomfort with a characteristic quality
and duration that is 2) provoked by exertion or emotional
stress and 3) relieved by rest or NTG.
Atypical angina (probable)
- Meets 2 of the above characteristics.
Noncardiac chest pain
- Meets one or none of the typical anginal characteristics.
Modified from Diamond, JACC, 1983 (45).
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presents in one of three principal ways: rest angina, severe
new-onset angina, or increasing angina (Tables 6 and 7).
Most important, unstable angina patients can be subdivided
by their short-term risk (Table 8). Patients at high or
moderate risk often have coronary artery plaques that have
recently ruptured. Their risk of death is intermediate,
between that of patients with acute MI and patients with
stable angina. The initial evaluation of high- or moderate-
risk patients with unstable angina is best carried out in the
inpatient setting. However, low-risk patients with unstable
angina have a short-term risk not substantially different
from those with stable angina. Their evaluation can be
accomplished safely and expeditiously in an outpatient
setting. The recommendations made in these guidelines do
not apply to high- and moderate-risk unstable angina but
are applicable to the low-risk unstable angina group.
After a detailed chest pain history is taken, the presence
of risk factors for CAD (23) should be determined. Ciga-
rette smoking, hyperlipidemia, diabetes, hypertension and a
family history of premature CAD are all important. Past
history of cerebrovascular or peripheral vascular disease
increases the likelihood that CAD will be present.
Physical
The physical examination is often normal in patients with
stable angina (33). However, an exam made during an
episode of pain can be beneficial. An S4 or S3 sound or
gallop, mitral regurgitant murmur, a paradoxically split S2 or
bibasilar rales or chest wall heave that disappears when the
pain subsides are all predictive of CAD (34). Even though
the physical is generally not helpful for confirming CAD, a
careful cardiovascular exam may reveal other conditions
associated with angina, such as valvular heart disease or
hypertrophic cardiomyopathy. Evidence of noncoronary
atherosclerotic disease—a carotid bruit, diminished pedal
pulse or abdominal aneurysm—increases the likelihood of
CAD. Elevated blood pressure, xanthomas and retinal
exudates point to the presence of CAD risk factors. Palpa-
tion of the chest wall often reveals tender areas in patients
whose chest pain is caused by musculoskeletal chest wall
syndromes (35). However, pain produced by pressure on the
chest wall may be present even if the patient has angina due
to ischemic heart disease. The presence of a rub will point to
pericardial or pleural disease.
Developing the Probability Estimate
When the initial history and physical are complete, the
physician and patient find themselves asking the same
question: “Is it the heart?” In certain instances, the physician
can confidently assure the patient that it is not. Patients
with noncardiac chest pain are generally at lower risk for
ischemic heart disease. As indicated on the flow diagram,
the history and appropriate diagnostic tests will usually
focus on noncardiac causes of chest pain. Appropriate
treatment and follow-up for the noncardiac condition can
be prescribed, and the patient can be educated about CAD
and risk factors, especially if he or she rarely sees a physician.
When there is sufficient suspicion of heart disease to
warrant cardiac evaluation, the clinician should make a
probability estimate of the likelihood of CAD. The impor-
tance of doing so is obvious when considering how this
estimate affects the utility of a commonly used diagnostic
test: the standard exercise test. Consider how interpretation
of the standard exercise test would be affected by varying the
pretest probability of disease from 5% to 50% to 90% (36).
In this example, the exercise test is considered positive if
$1-mm ST-segment depression is observed. The test
sensitivity is 50% and specificity 90% (14).
In patients with a low probability of CAD (5%), the positive
predictive value of an abnormal test result is only 21%. If 1,000
low-probability patients are tested, 120 will test positive. Of
these, 95 will not have significant CAD. Before testing such a
Table 6. Three Principal Presentations of Unstable Angina (2)
Rest angina Angina occurring at rest and usually prolonged
.20 minutes occurring within a week of
presentation.
New onset angina Angina of at least CCSC III severity with
onset within 2 months of initial
presentation.
Increasing angina Previously diagnosed angina that is distinctly
more frequent, longer in duration or lower
in threshold (i.e., increased by at least one
CCSC class within 2 months of initial
presentation to at least CCSC III severity).
Note: CCSC 5 Canadian Cardiovascular Society Classification.
Table 7. Grading of Angina Pectoris by the Canadian
Cardiovascular Society Classification System (46)
Class I
Ordinary physical activity does not cause angina, such as
walking, climbing stairs. Angina (occurs) with strenuous,
rapid or prolonged exertion at work or recreation.
Class II
Slight limitation of ordinary activity. Angina occurs on
walking or climbing stairs rapidly, walking uphill, walking or
stair climbing after meals, or in cold, or in wind, or under
emotional stress, or only during the few hours after
awakening. Angina occurs on walking more than 2 blocks on
the level and climbing more than one flight of ordinary stairs
at a normal pace and in normal condition.
Class III
Marked limitations of ordinary physical activity. Angina
occurs on walking one to two blocks on the level and
climbing one flight of stairs in normal conditions and at a
normal pace.
Class IV
Inability to carry on any physical activity without discomfort–
anginal symptoms may be present at rest.
Source: Campeau L. Grading of angina pectoris [letter]. Circulation, 54:522–523,
1976. Copyright © 1976, American Heart Association, Inc. Reprinted with permis-
sion.
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group, the clinician must weigh the value of correctly diagnos-
ing CAD in 25 patients against the cost of a stress test for all
1,000 patients plus the cost of misdiagnosis—undue anxiety,
further invasive testing, unnecessary medications or higher
insurance premiums—for the 95 patients with a false-positive
test result. In patients with a high probability of CAD (90%),
a positive test result raises the probability of disease to 98% and
a negative test result lowers probability to 83%. Although
exercise testing has prognostic value in these patients (see
Section III, C-2) (37), a negative test result obviously does not
allow the clinician to discard the diagnosis of CAD. In patients
with a 50% probability of CAD, a positive test result increases
the likelihood of disease to 83% and a negative test result
decreases the likelihood to 36%. The test separates this group
of patients into two distinct subgroups: one in whom CAD
almost certainly exists and the other for whom the diagnosis,
although far from being excluded, is doubtful. An accurate
estimate of the likelihood of CAD is necessary for interpreta-
tion of further test results and good clinical decision making
about therapy.
Although it may seem premature to predict the probability
of CAD after the history and physical, the clinicopathological
study performed by Diamond and Forrester (38) demonstrated
that it is possible. By combining data from a series of
angiography studies performed in the 1960s and the 1970s,
they showed that the simple clinical observations of pain type,
age, and gender were powerful predictors of the likelihood of
CAD. For instance, a 64-year-old man with typical angina has
a 94% likelihood of having significant CAD. A 32-year-old
woman with nonanginal chest pain has a 1% chance of CAD
(14).
The value of the Diamond and Forrester approach was
subsequently confirmed in prospective studies at Duke and
Stanford. In these studies, both men and women were
referred to cardiology specialty clinics for cardiac catheter-
ization (39,40) or cardiac stress testing (41), and the initial
clinical exam characteristics most helpful in predicting
CAD were determined. With these characteristics, predic-
tive models (logistic regression equations) were developed.
When prospectively applied to another group of patients
referred to the same specialty clinic, the models worked
well. As in Diamond and Forrester’s original work, age,
gender and pain type were the most powerful predictors.
Other characteristics that strengthened the predictive abil-
ities of the models were smoking (defined as a history of
smoking half a pack or more of cigarettes per day within five
years of the study or at least 25 pack-years), Q wave or
ST-T-wave changes, hyperlipidemia (defined as a choles-
terol level .250 mg/dL) and diabetes (glucose .140). Of
these risk factors, diabetes had the greatest influence on
increasing risk. Other significant risk factors, such as family
history and hypertension, were not as strongly predictive
and did not improve the power of equations.
Generalizability of the Predictive Models
Although these models worked well prospectively in the
settings in which they were developed, clinicians must assess
how reliable they will be when used in their own practices. The
Diamond and Forrester probabilities were compared with
those published in the Coronary Artery Surgery Study (CASS)
(42), a large 15-center study that compared clinical and
angiographic findings in .20,000 patients. In both studies,
Table 8. Short-Term Risk of Death or Nonfatal Myocardial Infarction in Patients With Unstable Angina (2)
High Risk Intermediate Risk Low Risk
At least one of the following features
must be present:
No high-risk features but must have any
of the following:
No high- or intermediate-risk feature
but may have any of the following
features:
Prolonged ongoing (.20 min) rest
pain
Prolonged (.20 min) rest angina, now
resolved, with moderate or high
likelihood of CAD
Increased angina frequency, severity,
or duration
Pulmonary edema, most likely
related to ischemia
Rest angina (.20 min or relieved with
sublingual nitroglycerin)
Angina provoked at a lower threshold
Angina at rest with dynamic ST
changes $1 mm
Nocturnal angina New onset angina with onset 2 weeks
to 2 months prior to presentation
Angina with new or worsening MR
murmur
Angina with dynamic T-wave changes Normal or unchanged ECG
Angina with S3 or new/worsening
rales
New onset CCSC III or IV angina in
the past 2 weeks with moderate or
high likelihood of CAD
Angina with hypotension Pathologic Q waves or resting ST
depression #1 mm in multiple lead
groups (anterior, inferior, lateral)
Age . 65 years
CCSC 5 Canadian Cardiovascular Society Classification.
Note: Estimation of the short-term risks of death and nonfatal MI in unstable angina is a complex multivariable problem that cannot be fully specified in a table such as this.
Therefore, the table is meant to offer general guidance and illustration rather than rigid algorithms.
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probability tables were presented in which patients were
categorized by age, gender, and pain type. Tables with 24
patient groupings were published. With the exception of adults
,50 years old with atypical angina for whom the CASS data
estimated a probability of disease 17% higher than the
Diamond-Forrester data, the agreement between studies was
very close: the difference averaged 5%. Because the results were
so similar, the committee combined the probabilities from
both studies in one evidence table (Table 9).
It is more difficult to compare the Duke data directly with
the CASS and Diamond-Forrester tables because within
each age, gender, and pain type grouping, the patient’s
predicted probability of disease varies, depending on the
presence or absence of electrocardiogram (ECG) findings
(Q waves or ST-T changes) or risk factors (smoking,
diabetes, hyperlipidemia). Table 10 presents the Duke data
for mid-decade patients (35, 45, 55, and 65 years old). Two
probabilities are given. The first is for a low-risk patient
with no risk factors and a normal ECG. The second is for
a high-risk patient who smokes and has diabetes and
hyperlipidemia but has a normal ECG. The presence of
ECG changes would increase the probability of coronary
disease even more. When Tables 9 and 10 are compared, the
correlation between studies is quite strong. Apparent in the
Duke data is the importance of risk factors in modifying the
likelihood of disease. This becomes more important the
younger the patient and the more atypical the pain. For
example, the likelihood of disease for women ,55 years old
with atypical angina and no risk factors is ,10%, but if
diabetes, smoking and hyperlipidemia are present, the
likelihood jumps to 40%.
Applicability of Models to Primary-Care Practices
All the studies mentioned above were university-based.
The patients used to develop the models were largely
referred. The only study that directly looked at applica-
bility of the university-derived model to primary-care
practices was the Stanford study (40). The university-
derived equation was used and the likelihood of CAD
was predicted for patients presenting to two urban
primary-care clinics. The equation worked well for typ-
ical angina patients but substantially overpredicted CAD
for patients at less risk.
Referral (or ascertainment) bias in these studies likely
explains these differences (43,44) because the clinical
decision-making process before the patient was referred is
unknown. Primary-care providers do not unselectively refer
all chest pain patients for cardiac evaluation. The disease
probabilities for high-risk patients will vary little from the
study because few primary-care physicians will fail to
recommend cardiac evaluation for typical angina patients.
However, younger patients with less classic pain stories will
often be referred only after therapeutic trials, time or
noncardiac diagnostic studies fail to eliminate CAD as a
possibility. Correcting for referral bias is required before
these models can be applied to primary-care practices. The
Stanford study showed that it was possible to correct the
model predictions by using the overall prevalence of CAD
in the primary care population (40). Unfortunately, while
Bayesian analysis might help a primary care provider im-
prove the models, there are no studies examining how
accurately providers calculate the prevalence of CAD among
their chest pain patients, or how the prevalence of CAD
varies among primary care settings. Primary-care physicians
must therefore exercise caution when using these predictive
equations, tables, or nomograms with patients presenting
for the first time with chest pain. Whether the difference
between the model estimates and actual likelihood of CAD
is great enough to lead to a different diagnostic and
therapeutic strategy is not known.
Ideally, the strategy a clinician uses to evaluate a patient
with chest pain will also take into account the patient’s
preferences. Two patients with the same pretest probability
of CAD may prefer different approaches because of varia-
tions in personal beliefs, economic situation or stage of life.
Patient preference studies that inform physicians about
what is an acceptable balance between the underdiagnosis
and overdiagnosis of CAD have not been done.
Table 9. Pretest Likelihood of CAD in Symptomatic Patients
According to Age and Sex* (Combined Diamond/Forrester and
CASS Data) (38,42)
Age
Years
Nonanginal
Chest Pain Atypical Angina Typical Angina
Men Women Men Women Men Women
30–39 4 2 34 12 76 26
40–49 13 3 51 22 87 55
50–59 20 7 65 31 93 73
60–69 27 14 72 51 94 86
*Each value represents the percent with significant CAD on catheterization.
Table 10. Comparing Pretest Likelihoods of CAD in Low-Risk
Symptomatic Patients With High-Risk Symptomatic
Patients—Duke Database (41)
Age
Years
Nonanginal
Chest Pain Atypical Angina Typical Angina
Men Women Men Women Men Women
35 yr 3–35 1–19 8–59 2–39 30–88 10–78
45 yr 9–47 2–22 21–70 5–43 51–92 20–79
55 yr 23–59 4–25 45–79 10–47 80–95 38–82
65 yr 49–69 9–29 71–86 20–51 93–97 56–84
Each value represents the percent with significant CAD. The first is the percentage
for a low-risk, mid-decade patient without diabetes, smoking, or hyperlipidemia. The
second is that of the same age patient with diabetes, smoking, and hyperlipidemia.
Both high- and low-risk patients have normal resting ECG’s. If ST-T-wave changes
or Q waves had been present, the likelihood of CAD would be higher in each entry
of the table.
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B. Associated Conditions
Recommendations for Initial Laboratory Tests for
Diagnosis
Class I
1. Hemoglobin. (Level of Evidence: C)
2. Fasting glucose. (Level of Evidence: C)
3. Fasting lipid panel, including total cholesterol,
HDL cholesterol, triglycerides, and calculated
LDL cholesterol. (Level of Evidence: C)
Using information gathered from the history and physical
examination, the clinician should consider possibilities other
than CAD in the differential diagnosis, because a number of
other conditions can both cause and contribute to angina. In
those patients with risk factors for CAD but an otherwise
low probability history for angina, alternative diagnoses
should be considered (Table 11).
In all patients, particularly those with typical angina,
comorbid conditions that may precipitate “functional” an-
gina (i.e., myocardial ischemia in the absence of significant
anatomic coronary obstruction) should be considered. Gen-
erally, these are pathological entities that cause myocardial
ischemia either by placing increased myocardial oxygen
demands on the heart or by decreasing the myocardial
oxygen supply (Table 12).
Increased oxygen demand can be produced by such
entities as hyperthermia, hyperthyroidism, and cocaine
abuse. Hyperthermia, particularly if accompanied by
volume contraction due to diaphoresis or other fluid
losses, can precipitate angina in the absence of significant
CAD (47).
Hyperthyroidism, with its associated tachycardia and
increased metabolic rate, increases oxygen demand and,
perhaps because of inceased platelet aggregation, may also
decrease supply. These effects can readily lead to angina. In
addition, elderly patients may not present with a typical
clinical picture of thyrotoxicosis. Therefore, this possibility
should be considered in the setting of minimal risk factors
accompanied by a history of typical angina, particularly in
older patients.
Sympathomimetic toxicity, of which cocaine is the
prototype, not only increases myocardial oxygen demand
but, through coronary vasospasm, simultaneously de-
creases supply, sometimes leading to infarction in young
patients. Long-term cocaine use may also lead to devel-
opment of angina by causing premature development of
CAD (48).
Angina may occur in patients with severe uncontrolled
hypertension due to increased wall tension, which increases
myocardial oxygen demand, and increased left ventricular
(LV) end-diastolic pressure, which decreases subendocardial
perfusion. These same mechanisms contribute to angina in
hypertrophic cardiomyopathy and aortic stenosis; however,
in these conditions, wall tension may be even greater due to
an outflow tract gradient, and end-diastolic pressure may be
even higher due to severe LV hypertrophy.
Table 11. Alternative Diagnoses to Angina for Patients With Chest Pain
Non-Ischemic Cardiovascular Pulmonary Gastrointestinal Chest Wall Psychiatric
Aortic dissection Pulmonary embolus Esophageal Costochondritis Anxiety disorders
Pericarditis Pneumothorax Esophagitis Fibrositis Hyperventilation
Pneumonia Spasm Rib fracture Panic disorder
Pleuritis Reflux Sternoclavicular arthritis Primary anxiety
Biliary Herpes zoster Affective disorders
Colic (before the rash) (e.g., depression)
Cholecystitis Somatiform disorders
Choledocholithiasis Thought disorders
Cholangitis (e.g., fixed delusions)
Peptic ulcer
Pancreatitis
Table 12. Conditions Provoking or Exacerbating Ischemia
Increased Oxygen Demand Decreased Oxygen Supply
Non-Cardiac
Hyperthermia
Hyperthyroidism
Sympathomimetic toxicity
(e.g., cocaine use)
Hypertension
Anxiety
Arteriovenous fistulae
Cardiac
Hypertrophic cardiomyopathy
Aortic stenosis
Dilated cardiomyopathy
Tachycardia
Ventricular
Supraventricular
Non-Cardiac
Anemia
Hypoxemia
Pneumonia
Asthma
Chronic obstructive pulmonary
disease
Pulmonary hypertension
Interstitial pulmonary fibrosis
Obstructive sleep apnea
Sickle cell disease
Sympathomimetic toxicity
(e.g., cocaine use)
Hyperviscosity
Polycythemia
Leukemia
Thrombocytosis
Hypergammaglobulinemia
Cardiac
Aortic stenosis
Hypertrophic cardiomyopathy
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Sustained tachycardia, either ventricular or supraventric-
ular, may also increase myocardial oxygen demand. Parox-
ysmal tachycardias are more frequent conditions that con-
tribute to angina. Unfortunately, they are often more
difficult to diagnose.
Conditions that reduce myocardial oxygen supply must
also be considered in the differential diagnosis of patients
with angina.
Anemia reduces the oxygen-carrying capacity of the
blood and also increases the cardiac workload. An increased
cardiac output is associated with ,9 g/dL of hemoglobin,
and ST-T wave changes (depression or inversion) may be
seen when hemoglobin drops below 7 g/dL.
Hypoxemia resulting from pulmonary disease (e.g., pneu-
monia, asthma, chronic obstructive pulmonary disease, pul-
monary hypertension, interstitial fibrosis, obstructive sleep
apnea) may also precipitate angina. Obstructive sleep apnea
should be seriously considered in patients with only noctur-
nal symptoms.
Conditions that are associated with increased blood
viscosity can increase coronary resistance and thereby de-
crease coronary artery blood flow, precipitating angina in
patients without severe coronary stenoses. Increased viscos-
ity is seen with polycythemia, leukemia, thrombocytosis and
hypergammaglobulinemia.
C. Noninvasive Testing
1. ECG/Chest X-Ray
Recommendations for Electrocardiography, Chest
X-Ray, or Electron Beam Computed Tomography in
the Diagnosis of Chronic Stable Angina
Class I
1. Rest ECG in patients without an obvious non-
cardiac cause of chest pain. (Level of Evidence: B)
2. Rest ECG during an episode of chest pain. (Level of
Evidence: B)
3. Chest X-ray in patients with signs or symptoms of
congestive heart failure, valvular heart disease,
pericardial disease, or aortic dissection/aneurysm.
(Level of Evidence: B)
Class IIa
Chest X-ray in patients with signs or symptoms of
pulmonary disease. (Level of Evidence: B)
Class IIb
1. Chest X-ray in other patients. (Level of Evidence: C)
2. Electron beam computed tomography (EBCT).
(Level of Evidence: B)
A rest 12-lead ECG should be recorded in all patients
with symptoms suggestive of angina pectoris; however, it
will be normal in $50% of patients with chronic stable
angina (49). A normal rest ECG does not exclude severe
CAD. ECG evidence of LV hypertrophy or ST-T wave
changes consistent with myocardial ischemia favor the
diagnosis of angina pectoris (50). Evidence of prior Q-wave
MI on the ECG makes CAD very likely. However, certain
Q-wave patterns are equivocal, such as an isolated Q in lead
III or a QS pattern in leads V1 and V2.
The presence of arrhythmias such as atrial fibrillation or
ventricular tachyarrhythmia on the ECG in patients with
chest pain also increases the probability of underlying CAD;
however, these arrhythmias are frequently caused by other
types of cardiac disease. Various degrees of AV block can be
present in patients with chronic CAD but have many other
causes and a very low specificity for the diagnosis. Left
anterior fascicular block, right bundle-branch block and left
bundle-branch block often occur in patients with CAD and
frequently indicate the presence of multivessel CAD. How-
ever, these findings also lack specificity in the diagnosis of
chronic stable angina.
An ECG obtained during chest pain is abnormal in
'50% of patients with angina who have a normal rest
ECG. Sinus tachycardia occurs commonly; bradyarrhyth-
mia is less common. The ST-segment elevation or
depression establishes a high likelihood of angina and
indicates ischemia at a low workload, portending an
unfavorable prognosis. Many high-risk patients need no
further noninvasive testing. Coronary arteriography usu-
ally defines the severity of coronary artery stenoses and
the necessity and feasibility of myocardial revasculariza-
tion. In patients with ST-T wave depression or inversion
on the rest ECG, “pseudonormalization” of these abnor-
malities during pain is another indicator that CAD is
likely (51). The occurrence of tachyarrhythmias, atrio-
ventricular block, left anterior fascicular block or bundle-
branch block with chest pain also increases the probabil-
ity of coronary heart disease (CHD) and often leads to
coronary arteriography.
The chest roentgenogram is often normal in patients with
stable angina pectoris. Its usefulness as a routine test is not
well established. It is more likely to be abnormal in patients
with previous or acute MI, those with a noncoronary artery
cause of chest pain and those with noncardiac chest discom-
fort. Cardiac enlargement may be attributable to previous
MI, acute LV failure, pericardial effusion or chronic volume
overload of the left ventricle such as occurs with aortic or
mitral regurgitation. Abnormal physical findings, associated
chest X-ray findings (e.g., pulmonary venous congestion),
and abnormalities detected by noninvasive testing (echocar-
diography) may indicate the correct etiology.
Enlargement of the upper mediastinum often results from
an ascending aortic aneurysm with or without dissection.
Pruning or cutoffs of the pulmonary arteries or areas of
segmental oligemia may indicate pulmonary infarction/
embolism or other causes of pulmonary hypertension.
Coronary artery calcification increases the likelihood of
symptomatic CAD. Fluoroscopically detectable coronary
calcification is correlated with major-vessel occlusion in 94%
of patients with chest pain (52); however, the sensitivity of
the test is only 40%.
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Ultrafast Computed Tomography
Ultrafast (electron beam) computed tomography is being
used with increased frequency for the detection and quan-
tification of coronary artery calcification (25). In seven
studies including 50 to 710 patients, calcium of the coronary
arteries detected by EBCT was an important indicator of
angiographic coronary stenoses. In these studies of selected
patients, the sensitivity of a positive EBCT detection of
calcium for the presence of CAD varied from 85% to 100%;
specificity ranged from only 41% to 76%; the positive
predictive value varied considerably from 55% to 84% and
negative predictive value from 84% to 100% (25). The
presence and amount of calcium detected in coronary
arteries by EBCT in two studies appeared to correlate with
the presence and associated amount of atherosclerotic
plaque (53,54). However, several studies (55–57) have
shown a marked variability in repeated measures of coronary
calcium by EBCT. Therefore, the use of serial EBCT scans
in individual patients for identification and serial assessment
of the progression or regression of calcium remains prob-
lematic. The proper role of EBCT is controversial and will
be the subject of future ACC/AHA statements.
2. Exercise ECG for Diagnosis
Recommendations for Diagnosis of Obstructive CAD
With Exercise ECG Testing Without an Imaging
Modality
Class I
Patients with an intermediate pretest probability of
CAD based on age, gender and symptoms, including
those with complete right bundle-branch block or
<1 mm of ST depression at rest (exceptions are
listed below in classes II and III). (Level of Evidence:
B)
Class IIa
Patients with suspected vasospastic angina. (Level of
Evidence: C)
Class IIb
1. Patients with a high pretest probability of CAD by
age, gender and symptoms. (Level of Evidence: B)
2. Patients with a low pretest probability of CAD by
age, gender and symptoms. (Level of Evidence: B)
3. Patients taking digoxin whose ECG has <1 mm of
baseline ST-segment depression. (Level of Evidence:
B)
4. Patients with ECG criteria for LV hypertrophy and
<1 mm of baseline ST-segment depression. (Level
of Evidence: B)
Class III
1. Patients with the following baseline ECG abnor-
malities.
a. Pre-excitation (Wolff-Parkinson-White)
syndrome. (Level of Evidence: B)
b. Electronically paced ventricular rhythm.
(Level of Evidence: B)
c. More than 1 mm of ST depression at rest.
(Level of Evidence: B)
d. Complete left bundle-branch block. (Level
of Evidence: B)
2. Patients with an established diagnosis of CAD due
to prior MI or coronary angiography; however,
testing can assess functional capacity and progno-
sis, as discussed in section III. (Level of Evidence: B)
Description of the Exercise Testing Procedure
Exercise testing is a well-established procedure that has
been in widespread clinical use for many decades. Detailed
descriptions of exercise testing are available in other publi-
cations (58–60). This section provides a brief overview
based on the “ACC/AHA Guidelines for Exercise Testing”
(14).
Although exercise testing is generally a safe procedure,
both MI and death occur at a rate of #1/2500 tests (61).
The absolute contraindications to exercise testing include
acute MI within two days, cardiac arrhythmias causing
symptoms or hemodynamic compromise, symptomatic and
severe aortic stenosis, symptomatic heart failure, acute
pulmonary embolus or pulmonary infarction, acute myocar-
ditis or pericarditis and acute aortic dissection (14,59).
Additional factors are relative contraindications: left main
coronary stenosis, moderate aortic stenosis, electrolyte ab-
normalities, systolic hypertension .200 mm Hg, diastolic
blood pressure .110 mm Hg, tachyarrhythmias or brady-
arrhythmias, hypertrophic cardiomyopathy and other forms
of outflow tract obstruction, mental or physical impairment
leading to an inability to exercise adequately and high-
degree atrioventricular block (14,59). In the past, unstable
angina was a contraindication to exercise testing. However,
new information suggests that exercise treadmill (62–64)
and pharmacologic (65–68) testing are safe in low-risk
outpatients with unstable angina and in low- or intermediate-
risk patients hospitalized with unstable angina in whom an MI
has been ruled out and who are free of angina and congestive
heart failure.
Both treadmill and cycle ergometer devices are used for
exercise testing. Although cycle ergometers have important
advantages, fatigue in the quadricep muscles in patients who
are not experienced cyclists usually makes them stop before
reaching their maximum oxygen uptake. As a result, tread-
mills are more commonly used in the U.S.
There are clear advantages in customizing the protocol to
the individual patient to allow exercise lasting 6 to 12 min
(69). Exercise capacity should be reported in estimated
METs of exercise. (One MET is the standard basal oxygen
uptake of 3.5 mL/kg per min.) If exercise capacity is also
reported in minutes, the protocol should be described
clearly.
Exercise testing should be supervised by an appropriately
trained physician (70), although personal supervision (as
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defined by the Health Care Financing Administration
[HCFA]) is not always required. The ECG, heart rate and
blood pressure should be carefully monitored and recorded
during each stage of exercise as well as during ST-segment
abnormalities and chest pain. The patient should be mon-
itored continuously for transient rhythm disturbances, ST-
segment changes and other ECG manifestations of myo-
cardial ischemia. Although exercise testing is commonly
terminated when subjects reach a standard percentage (often
85%) of age-predicted maximum heart rate, there is great
variability in maximum heart rates among individuals, so
predicted values may be supramaximal for some patients and
submaximal for others. Therefore, it is important to monitor
the patient closely for other indications for stopping the test.
Absolute indications for stopping include a drop in systolic
blood pressure of .10 mm Hg from baseline blood pressure
despite an increase in workload when accompanied by other
evidence of ischemia; moderate to severe angina; increasing
ataxia, dizziness or near syncope; signs of poor perfusion
such as cyanosis or pallor; technical difficulties monitoring
the ECG or systolic blood pressure; the subject’s desire to
stop; sustained ventricular tachycardia; or ST elevation
$1 mm in leads without diagnostic Q waves (other than V1
or aVR). Relative indications for stopping include a drop in
systolic blood pressure of .10 mm Hg from baseline blood
pressure despite an increase in workload in the absence of
other evidence of ischemia; .2 mm of horizontal or
downsloping ST-segment depression; marked axis devia-
tion; arrhythmias such as multifocal premature ventricular
complexes (PVCs), triplets of PVCs, supraventricular tachy-
cardia, heart block or bradyarrhythmias; symptoms such as
fatigue, shortness of breath, wheezing, leg cramps or clau-
dication; bundle-branch block or IVCD that cannot be
distinguished from ventricular tachycardia; increasing chest
pain; systolic blood pressure .250 mm Hg; or diastolic
blood pressure .115 mm Hg (59). Rating the level of
perceived exertion with the Borg scale (71) helps measure
patient fatigue, and fatigue-limited testing is especially
important when assessing functional capacity.
Interpretation of the Exercise Test
Interpretation of the exercise test should include symp-
tomatic response, exercise capacity, hemodynamic response,
and ECG response. The occurrence of ischemic chest pain
consistent with angina is important, particularly if it forces
termination of the test. Abnormalities in exercise capacity,
systolic blood pressure response to exercise and heart rate
response to exercise are important findings. The most
important ECG findings are ST depression and ST eleva-
tion. The most commonly used definition for a positive
exercise test is $1 mm of horizontal or downsloping
ST-segment depression or elevation for $60 to 80 ms after
the end of the QRS complex, either during or after exercise
(14).
Cost and Availability
The exercise ECG is the least costly diagnostic test, with
the cost of stress echocardiography $2-fold higher, stress
SPECT myocardial imaging at least 5-fold higher, and
coronary angiography 20-fold higher. A lower cost of the
treadmill exercise test alone does not necessarily result in a
lower overall cost of patient care, however, as the cost of
additional testing and intervention may be higher because
the exercise test is less accurate.
Treadmill exercise tests are performed frequently but
somewhat less often than the most frequent imaging pro-
cedure, which is stress SPECT myocardial perfusion imag-
ing. An estimated two thirds of the treadmill exercise tests
charged to Medicare in 1994 were performed as office
procedures, and 33% of these charges were submitted by
noncardiologists (14).
Rationale
Diagnostic Characteristics of Exercise Tests
The sensitivity of the exercise test measures the proba-
bility that a patient with obstructive CAD will have a
positive test result, whereas the specificity measures the
probability that a patient without obstructive CAD will
have a negative test result. Sensitivity and specificity are
used to summarize the characteristics of diagnostic tests
because they provide standard measures that can be used to
compare different tests. Sensitivity and specificity alone,
however, do not provide the information needed to interpret
the results of exercise testing. That information can be
calculated and expressed as predictive values. These calcu-
lations require the sensitivity and specificity of the exercise
test along with the pretest probability that the patient has
obstructive CAD.
Positive Predictive Value 5
~Pretest Probability!~Sensitivity!
~Pretest Probability!~Sensitivity! 1
~1 2 Pretest Probability!~1 2 Specificity!
The numerator refers to positive test results that are
true-positive, and the denominator refers to all positive test
results, true-positive and false-positive. The positive predic-
tive value is the probability that the patient has obstructive
CAD when the exercise test result is positive.
Negative Predictive Value
5
~1 2 Pretest Probability!~Specificity!
~1 2 Pretest Probability!~Specificity! 1
~Pretest Probability!~1 2 Sensitivity!
The numerator refers to negative test results that are
true-negative, and the denominator refers to all negative test
results, both true-negative and false-negative. The negative
predictive value is the probability that the patient does not
have obstructive CAD when the exercise test result is
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negative. Therefore, knowing the sensitivity and specificity
of the exercise test and the patient’s pretest probability of
obstructive CAD is especially important when interpreting
the results of exercise testing.
When interpreting estimates of the sensitivity and spec-
ificity of exercise testing, it is important to recognize a type
of bias called workup verification, or posttest referral bias.
This type of bias occurs when the results of exercise testing
are used to decide which patients have the diagnosis of
CAD verified or ruled out with a gold-standard procedure.
This bias also occurs when patients with positive results on
exercise testing are referred for coronary angiography and
patients with negative results are not. Such a selection
process curtails the number of true-negative results. The
result of this type of bias is to raise the measured sensitivity
and lower the measured specificity in relation to their true
values.
Sensitivity and Specificity of the Exercise Test
A meta-analysis of 147 published reports describing
24,074 patients who underwent both coronary angiography
and exercise testing found wide variation in sensitivity and
specificity (14). Mean sensitivity was 68% with a standard
deviation of 16%; mean specificity was 77% with a standard
deviation of 17%. When the analysis considered only results
from the 58 studies that focused on diagnostic tests by
excluding patients with a prior MI, mean sensitivity was
67% and mean specificity 72%. When the analysis was
restricted to the few studies that avoided workup bias by
including only patients who agreed before any testing to
have both exercise testing and coronary angiography, sen-
sitivity was 50% and specificity 90% (73,74). In a more
recent study of 814 men that was carefully designed to
minimize workup bias, sensitivity was 45% and specificity
85% (75). Therefore, the true diagnostic value of the
exercise ECG lies in its relatively high specificity. The
modest sensitivity of the exercise ECG is generally lower
than the sensitivity of imaging procedures (12,13).
Although the sensitivity and specificity of a diagnostic
test are usually thought to be characteristics of the tests
themselves and not affected by patient differences, this is not
always the case. For instance, the exercise test has a higher
sensitivity in the elderly and persons with three-vessel
disease than in younger persons and those with one-vessel
disease. The test has a lower specificity in those with
valvular heart disease, LV hypertrophy and rest ST depres-
sion and those taking digoxin (14).
Physicians are often urged to consider more than just the
ST segment when interpreting the exercise test, and some
studies that use complex formulas to incorporate additional
test information have found diagnoses made with this
approach to be more accurate than those based only on the
ST response (76,77). However, the diagnostic interpretation
of the exercise test still centers around the ST response
because different studies produce different formulas, and the
formulas provide similar results when compared with the
judgment of experienced clinical cardiologists (75,78,79).
Pretest Probability
Diagnostic testing is most valuable when the pretest
probability of obstructive CAD is intermediate: for exam-
ple, when a 50-year-old man has atypical angina and the
probability of CAD is '50% (see Table 9). In these
conditions, the test result has the largest effect on the
posttest probability of disease and thus on clinical decisions.
The exact definition of the upper and lower boundaries of
intermediate probability (e.g., 10% and 90%, 20% and 80%,
30% and 70%) is a matter of physician judgment in an
individual situation. Among the factors relevant to the
choice of these boundaries are the degree of uncertainty that
is acceptable to physician and patient; the likelihood of an
alternative diagnosis; the reliability, cost, and potential risks
of further testing; and the benefits and risks of treatment in
the absence of additional testing. Pauker and Kassirer (80)
have described the application of decision analysis to this
important issue. As indicated earlier, it should be recognized
that the initial evaluation of patients with noncardiac pain
will focus on noncardiac conditions. Clinical judgment in
such patients may indicate that they are at low probability
and do not require cardiac evaluation.
For the diagnosis of CAD, one possible arbitrary defini-
tion of intermediate probability that appears in published
research is between 10% and 90%. This definition was first
advocated 20 years ago (81), and has been used in several
studies (82,83) and the “ACC/AHA Guidelines for Exer-
cise Testing” (14). Although this range may seem very
broad, many sizable patient groups (e.g., older men with
typical angina and younger women with nonanginal pain)
fall outside the intermediate probability range. When the
probability of obstructive CAD is high, a positive test result
only confirms the high probability of disease, and a negative
test result may not decrease the probability of disease
enough to make a clinical difference. Although the exercise
test is less useful for the diagnosis of CAD when pretest
probability is high, it can provide information about the
patient’s risk status and prognosis (see Section III). When
the probability of obstructive CAD is very low, a negative
test result only confirms the low probability of disease, and
a positive test result may not increase the probability of
disease enough to make a clinical difference.
Influence of Other Factors on Test Performance
Digoxin. Digoxin produces abnormal exercise-induced
ST depression in 25% to 40% of apparently healthy normal
subjects (84,85). The prevalence of abnormal responses is
directly related to age.
Beta-Adrenergic Blocking Agent Therapy. Whenever pos-
sible, it is recommended that beta-blockers (and other
anti-ischemic drugs) be withheld for four to five half-lives
(usually about 48 h) before exercise stress testing for the
diagnosis and initial risk stratification of patients with
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suspected CAD. Ideally, these drugs should be withdrawn
gradually to avoid a withdrawal phenomenon that may
precipitate events (86,87). When beta-blockers cannot be
stopped, stress testing may detect myocardial ischemia less
reliably, but it usually will still be positive in patients at the
highest risk.
Other Drugs. Antihypertensive agents and vasodilators
can affect test performance by altering the hemodynamic
response of blood pressure. Short-term administration of
nitrates can attenuate the angina and ST depression asso-
ciated with myocardial ischemia. Flecainide has been asso-
ciated with exercise-induced ventricular tachycardia (88,89).
Left Bundle-Branch Block. Exercise-induced ST depres-
sion usually occurs with left bundle-branch block and is not
associated with ischemia (90).
Right Bundle-Branch Block. Exercise-induced ST depres-
sion usually occurs with right bundle-branch block in the
anterior chest leads (V1–3) and has no association with
ischemia (91). However, when it occurs in the left chest
leads (V5,6) or inferior leads (II, aVF), it has the same
significance as it does when the rest ECG is normal.
LV Hypertrophy With Repolarization Abnormality on the
rest ECG is associated with more false-positive test results
due to decreased specificity.
Rest ST-Segment Depression is a marker for adverse car-
diac events in patients with and without known CAD
(92–99). Additional exercise-induced ST-segment depres-
sion in the patient with #1 mm rest ST-segment depression
is a reasonably sensitive indicator of CAD.
ST-Segment Interpretation Issues
Lead Selection. Twelve-lead ECGs provide the greatest
sensitivity. The V5 alone consistently outperforms the infe-
rior leads and the combination of V5 with lead II. In
patients without prior MI and with a normal rest ECG, the
precordial leads alone are a reliable marker for CAD. In
patients with a normal rest ECG, exercise-induced ST-
segment depression confined to the inferior leads is of little
value (100).
Upsloping ST Depression. Patients with ST-segment de-
pression that slopes upward at ,1 mV/s probably have an
increased probability of coronary disease (101,102). How-
ever, the ACC/AHA/ACP-ASIM Committee to Develop
Guidelines for the Management of Chronic Stable Angina
favors the use of the more common definition for a positive
test, which is 1 mm of horizontal or downsloping ST
depression or elevation for $60 to 80 milliseconds after the
end of the QRS complex (72), because most of the pub-
lished literature is based on this definition.
Atrial Repolarization. Atrial repolarization waves are op-
posite in direction to P waves and may extend into the ST
segment and T wave. Exaggerated atrial repolarization
waves during exercise can cause downsloping ST depression
in the absence of ischemia (103,104). Patients with false-
positive exercise tests have a high peak exercise heart rate,
absence of exercise-induced chest pain, and markedly
downsloping PR segments in the inferior leads. This issue
of atrial repolarization waves was not addressed in the
“ACC/AHA Guidelines for Exercise Testing” (14).
ST Elevation. When the rest ECG is normal, ST eleva-
tion (other than in aVR or V1) is very rare, represents
transmural ischemia caused by spasm or a critical lesion,
greatly increases the likelihood of arrhythmias, and localizes
the ischemia. When the rest ECG shows Q waves from an
old MI, the significance of ST elevation is controversial.
Some studies have suggested that it is due to wall motion
abnormalities (105,106); other studies (107–109) have
found it to be a marker of residual viability in the infarcted
area.
R-Wave Changes. A multitude of factors affect the
R-wave response to exercise (110), and the response does
not have diagnostic significance (111,112).
Heart Rate Adjustment. Several methods of heart rate
adjustment have been proposed to increase the diagnostic
accuracy of the exercise ECG (113–116), but there is no
convincing evidence of benefit (115–119). It is more impor-
tant to consider exercise capacity than heart rate.
Computer Processing. Although computer processing of
the exercise ECG can be helpful, it can also result in
false-positive ST depression (120). To avoid this problem,
the interpreting physician should always compare the un-
processed ECG with any computer-generated averages.
Special Groups
Women. The use of exercise testing in women presents
difficulties that are not experienced in men. These difficul-
ties reflect the differences between men and women regard-
ing the prevalence of CAD and the sensitivity and specific-
ity of exercise testing.
Although obstructive CAD is one of the principal causes
of death in women, the prevalence (and thus the pretest
probability) of this disease is lower in women than it is in
men of comparable age, especially in premenopausal
women. When compared with men, the lower pretest
probability of disease in women means that more test results
are false-positive. For example, almost half the women with
anginal symptoms in the CASS study, many of whom had
positive exercise test results, had normal coronary arterio-
grams (121).
Exercise testing is less sensitive in women than it is in
men, and some studies have found it also to be less specific
(14,73,83,122–131). Among the proposed reasons for these
differences are the use of different criteria for defining
coronary disease, differences in the prevalence of multivessel
disease and prior MI, differences in the criteria for ST-
segment positivity (132,133), differences in type of exercise,
the inability of many women to exercise to maximum
aerobic capacity (134,135), the greater prevalence of mitral
valve prolapse and syndrome X in women, differences in
microvascular function (leading perhaps to coronary spasm)
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and possibly, hormonal differences. To compensate for the
limitations of the test in women, some investigators have
developed predictive models that incorporate more infor-
mation from the test than simply the amount and type of
ST-segment change (130,131). Although this approach is
attractive, its clinical application remains limited.
The difficulties of using exercise testing for diagnosing
obstructive CAD in women have led to speculation that
stress imaging may be preferred over standard stress testing
(129). Although the optimal strategy for diagnosing ob-
structive CAD in women remains to be defined, the
ACC/AHA/ACP-ASIM Committee to Develop Guide-
lines for the Management of Chronic Stable Angina be-
lieves there are currently insufficient data to justify replacing
standard exercise testing with stress imaging when evaluat-
ing women for CAD. In many women with a low pretest
likelihood of disease, a negative exercise test result will be
sufficient, and imaging procedures will not be required (83).
The Elderly. Few data have been published about the use
of exercise testing in people $70 years old. The 1989
National Health Interview Survey (136) found that the
diagnosis of CAD was reported by 1.8% in men and 1.5% in
women .75 years old. Silent ischemia is estimated to be
present in 15% of 80-year-olds (137).
The performance of exercise testing poses additional
problems in the elderly. Functional capacity often is com-
promised from muscle weakness and deconditioning, mak-
ing the decision about an exercise test versus a pharmaco-
logic stress test more important. More attention must be
given to the mechanical hazards of exercise, and less
challenging protocols should be used (138). Elderly patients
are more likely to hold the hand rails tightly, thus reducing
the validity of treadmill time for estimating METs. Ar-
rhythmias occur more frequently with increasing age, espe-
cially at higher workloads (138). In some patients with
problems of gait and coordination, a bicycle exercise test
may be more attractive (139), but bicycle exercise is unfa-
miliar to most elderly patients.
The interpretation of exercise test results in the elderly
differs from that in the young. The greater severity of
coronary disease in this group increases the sensitivity of
exercise testing (84%), but it also decreases the specificity
(70%). The high prevalence of disease means that more test
results are false-negative (140). False-positive test results
may reflect the coexistence of LV hypertrophy from valvular
disease and hypertension, as well as conduction distur-
bances. Other rest ECG abnormalities that complicate
interpretation, including prior MI, also are more frequent.
Exercise testing in the elderly is more difficult both to do
and to interpret, and the follow-up risks of coronary
angiography and revascularization are greater. Despite these
differences, exercise testing remains important in the elderly
because the alternative to revascularization is medical ther-
apy, which also has greater risks in this group.
3. Echocardiography (Resting)
Recommendations for Echocardiography for Diagnosis
of Cause of Chest Pain in Patients With Suspected
Chronic Stable Angina Pectoris
Class I
1. Patients with systolic murmur suggestive of aortic
stenosis or hypertrophic cardiomyopathy. (Level of
Evidence: C)
2. Evaluation of extent (severity) of ischemia (e.g., LV
segmental wall motion abnormality) when the
echocardiogram can be obtained during pain or
within 30 min after its abatement. (Level of Evi-
dence: C)
Class IIb
Patients with a click or murmur to diagnose mitral
valve prolapse (15). (Level of Evidence: C)
Class III
Patients with a normal ECG, no history of MI and
no signs or symptoms suggestive of heart failure,
valvular heart disease, or hypertrophic cardiomyo-
pathy. (Level of Evidence: C)
Echocardiography can be a useful tool for assisting in
establishing a diagnosis of CAD. Echocardiography can
also assist in defining the consequences of coronary disease
in selected patients with chronic chest pain presumed to be
chronic stable angina. However, most patients undergoing a
diagnostic evaluation for angina do not need an echocardio-
gram.
Cause of Chest Pain Unclear: Confounding or Concurrent
Cardiac Diagnoses
Transthoracic echocardiographic imaging and Doppler
recording are useful when there is a murmur or other
evidence for conditions such as aortic stenosis or hypertro-
phic cardiomyopathy coexisting with CAD. Echo-Doppler
techniques usually provide accurate quantitative information
regarding the presence and severity of a coexisting lesion,
such as 1) whether there is concentric hypertrophy or
asymmetric hypertrophy of the ventricular septum, LV apex,
or free wall; 2) the severity of any aortic valvular or
subvalvular gradient; and 3) the status of LV function (13).
Echocardiography is useful for establishing or excluding
the diagnosis of mitral valve prolapse and establishing the
need for infective endocarditis prophylaxis (15).
Global LV Systolic Function
Chronic ischemic heart disease, whether associated with
angina pectoris or not, can result in impaired systolic LV
function. The extent and severity of regional and global
abnormalities are important considerations in choosing
appropriate medical or surgical therapy. Routine estimation
of parameters of global LV function, such as LV ejection
fraction, is unnecessary for the diagnosis of chronic angina
pectoris. For example, in patients with suspected angina and
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a normal ECG, no history of MI, and no signs or symptoms
of heart failure, echocardiography and radionuclide imaging
are not indicated (141,142).
Segmental LV Wall Motion Abnormalities
Echocardiographic findings that may help establish the
diagnosis of chronic ischemic heart disease include regional
systolic wall motion abnormalities, e.g., hypokinesis (re-
duced wall motion), akinesis (absence of wall motion),
dyskinesis (paradoxical wall motion) and failure of a wall
segment to thicken normally during systole (13). Care must
be taken to distinguish chronic CAD as a cause of ventric-
ular septal wall motion abnormalities from other conditions,
such as left bundle-branch block, presence of an intraven-
tricular pacemaker, right ventricular volume overload, or
prior cardiac surgery (13).
The extent of regional (segmental) LV dysfunction can be
described by scoring LV wall segments individually as to
degree of wall motion abnormality (e.g., hypokinesis, dys-
kinesis, akinesis) or by using a scoring system that describes
the summated wall motion score reflecting the normality or
abnormality of each segment (143–146). Segmental wall
motion abnormalities are often detected in patients with a
prior history of MI or significant Q waves on their ECGs.
Their locations correlate well with the distribution of CAD
and pathologic evidence of infarction (143,144,147–154).
Regional wall motion abnormalities can also be seen in
patients with transient myocardial ischemia, chronic isch-
emia (hibernating myocardium) and myocardial scar and in
some patients with myocarditis or other conditions not
associated with coronary occlusion (13). In patients in
whom the LV endocardium is suboptimally imaged by
standard transthoracic echocardiography, tissue harmonic
imaging (155,156) with newer transducers and contrast
echocardiography with intravenous injections of encapsu-
lated gaseous microbubbles represent promising new solu-
tions (157–159).
In patients with chronic stable angina pectoris without
previous MI, LV wall motion is typically normal on the rest
echocardiogram in the absence of ischemia. However, in the
uncommon situation in which an echocardiogram can be
recorded during ischemia or, in some cases (e.g., with
stunned myocardium), up to 30 min after ischemia, the
presence of regional systolic wall motion abnormalities (in a
patient without known CAD) is a moderately accurate
indicator of an increased likelihood of clinically significant
CAD. According to pooled data, the positive predictive
accuracy of this finding for acute ischemia or infarction has
been reported to be '50% (13). Conversely, the absence of
regional wall motion abnormalities identifies a subset of
patients at low risk for an acute infarction (147,160), with a
pooled negative predictive accuracy of about 95%.
Ischemic Mitral Regurgitation
Other structural and functional alterations can complicate
chronic ischemic heart disease associated with stable angina
pectoris. Mitral regurgitation may result from global LV
systolic dysfunction (161), regional papillary muscle dys-
function (162), scarring and shortening of the submitral
chords (163), papillary muscle rupture (164), or other
causes. The presence, severity and mechanism of mitral
regurgitation can be reliably detected with transthoracic
imaging and Doppler echocardiographic techniques. Poten-
tial surgical approaches to mitral valve repair or replacement
can also be defined echocardiographically (15).
4. Stress Imaging Studies: Echocardiographic and
Nuclear
Recommendations for Cardiac Stress Imaging as the
Initial Test for Diagnosis in Patients With Chronic
Stable Angina Who Are Able to Exercise
Class I
1. Exercise myocardial perfusion imaging or exercise
echocardiography in patients with an intermediate
pretest probability of CAD who have one of the
following baseline ECG abnormalities:
a. Pre-excitation (Wolff-Parkinson-White)
syndrome. (Level of Evidence: B)
b. More than 1 mm of ST depression at rest.
(Level of Evidence: B)
2. Exercise myocardial perfusion imaging or exercise
echocardiography in patients with prior revascular-
ization (either PTCA or CABG). (Level of Evi-
dence: B)
3. Adenosine or dipyridamole myocardial perfusion
imaging in patients with an intermediate pretest
probability of CAD and one of the following base-
line ECG abnormalities:
a. Electronically paced ventricular rhythm.
(Level of Evidence: C)
b. Left bundle-branch block. (Level of Evi-
dence: B)
Class IIb
1. Exercise myocardial perfusion imaging and exercise
echocardiography in patients with a low or high
probability of CAD who have one of the following
baseline ECG abnormalities:
a. Pre-excitation (Wolff-Parkinson-White)
syndrome. (Level of Evidence: B)
b. More than 1 mm of ST depression. (Level
of Evidence: B)
2. Adenosine or dipyridamole myocardial perfusion
imaging in patients with a low or high probability of
CAD and one of the following baseline ECG
abnormalities:
a. Electronically paced ventricular rhythm.
(Level of Evidence: C)
b. Left bundle-branch block. (Level of Evi-
dence: B)
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3. Exercise myocardial perfusion imaging or exercise
echocardiography in patients with an intermediate
probability of CAD who have one of the following:
a. Digoxin use with <1 mm ST depression on
the baseline ECG. (Level of Evidence: B)
b. LVH with <1 mm ST depression on the
baseline ECG. (Level of Evidence: B)
4. Exercise myocardial perfusion imaging, exercise
echocardiography, adenosine or dipyridamole myo-
cardial perfusion imaging or dobutamine echocar-
diography as the initial stress test in a patient with
a normal rest ECG who is not taking digoxin.
(Level of Evidence: B)
5. Exercise or dobutamine echocardiography in pa-
tients with left bundle-branch block. (Level of Ev-
idence: C)
Recommendations for Cardiac Stress Imaging as the
Initial Test for Diagnosis in Patients With Chronic
Stable Angina Who Are Unable to Exercise
Class I
1. Adenosine or dipyridamole myocardial perfusion
imaging or dobutamine echocardiography in pa-
tients with an intermediate pretest probability of
CAD. (Level of Evidence: B)
2. Adenosine or dipyridamole stress myocardial per-
fusion imaging or dobutamine echocardiography in
patients with prior revascularization (either PTCA
or CABG). (Level of Evidence: B)
Class IIb
1. Adenosine or dipyridamole stress myocardial per-
fusion imaging or dobutamine echocardiography in
patients with a low or high probability of CAD in
the absence of electronically paced ventricular
rhythm or left bundle-branch block. (Level of Evi-
dence: B)
2. Adenosine or dipyridamole myocardial perfusion
imaging in patients with a low or a high probability
of CAD and one of the following baseline ECG
abnormalities
a. Electronically paced ventricular rhythm.
(Level of Evidence: C)
b. Left bundle-branch block. (Level of Evi-
dence: B)
3. Dobutamine echocardiography in patients with left
bundle-branch block. (Level of Evidence: C)
When to Do Stress Imaging
Patients who are good candidates for cardiac stress testing
with imaging, as opposed to exercise ECG, include those in
the following categories (see also Section II.C.3) (14): 1)
complete left bundle-branch block, electronically paced
ventricular rhythm, preexcitation (Wolff-Parkinson-White)
syndrome and other similar ECG conduction abnormalities;
2) patients who have .1 mm of ST-segment depression at
rest, including those with LV hypertrophy or taking drugs
such as digitalis; 3) patients who are unable to exercise to a
level high enough to give meaningful results on routine
stress ECG who should be considered for pharmacologic
stress imaging tests; and 4) patients with angina who have
undergone prior revascularization, in whom localization of
ischemia, establishing the functional significance of lesions
and demonstrating myocardial viability are important con-
siderations.
Exercise and Pharmacologic Modalities Used in Stress
Imaging
A variety of methods can be used to induce stress: 1)
exercise (treadmill or upright or supine bicycle [see Section
II.C.3]), and 2) pharmacologic techniques (either dobut-
amine or vasodilators). When the patient can exercise to
develop an appropriate level of cardiovascular stress (e.g., 6
to 12 min), exercise stress testing (generally with a tread-
mill) is preferable to pharmacologic stress testing (see
Section II.C.3). However, when the patient cannot exercise
to the necessary level or in other specified circumstances
(e.g., when stress echocardiography is being used in the
assessment of myocardial viability), pharmacologic stress
testing may be preferable. Three drugs are commonly used
as substitutes for exercise stress testing: dipyridamole, aden-
osine and dobutamine. Dipyridamole and adenosine are
vasodilators that are commonly used in conjunction with
myocardial perfusion scintigraphy, whereas dobutamine is a
positive inotropic (and chronotropic) agent commonly used
with echocardiography.
Dipyridamole indirectly causes coronary vasodilation by
inhibiting cellular uptake of adenosine, thereby increasing
the blood and tissue levels of adenosine, which is a potent,
direct coronary vasodilator and markedly increases coronary
blood flow. The flow increase with adenosine or dipyrida-
mole is of a lesser magnitude through stenotic arteries,
creating heterogeneous myocardial perfusion, which can be
observed with a perfusion tracer. Although this mechanism
can exist independent of myocardial ischemia, in some
patients, true myocardial ischemia can occur with either
dipyridamole or adenosine because of a coronary steal
phenomenon.
Both dipyridamole and adenosine are safe and well
tolerated despite frequent mild side effects, which occur in
50% (165) and 80% (166,167) of patients, respectively.
With dipyridamole infusion, the most common side effect
was angina (18% to 42%), with arrhythmia occurring in
,2%. Noncardiac side effects have included headache (5%
to 23%), dizziness (5% to 21%), nausea (8% to 12%), and
flushing (3%) (165). With adenosine infusion, chest pain
has been reported in 57%, headache in 35%, flushing in
25%, shortness of breath in 15%, and first-degree AV block
in 18%. Severe side effects are rare, but both dipyridamole
and adenosine may cause severe bronchospasm in patients
with asthma or chronic obstructive lung disease; therefore,
they should be used with extreme caution—if at all—in
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these patients. Dipyridamole and adenosine side effects are
antagonized by theophylline, although this drug is ordi-
narily not needed after adenosine because of the latter’s
ultrashort half-life (,10 s).
Dobutamine in high doses (20 to 40zmg kg21zmin21)
increases the three main determinants of myocardial oxygen
demand, namely, heart rate, systolic blood pressure and
myocardial contractility, thereby eliciting a secondary in-
crease in myocardial blood flow and provoking ischemia.
The flow increase (2-fold to 3-fold baseline values) is less
than that elicited by adenosine or dipyridamole but is
sufficient to demonstrate heterogeneous perfusion by radio-
nuclide imaging. Although side effects are frequent during
dobutamine infusion, the test appears to be relatively safe,
even in the elderly (168–173). The most frequently reported
noncardiac side effects (total 26%) in a study of 1118
patients included nausea (8%), anxiety (6%), headache (4%)
and tremor (4%) (172). Common arrhythmias included
premature ventricular beats (15%), premature atrial beats
(8%), and supraventricular tachycardia and nonsustained
ventricular tachycardia (3% to 4%). Atypical chest pain was
reported in 8% and angina pectoris in approximately 20%.
Factors Affecting Accuracy of Noninvasive Testing
As already described for exercise ECG, apparent test
performance can be altered by the pretest probability of
CAD (38,174,175). The positive predictive value of a test
declines as the disease prevalence decreases in the popula-
tion under study, whereas the negative predictive accuracy
increases (176). Stress imaging should generally not be used
for routine diagnostic purposes in patients with a low or
high pretest probability of disease. However, although stress
imaging is less useful for diagnosis when the pretest prob-
ability of CAD is high, it can provide information about the
patient’s risk status and prognosis (see Section III.C.3).
As it is for exercise electrocardiography, the phenomenon
of workup, verification, or posttest referral bias is an
important factor influencing the sensitivity, specificity and
predictive value of myocardial perfusion imaging and stress
echocardiography (see Section II.C.3). The effects of post-
test referral bias have been similar for myocardial perfusion/
imaging (177,178) and exercise echocardiography (179).
Correction for posttest referral bias results in strikingly
lower sensitivity and higher specificity for both techniques
(Tables 13 through 17). As a result of these changes in
sensitivity and specificity, in a patient with an intermediate
pretest probability of disease, correction for verification bias
actually improves the diagnostic value of a positive test
result while the value of a negative test result decreases
(175).
Diagnostic Accuracy of Stress Imaging Techniques
Radionuclide Imaging. An excellent review of the use of
radionuclide imaging in the diagnosis and localization of
CAD was included in the “ACC/AHA Guidelines for
Clinical Use of Cardiac Radionuclide Imaging,” which was
published in 1995 (12). This discussion, which focuses on
myocardial perfusion imaging, borrows from this previous
document but has been updated to reflect more recent
publications. In patients with suspected or known chronic
stable angina, the largest accumulated experience in myo-
cardial perfusion imaging has been with the tracer 201Tl, but
the available evidence suggests that the newer tracers 99mTc
sestamibi and 99mTc tetrofosmin yield similar diagnostic
accuracy (180–190). Thus, for the most part, 201Tl, 99mTc
sestamibi or 99mTc tetrofosmin can be used interchangeably
with similar diagnostic accuracy in CAD.
Table 13. Exercise SPECT Scintigraphy—Without Correction for Referral Bias
Author Year
Total
Patients Sensitivity Specificity
Tamaki (259) 1984 104 0.98 0.91
DePasquale (260) 1988 210 0.95 0.74
Iskandrian (226) 1989 461 0.82 0.60
Maddahi (261) 1989 138 0.95 0.56
Fintel (204) 1989 135 0.92 0.92
Van Train (262) 1990 318 0.94 0.43
Mahmarian (263) 1990 360 0.87 0.87
Gupta (214) 1992 144 0.82 0.80
Quin˜ones (264) 1992 112 0.76 0.81
Christian (265) 1992 688 0.92 0.74
Chae (128) 1993 243 0.71 0.65
Solot (266) 1993 128 0.89 0.90
Van Train (267) 1994 161 0.87 0.36
Rubello (268) 1995 120 0.92 0.61
Taillefer (248) 1997 115 0.87 0.92
Iskandrian (269) 1997 993 0.87 0.70
Others* (270–283) 1990–1998 842 0.87 0.75
*Fourteen other studies, each with ,100 subjects combined.
2114 Gibbons et al. JACC Vol. 33, No. 7, 1999
ACC/AHA/ACP-ASIM Chronic Stable Angina Guidelines June 1999:2092–197
Myocardial perfusion imaging may use either planar or
single-photon emission computed tomographic (SPECT)
techniques and visual analyses (191–194) or quantitative
techniques (195–202). Quantification (e.g., using horizontal
[195] or circumferential [196–198] profiles) may improve
the sensitivity of the test, especially in patients with one-
vessel disease (194,198–202). For 201Tl planar scintigraphy,
average reported values of sensitivity and specificity (not
corrected for posttest referral bias) have been in the range of
83% and 88%, respectively, by visual analysis (191–194), and
90% and 80%, respectively, for quantitative analyses (194–
203). The 201Tl SPECT is generally more sensitive than
planar imaging for diagnosing CAD, localizing hypoper-
fused vascular territories, identifying left anterior descend-
ing and left circumflex coronary artery stenoses (204), and
correctly predicting the presence of multivessel CAD (205).
The average (uncorrected for referral bias) sensitivity and
specificity of exercise 201Tl SPECT imaging are in the range
of 89% and 76%, respectively, for qualitative analyses
(201,202,206) and 90% and 70%, respectively, for quanti-
tative analyses (206).
The less-than-perfect sensitivity and specificity may in part
be explained by the fact that visually estimated angiographic
severity of coronary stenoses does not closely correlate with
functional severity as assessed by coronary flow reserve after
maximal pharmacologic coronary vasodilation (203). Further-
more, the lower-than-expected specificity in the more recent
series, which has generally involved SPECT rather than planar
imaging, may well be related to posttest referral bias (see
above). Although patient selection undoubtedly plays a role in
decreasing the specificity observed with SPECT compared
with planar imaging, other factors, such as photon attenuation
and artifacts created by the tomographic reconstruction pro-
cess, are also likely important.
Since the introduction of dipyridamole-induced coronary
vasodilation as an adjunct to 201Tl myocardial perfusion
Table 14. Exercise Echocardiography—Without Correction for Referral Bias
Author Year
Total
Patients Sensitivity Specificity
Armstrong (284) 1987 123 0.88 0.86
Crouse (285) 1991 228 0.97 0.64
Marwick (286) 1992 150 0.84 0.86
Quin˜ones (264) 1992 112 0.74 0.88
Ryan (287) 1993 309 0.91 0.78
Hecht (288) 1993 136 0.94 0.88
Roger (289) 1994 150 0.91 —
Beleslin (224) 1994 136 0.88 0.82
Sylven (277) 1994 160 0.72 0.50
Roger (145) 1995 127 0.88 0.72
Marwick (290) 1995 147 0.71 0.91
Marwick (129) 1995 161 0.80 0.81
Luotolahti (291) 1996 108 0.94 0.70
Others*
(130,225,278–280,292–299)
1988–1996 741 0.83 0.91
*Fourteen other studies, each with ,100 subjects combined.
Table 15. Adenosine SPECT Scintigraphy—Without Correction for Referral Bias
Author Year
Total
Patients Sensitivity Specificity
Nishimura (210) 1991 101 0.87 0.90
Coyne (213) 1991 100 0.83 0.75
O’Keefe (300) 1992 121 0.92 0.64
Gupta (214) 1992 144 0.83 0.87
Iskandrian (301) 1993 339 0.90 0.90
Mohiuddin (302) 1996 202 0.87 (m) 0.83 (m)
0.94 (f) 0.89 (f)
Amanullah (303) 1997 222 0.93 0.73
Amanullah (304) 1997 130 0.91 0.70
Iskandrian (269) 1997 550 0.90 0.86
Other*
(170,212,305,306)
1990–1995 228 0.91 0.74
*Four other studies, each with ,100 subjects combined.
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imaging (207–209), pharmacologic interventions have be-
come an important tool in noninvasive diagnosis of CAD
(165,166,168–171,208–217). Dipyridamole planar scintig-
raphy has a high sensitivity (90% average, uncorrected) and
acceptable specificity (70% average, uncorrected) for detec-
tion of CAD (165). Dipyridamole SPECT imaging with
201Tl or 99mTc sestamibi appears to be at least as accurate as
planar imaging (218–220). Results of myocardial perfusion
imaging during adenosine infusion are similar to those
obtained with dipyridamole and exercise imaging (212–
214,216). Dobutamine perfusion imaging has significant
limitations compared with vasodilator (dipyridamole or
adenosine) perfusion imaging because it does not provoke as
great an increase in coronary flow (221,222). Its use should
therefore be restricted to patients with contraindications to
dipyridamole and adenosine, although dobutamine perfu-
sion imaging has reasonable diagnostic accuracy (223).
Because it should be used far less commonly than dipyrid-
amole and adenosine, dobutamine perfusion imaging is not
included in the recommendations.
Exercise and dobutamine radionuclide angiography are
now performed very infrequently and are therefore also not
included in the recommendations.
Stress Echocardiography. Stress echocardiography relies on
imaging LV segmental wall motion and thickening during
stress compared with baseline. Echocardiographic findings
suggestive of myocardial ischemia include 1) a decrease in
wall motion in $1 LV segment with stress, 2) a decrease in
wall thickening in $1 LV segment with stress, and 3)
compensatory hyperkinesis in complementary (nonisch-
emic) wall segments. The advent of digital acquisition and
storage, as well as side-by-side (or quad screen) display of
Table 16. Dobutamine Echocardiography—Without Correction for Referral Bias
Author Year
Total
Patients Sensitivity Specificity
Sawada (307) 1991 103 0.89 0.85
Marcovitz (308) 1992 141 0.96 0.66
Marwick (170) 1993 217 0.72 0.83
Takeuchi (309) 1993 120 0.85 0.93
Baudhuin (310) 1993 136 0.79 0.83
Ostojic (311) 1994 150 0.75 0.79
Beleslin (224) 1994 136 0.82 0.76
Pingitore (312) 1996 110 0.84 0.89
Wu (313) 1996 104 0.94 0.38
Hennessy (314) 1997 116 0.82 0.63
Dionisopoulos (315) 1997 288 0.85 (m) 0.96 (m)
0.90 (f) 0.79 (f)
Elhendy (316) 1997 306 0.73 (m) 0.77 (m)
0.76 (f) 0.94 (f)
Hennessy (317) 1997 219 0.82 0.65
Others*
(225,280–283,318,319)
1993–1998 436 0.75 0.83
*Seven other studies, each with ,100 subjects combined.
Table 17. Noninvasive Tests Before and After Adjustment for Referral Bias
Modality Author Year Total Patients
Sensitivity Specificity
Biased Adjusted Biased Adjusted
Exercise ECG Morise and Diamond (73) 1995 Men: 508 0.56 0.40 0.81 0.96
Women: 284 0.47 0.33 0.73 0.89
Exercise planar thallium Schwartz et al. (178) 1993 Men: 845 0.67 0.45 0.59 0.78
Exercise planar thallium Diamond (177) 1986 Overall: 2269 0.91 0.68 0.34 0.71
Exercise SPECT
thallium
Cecil et al. (320) 1996 Overall: 2688 0.98 0.82 0.14 0.59
Exercise/dipyridamole Santana-Boado et al. (321) 1998 Men: 100 0.93 0.88 0.89 0.96
and SPECT Women: 63 0.85 0.87 0.91 0.91
sestamibi
Exercise echo Roger et al. (179) 1997 Men: 244 0.78 0.42 0.37 0.83
Women: 96 0.79 0.32 0.34 0.86
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cineloops of LV images acquired at different levels of rest or
stress, has facilitated efficiency and accuracy in interpreta-
tion of stress echocardiograms (13).
Stress echocardiography has been reported to have sen-
sitivity and specificity for detecting CAD approximately in
the range reported for stress myocardial imaging. In 36
studies reviewed that included 3,210 patients, the range of
reported overall sensitivities, uncorrected for posttest refer-
ral bias, ranged from 70% to 97%; an average figure was
approximately 85% for overall sensitivity for exercise echo-
cardiography and 82% for dobutamine stress echocardiog-
raphy (13). As expected, the reported sensitivity of exercise
echocardiography for multivessel disease was higher (73% to
100%, average approximately 90%) than the sensitivity for
one-vessel disease (63% to 93%, average approximately
79%) (13). In this series of studies, specificity ranged from
72% to 100%, with an average of approximately 86% for
exercise echocardiography and 85% for dobutamine echo-
cardiography.
Pharmacologic stress echocardiography is best accom-
plished with the use of dobutamine because it enhances
myocardial contractile performance and wall motion, which
can be evaluated directly by echocardiography. Dobutamine
stress echocardiography has substantially higher sensitivity
than vasodilator (dipyridamole or adenosine) stress echocar-
diography for detecting coronary stenoses (170,224,225). In
a recent review of 36 studies, average sensitivity and speci-
ficity (uncorrected for referral bias) of dobutamine stress
echocardiography in the detection of CAD were in the
range of 82% (86% for multivessel disease) and 85%,
respectively (13). Although dipyridamole echocardiography
is performed abroad, it is used far less commonly in the U.S.
and is not included in the recommendations.
Special Issues Related to Stress Cardiac Imaging
Concomitant Use of Drugs. The sensitivity of the exercise
imaging study for diagnosis of CAD appears to be lower in
patients taking beta-blockers (226–230). As recommended
earlier for the exercise ECG (Section II.C.2), whenever
possible, it is recommended that beta-blockers (and other
anti-ischemic drugs) be withheld for four to five half-lives
(usually about 48 h) before exercise imaging studies for the
diagnosis and initial risk stratification of patients with
suspected CAD. Nonetheless, in patients who exercise to a
submaximal level because of the effect of drugs, perfusion or
echocardiographic imaging still affords higher sensitivity
than the exercise ECG alone (231).
Bundle-Branch Blocks. Several studies have observed an
increased prevalence of myocardial perfusion defects during
exercise imaging, in the absence of angiographic coronary
disease, in patients with left bundle-branch block (232–
234). These defects often involve the interventricular sep-
tum, may be reversible or fixed and are often absent during
pharmacologic stress. Their exact mechanism is uncertain.
Multiple studies (involving .200 patients) have found that
perfusion imaging with pharmacologic vasodilation is more
accurate for identifying CAD in patients with left bundle-
branch block (235–243). In contrast, only one small study of
24 patients has reported on the diagnostic usefulness of
stress echocardiography in the presence of left bundle-
branch block (244). The committee therefore believed that
adenosine or dipyridamole myocardial perfusion imaging is
preferred in these patients. Right bundle-branch block and
left anterior hemiblock are not ordinarily associated with
such perfusion defects.
Cardiac Stress Imaging in Selected Patient Subsets (Female,
Elderly or Obese Patients, and Patients With Special Occupa-
tions). The treadmill ECG test is less accurate for diagnosis
in women, who have a generally lower pretest likelihood of
CAD than men (14). Myocardial perfusion imaging or
echocardiography could be a logical addition to treadmill
testing in this circumstance. However, the sensitivity of
thallium perfusion scans may be lower in women than men
(203,245). Artifacts due to breast attenuation, usually man-
ifest in the anterior wall, can be an important caveat in the
interpretation of women’s perfusion scans, especially when
201Tl is used as a tracer. More recently, the use of gated
99mTc sestamibi SPECT imaging has been associated with
an apparent reduction in breast artifacts (246,247). In a
recent prospective study of 115 women with either sus-
pected or a low pretest likelihood of CAD, both 201Tl
SPECT and 99mTc sestamibi had a similar sensitivity for
detection of CAD in women (84.3% and 80.4% for $70%
stenosis) (248). However, 99mTc sestamibi SPECT imaging
had a better specificity (84.4% vs. 67.2%) and was further
enhanced to 92.2% with ECG gating. Similarly, exercise or
pharmacologic stress echocardiography may help avoid ar-
tifacts specifically due to breast attenuation. However,
echocardiographic imaging in obese persons tends both to
be technically more difficult and to produce images of less
quality. As indicated earlier (Section II.C.2), the committee
believes that there currently are insufficient data to justify
replacing standard exercise testing with stress imaging in the
initial evaluation of women.
Although some elderly patients can perform an adequate
exercise test, many are unable to do so because of physical
impairment. Pharmacologic stress imaging is an appropriate
option in such patients. Very obese patients constitute a
special problem because most imaging tables used for
SPECT have weight-bearing limits (often 300 lb [135 kg])
that preclude imaging very heavy subjects. These subjects
can still be imaged by planar scintigraphy. Obese patients
often have suboptimal perfusion images, especially with
201Tl, owing to the marked photon attenuation by soft
tissue. In these patients, 99mTc sestamibi is probably most
appropriate and should yield images of better quality than
201Tl. Positron emission tomographic imaging is also likely
to be superior to conventional myocardial perfusion imaging
in these subjects. As noted above, exercise or pharmacologic
stress echocardiography may yield suboptimal images in
significantly obese subjects. Suboptimal images are also not
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uncommon in patients with chest deformities and signifi-
cant lung disease.
Persons whose occupation may affect public safety (e.g.,
airline pilots, truckers, bus drivers, railroad engineers, fire-
fighters and law enforcement officers) or who are profes-
sional or high-profile athletes not uncommonly undergo
periodic exercise testing for assessment of exercise capacity
and prognostic evaluation of possible CAD (14). Although
there are insufficient data to justify this approach, these
evaluations are done for statutory reasons in some cases (27).
For patients in these groups with chronic chest pain who are
in the intermediate-to-high likelihood range for CAD, the
threshold for adding imaging to standard exercise electro-
cardiography may properly be lower than in the average
patient. Specifically, one might recommend that for persons
in this risk category, in whom stress testing is being
contemplated, stress imaging (with echocardiography or
radionuclide perfusion imaging) should be the initial stress
test.
Comparison of Myocardial Perfusion Imaging and
Echocardiography
Sensitivity and Specificity. In an analysis of 11 studies
involving 808 patients who had contemporaneous treadmill
(or pharmacologic) stress echocardiography and perfusion
scintigraphy, the overall (uncorrected for referral bias) sen-
sitivity was 83% for stress perfusion imaging versus 78% for
stress echocardiography (p 5 NS). On the other hand,
overall specificity (uncorrected for referral bias) tended to
favor stress echocardiography (86% vs. 77%; p 5 NS) (249).
More recently, Fleischmann et al. (250) performed a
meta-analysis on 44 articles (published between 1990 and
1997), which examined the diagnostic accuracy of exercise
tomographic myocardial perfusion imaging or exercise
echocardiography. The overall sensitivity and specificity,
respectively, were 85% and 77% for exercise echocardiogra-
phy, 87% and 64% for exercise myocardial perfusion imag-
ing, and 52% and 71% for exercise ECG. These estimates
were not adjusted for referral bias. On the basis of receiver
operator characteristic curves, which were also not adjusted
for referral bias, exercise echocardiography had significantly
better discriminatory power than exercise myocardial perfu-
sion imaging.
Localization of Disease to Individual Coronary Arteries.
Use of SPECT has provided diagnostic improvement over
planar imaging for more precise localization of the vascular
territories involved, particularly the identification of left
circumflex coronary artery stenoses and prediction of mul-
tivessel CAD (201,202,206). O’Keefe et al. (141) reviewed
data on 770 patients (1,328 diseased coronary arteries) in
multiple studies who had exercise perfusion imaging versus
200 (704 diseased coronary arteries) who had undergone
exercise echocardiography. In these data derived from 10
published studies, there was a nonsignificant trend toward
improvement in localization of coronary disease by the
radionuclide technique (79% vs. 65% uncorrected sensitiv-
ity; p 5 NS). For localization of disease to the circumflex
coronary artery, however, the radionuclide method con-
ferred a significant advantage in sensitivity (72% vs. 33%,
uncorrected p , 0.001).
Importance of Local Expertise and Facilities. Echocardio-
graphic and radionuclide stress imaging have complemen-
tary roles, and both add value to routine stress electrocar-
diography under the circumstances outlined above. The
choice of which test to perform depends on issues of local
expertise, available facilities and considerations of cost-
effectiveness (see following text). Because of its lower cost
and generally greater portability, stress echocardiography is
more likely to be performed in the physician’s office than
stress radionuclide imaging; the availability of stress imaging
in the office setting has both advantages and disadvantages
for the patient (176).
Cost-Effectiveness Considerations. In this era of managed
care, cost-effectiveness considerations have come into
sharper focus in medical decision making. Commonly used
measures of cost-effectiveness include the change in quality-
adjusted life-years (QALY) per dollar of cost. The cost/D
QALY ratio is importantly affected by the pretest likelihood
of CAD, test accuracy, and the cost and complication rates
of the test (176,251,252). Patterson and Eisner (251) used
an assumption for detection of significant CAD of 75%
sensitivity and 90% specificity for stress echocardiography
and 84% sensitivity and 87% specificity for SPECT perfu-
sion imaging. They found that the cost/D QALY ratio was
8% to 12% higher for stress echocardiography than for
SPECT thallium imaging (251). However, Marwick (252)
has argued that if Medicare reimbursement rates had been
substituted for costs quoted by the authors and sensitivity/
specificity data adjusted to 80% and 85%, respectively, for
stress echocardiography, and 70% and 90%, respectively, for
SPECT thallium imaging, that the cost/D QALY ratios
would have decreased for both tests. Marwick also argued
that the cost/D QALY ratio would have been slightly lower
for stress echocardiography (compared with stress perfusion
imaging) at coronary disease probability rates of 20% to 30%
and slightly higher for stress echocardiography at probability
rates of 40% to 80%.
A subsequent decision and cost-effectiveness analysis
(253) used published data (uncorrected for referral bias) to
compare exercise electrocardiography, exercise thallium per-
fusion imaging, exercise echocardiography and coronary
angiography for the diagnosis of suspected CAD in a
55-year-old woman. Coronary angiography was most cost-
effective in a woman of this age with definite angina,
whereas exercise echocardiography was most cost-effective
in the presence of atypical angina or nonanginal chest pain.
A summary of comparative advantages of stress myocar-
dial perfusion imaging and stress echocardiography is pro-
vided in Table 18.
Recent Technical Developments. The published compari-
sons between stress echocardiography and stress myocardial
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perfusion imaging do not fully reflect the ongoing develop-
ments in both techniques.
For stress echocardiography, recent developments include
tissue harmonic imaging and intravenous contrast agents,
which can improve detection of endocardial borders
(254,255).
For stress myocardial perfusion imaging, newer-
generation gamma cameras and scatter correction improve
resolution (256), and gating permits assessment of global
and regional function (257) as well as more accurate
characterization of equivocal findings (247). Attenuation
correction is under development (258).
These recent advances in both stress echocardiography
and stress myocardial perfusion imaging should improve
diagnostic accuracy.
D. Invasive Testing: Value of Coronary Angiography
Recommendations for Coronary Angiography to
Establish a Diagnosis in Patients With Suspected
Angina, Including Those With Known CAD Who
Have a Significant Change in Anginal Symptoms
Class I
Patients with known or possible angina pectoris who
have survived sudden cardiac death. (Level of Evi-
dence: B)
Class IIa
1. Patients with an uncertain diagnosis after noninva-
sive testing in whom the benefit of a more certain
diagnosis outweighs the risk and cost of coronary
angiography. (Level of Evidence: C)
2. Patients who cannot undergo noninvasive testing
due to disability, illness or morbid obesity. (Level of
Evidence: C)
3. Patients with an occupational requirement for a
definitive diagnosis. (Level of Evidence: C)
4. Patients who by virtue of young age at onset of
symptoms, noninvasive imaging, or other clinical
parameters are suspected of having a nonathero-
sclerotic cause for myocardial ischemia (coronary
artery anomaly, Kawasaki disease, primary coronary
artery dissection, radiation-induced vasculoplasty).
(Level of Evidence: C)
5. Patients in whom coronary artery spasm is sus-
pected and provocative testing may be necessary.
(Level of Evidence: C)
6. Patients with a high pretest probability of left main
or three-vessel CAD. (Level of Evidence: C)
Class IIb
1. Patients with recurrent hospitalization for chest
pain in whom a definite diagnosis is judged neces-
sary. (Level of Evidence: C)
2. Patients with an overriding desire for a definitive
diagnosis and a greater-than-low probability of
CAD. (Level of Evidence: C)
Class III
1. Patients with significant comorbidity in whom the
risk of coronary arteriography outweighs the benefit
of the procedure. (Level of Evidence: C)
2. Patients with an overriding personal desire for a
definitive diagnosis and a low probability of CAD.
(Level of Evidence: C)
This invasive technique for imaging the coronary artery
lumen remains the most accurate for the diagnosis of
clinically important obstructive coronary atherosclerosis and
less common nonatherosclerotic causes of possible chronic
stable angina pectoris such as coronary artery spasm, coro-
nary anomaly, Kawasaki disease, primary coronary artery
dissection and radiation-induced coronary vasculopathy
(322–331). Early case studies correlating symptoms with the
findings at coronary angiography reported that between
26% and 65% of patients with chest discomfort that was
suggestive of but was not classical angina (i.e., atypical
symptoms) had significant coronary stenoses due to athero-
sclerosis (38,332–334). In many patients with symptoms
suggestive but not typical of chronic stable angina pectoris
(i.e., pretest probability '50%), the incremental value of
noninvasive testing, when considered with other clinical
data, may permit a sufficiently accurate diagnosis on which
to base clinical management strategies (12–14) (see Section
II.C). Incumbent on the physician is the responsibility for
estimating the probability that the patient’s symptoms are
due to myocardial ischemia and matching the intensity of
the evaluation to this estimation. All decisions regarding
testing for possible CAD must be modulated by patient
preference and comorbidity. It is important to reemphasize
the value of a history of typical effort angina in middle-aged
or elderly men in whom '90% have significant coronary
disease (38,332–334) and many have multivessel disease (see
Fig. 6). In women, only about one half with classic angina
Table 18. Comparative Advantages of Stress Echocardiography
and Stress Radionuclide Perfusion Imaging in Diagnosis
of CAD
Advantages of Stress Echocardiography
1. Higher specificity
2. Versatility—more extensive evaluation of cardiac anatomy
and function
3. Greater convenience/efficacy/availability
4. Lower cost
Advantages of Stress Perfusion Imaging
1. Higher technical success rate
2. Higher sensitivity—especially for single vessel coronary
disease involving the left circumflex
3. Better accuracy in evaluating possible ischemia when
multiple resting LV wall motion abnormalities are present
4. More extensive published data base—especially in
evaluation of prognosis
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pectoris have significant obstructive coronary disease (see
following section).
Indications for Coronary Angiography
Direct referral for diagnostic coronary angiography may
be indicated in patients with chest pain possibly attributable
to myocardial ischemia when noninvasive testing is contra-
indicated or unlikely to be adequate due to illness, disability
or physical characteristics. For example, a patient with chest
pain suggestive of chronic stable angina and coexisting
chronic obstructive pulmonary disease who is not a candi-
date for exercise testing because of dyspnea, perfusion
imaging with dipyridamole or adenosine because of bron-
chospasm and theophylline therapy or stress-echocardiography
because of poor images may undergo coronary angiography
with minimal risk.
Patients in whom noninvasive testing is abnormal but not
clearly diagnostic may warrant clarification of an uncertain
diagnosis by coronary angiography or in some cases by a
second noninvasive test (imaging modality), which may be
recommended for a low-likelihood patient with an
intermediate-risk treadmill result (335). Coronary angiog-
raphy may be most appropriate for a patient with a high-risk
treadmill outcome.
In patients with symptoms suggestive but not character-
istic of stable angina, direct referral to coronary angiography
may be indicated when the patient’s occupation or activity
could constitute a risk to themselves or others (pilots,
firefighters, police, professional athletes or serious runners)
(27). In certain patients with typical or atypical symptoms
suggestive of stable angina and a high clinical probability of
severe CAD, direct referral to coronary angiography may be
indicated and prove cost-effective (335). The diagnosis of
chronic stable angina in diabetic persons can be particularly
difficult because of the paucity of symptomatic expressions
of myocardial ischemia due to autonomic and sensory
neuropathy, and a lowered threshold for coronary angiog-
raphy is appropriate (336). The use of coronary angiography
in patients with a high pretest probability of disease is in
some patients as important in risk assessment (see Section
III.A) as in diagnosis.
Women. The evaluation of chest pain in women has been
scrutinized recently, and available data suggest that gender
differences in presentation and disease manifestations
should be considered (337). Atypical chest pain is more
common in women, perhaps in relation to an increased
prevalence of vasospasm as well as mitral valve prolapse and
noncoronary chest pain syndromes. ECG treadmill exercise
testing has a higher false-positive rate in women (38% to
67%) than men (7% to 44%) (338), largely because of the
lower pretest likelihood of disease (339), but a low false-
negative rate, which indicates that routine testing reliably
excludes the presence of coronary disease when the results of
noninvasive tests are negative. Despite the limitations of
routine exercise ECG testing in women, it has been shown
to reduce procedures without loss of diagnostic accuracy.
Only 30% of women (in whom a reasonably certain diag-
nosis of CAD could not be reached or excluded) need be
referred for further testing (83). Recent studies examining
the outcome of patients undergoing diagnostic testing
indicate that women with positive stress ECGs or stress
thallium examinations were less frequently referred for
additional noninvasive testing (4% vs. 20% for men) or
coronary angiography (34% vs. 45%) (340). Although these
findings suggest that a gender-based difference in clinical
practice exists in this country, 2 reports indicate that the
Figure 6. Coronary angiography findings in patients with chronic effort-induced angina pectoris. Top: Percentage of men with one-vessel,
two-vessel, three-vessel, left main or no coronary artery disease on coronary angioraphy. Bottom: Percentage of women with one-vessel,
two-vessel, three-vessel, left main, or no coronary artery disease on coronary angiography. N 5 normal or ,50% stenosis; 1 5 one-vessel
disease; two 5 2-vessel disease; three 5 3-vessel disease; LM 5 left main disease. Data from Douglas and Hurst (333).
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reduced referral rate of women was clinically appropriate
(341,342). As mentioned in Section II.C, a recent cost-
effectiveness analysis concluded that coronary angiography
was the preferred initial diagnostic test in a 55-year-old
woman with typical angina (253).
The Elderly. The evaluation of chest pain syndromes in
the elderly can be difficult because complaints of chest
discomfort, weakness and dyspnea are common, and comor-
bid conditions that mimic angina pectoris are frequently
present. Reduced activity levels and blunted appreciation of
ischemic symptoms become the norm with advancing age
(343). In large community studies of men and women $65
years old, those with atypical symptoms and typical angina
were shown to have similar three-year cardiac mortality
rates (344). An increased frequency of abnormal ECGs at
rest and inability to exercise complicate noninvasive diag-
nostic testing, as does the increased prevalence of disease,
which reduces the value of a negative noninvasive test.
Diagnostic coronary angiography has very little increased
risk (compared with younger patients) in older patients
undergoing elective evaluation and is commonly used; in
many centers, most patients who undergo this study are
.65-years-old (345).
Coronary Spasm. Coronary artery spasm is a well-
recognized cause of chest pain at rest (346) and may also
lead to variable threshold effort angina (323,324), but in a
10-year study of 3,447 patients who underwent provocative
testing with ergonovine maleate, coronary spasm was most
often associated with an atypical chest pain syndrome (322)
and cigarette smoking. The lack of a classic presentation and
requirement for provocative testing during coronary angio-
graphy may hinder making this diagnosis. Although some
investigators have advocated noninvasive, provocative test-
ing for coronary spasm (347), there is some risk of irrevers-
ible coronary spasm (348); for this reason, most recommend
that provocative testing for coronary spasm be done in the
cardiac catheterization environment, where administration
of intracoronary nitroglycerin and other vasodilators is
feasible and other support systems are available (349).
Coronary Anomaly. The anomalous origin and course of
coronary arteries is an uncommon cause of chronic stable
angina usually recognized unexpectedly at coronary angiog-
raphy, but this diagnosis may be suspected in younger
patients with signs or symptoms of myocardial ischemia
(325–327) and recognized by noninvasive imaging modali-
ties such as transesophageal echocardiography, computer-
ized tomography, or magnetic resonance imaging. The
presence of a continuous murmur can point to a diagnosis of
anomalous origin of the left anterior descending or circum-
flex artery from the pulmonary artery or coronary arterio-
venous fistula that should be confirmed by coronary angiog-
raphy.
Resuscitation From Ventricular Fibrillation or Sustained
Ventricular Tachycardia. Most patients experiencing sudden
cardiac arrest or malignant arrhythmia have severe CAD
(350). Therefore, coronary arteriography is warranted to
establish as precise a diagnosis as possible as well as to
establish revascularization options (see Section IV).
III. RISK STRATIFICATION
A. Clinical Assessment
Prognosis of CAD for Death or Nonfatal MI: General
Considerations
Coronary artery disease is a chronic disorder with a
natural history that spans multiple decades. In each affected
person, the disease typically cycles in and out of clinically
defined phases: asymptomatic, stable angina, progressive
angina and unstable angina or acute MI. Although the
specific approach to risk stratification of the coronary
disease patient can vary according to the phase of the disease
in which the patient presents, some general concepts apply
across the spectrum of disease.
The patient’s risk is usually a function of four types of
patient characteristic. The strongest predictor of long-term
survival with CAD is the functioning of the LV. Ejection
fraction is the most commonly used measure of the extent of
LV dysfunction. A second patient characteristic is the
anatomic extent and severity of atherosclerotic involvement
of the coronary tree. The number of diseased vessels is the
most common measure of this characteristic. A third char-
acteristic provides evidence of a recent coronary plaque
rupture, indicating a substantially increased short-term risk
for cardiac death or nonfatal MI. Worsening clinical symp-
toms with unstable features is the major clinical marker of a
plaque event. The fourth patient characteristic is general
health and noncoronary comorbidity.
The probability that a given patient will progress to a
higher or lower risk disease state depends primarily on
factors related to the aggressiveness of the underlying
atherosclerotic process. Patients with major cardiac risk
factors, including smoking, hypercholesterolemia, diabetes
mellitus and hypertension, are most likely to have progres-
sive atherosclerosis with repeated coronary plaque events.
Patients presenting at a younger age also may have more
aggressive disease.
A growing body of pathologic, angiographic, angioscopic
and intravascular ultrasonographic data support a patho-
physiologic model in which most major cardiac events are
initiated by microscopic ulcerations of vulnerable athero-
sclerotic plaques. Several lines of evidence have shown that
the majority of vulnerable plaques appear “angiographically
insignificant” before their rupture (,75% diameter steno-
sis). In contrast, most of the “significant” plaques (.75%
stenosis) visualized at angiography are at low risk for plaque
rupture. Thus, the ability of stress testing of any type to
detect vulnerable atherosclerotic lesions may be limited by
the smaller size and lesser effect on coronary blood flow of
these plaques and may explain the occasional acute coronary
event that occurs shortly after a negative treadmill test
result.
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Risk Stratification With Clinical Parameters
Rigorous evidence for predictors of severe CAD (three-
vessel and left main disease) derived solely from the history
and physical examination in patients with chest pain is
surprisingly limited. Presumably, this is because physicians
routinely incorporate additional information (e.g., an ECG)
into risk stratification.
Nevertheless, very useful information relevant to progno-
sis can be obtained from the history. This includes demo-
graphics such as age and gender as well as a medical history
focusing on hypertension, diabetes, hypercholesterolemia,
smoking, peripheral vascular or arterial disease and previous
MI. As previously discussed, the description of the patient’s
chest discomfort can usually be easily assigned to one of
three categories: typical angina, atypical angina and nonan-
ginal chest pain (38).
The physical examination may also aid in risk stratifica-
tion by determining the presence or absence of signs and
symptoms that might alter the probability of severe CAD.
Useful findings include those suggesting vascular disease
(abnormal fundi, decreased peripheral pulses, bruits), long-
standing hypertension (blood pressure, abnormal fundi),
aortic valve stenosis or idiopathic hypertrophic subaortic
stenosis (systolic murmur, abnormal carotid pulse, abnormal
apical pulse), left-heart failure (third heart sound, displaced
apical impulse, bibasilar rales), and right-heart failure (jug-
ular venous distension, hepatomegaly, ascites, pedal edema).
Several studies have examined the value of clinical pa-
rameters for identifying the presence of severe (three-vessel
or left main) CAD. Pryor et al. (134) identified 11 clinical
characteristics that are important in estimating the likeli-
hood of severe CAD: typical angina, previous MI, age,
gender, duration of chest pain symptoms, risk factors
(hypertension, diabetes, hyperlipidemia, smoking), carotid
bruit and chest pain frequency. In a subsequent study, Pryor
et al. (41) provided detailed equations for the prediction of
both severe CAD and survival based on clinical parameters.
Hubbard et al. (351) identified five clinical parameters
that were independently predictive of severe (three-vessel or
left main) CAD: age, typical angina, diabetes, gender and
prior MI (history or ECG). Hubbard then developed a
five-point cardiac risk score. A composite graph (Fig. 7)
estimates the probability of severe CAD. Each curve shows
the probability of severe CAD as a function of age for a
given cardiac risk score. As shown on this graph, some
patients have a high likelihood (.1 chance in 2) of severe
disease on the basis of clinical parameters alone. Such
patients should be considered for direct referral to angiog-
raphy, as noninvasive testing is highly unlikely to be normal
and, if it is, may conceivably be false-negative. An example
would be a 50-year-old male patient with diabetes, taking
insulin, with typical angina and history and ECG evidence
of previous MI. His estimated likelihood of severe disease is
60%; such a patient should be considered for angiography
without further testing.
Descriptive information about the chest pain is very
important in assessment of patient prognosis as well as risk
of severe CAD. However, because the extent and location of
angiographically demonstrated occlusion, together with the
degree of LV dysfunction, appear to have substantially
greater prognostic power than symptom severity (96,352),
many clinicians have come to rely almost exclusively on
these “objective” measurements of disease and very little on
the patient’s history in choosing among the alternative
management strategies for their patients. However, clinical
parameters should not be ignored for risk stratification
(41,353,354).
Califf et al. (95) have provided evidence that the aggre-
gation of certain historical and ECG variables in an “angina
score” offers prognostic information that is independent of
and incremental to that detected by catheterization. The
angina score was composed of three differentially weighted
variables: the “anginal course,” anginal frequency, and rest
ECG ST-T wave abnormalities. Two features of the prog-
nostic power of the angina score seem intuitively correct: 1)
it had a greater impact on short-term prognosis than
long-term prognosis, presumably reflecting the importance
of a plaque rupture; and 2) it had greater prognostic value
when the LV was normal than when it was abnormal,
presumably because so much of the overall prognosis was
determined by LV function when it was abnormal.
Peripheral vascular disease is another clinical parameter
that is useful in stratifying risk. The presence of a carotid
bruit, like male gender and previous MI, nearly doubles the
risk for severe CAD (134). In addition to peripheral vascular
disease, signs and symptoms related to congestive heart
failure (CHF), which reflect LV function, convey an adverse
prognosis.
All the studies evaluating clinical characteristics as pre-
dictors of severe CAD use only patients referred for further
Figure 7. Nomogram showing the probability of severe (three-
vessel or left main) coronary disease based on a five-point score.
One point is awarded for each of the following variables: male
gender, typical angina, history and electrocardiographic evidence
of myocardial infarction, diabetes and use of insulin. Each curve
shows the probability of severe coronary disease as a function of
age. From Hubbard et al. (135), with permission.
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evaluation of chest pain and cardiac catheterization. Al-
though it does not undercut internal validity, this bias in the
assembly of a cohort severely limits the generalizability
(external validity) of study findings to all patients with
CAD. However, it is likely that the overall “risk” of an
unselected population is lower, so that patients described as
“low risk” by these findings are still likely to be low risk.
Risk stratification of patients with stable angina using
clinical parameters may facilitate the development of clearer
indications of referral for exercise testing and cardiac cath-
eterization. Long-term follow-up data from the CASS
Registry (352) showed that 72% of the deaths occurred in
the 38% of the population that had either LV dysfunction or
severe coronary disease. The prognosis of patients with a
normal ECG (which implies normal LV function at rest)
and a low clinical risk for severe CAD is therefore excellent.
Pryor et al. (41) showed that 37% of outpatients referred for
noninvasive testing met the criteria for low risk. Fewer than
1% of these patients had left main artery disease or died
within three years. The value of additional testing for risk
stratification in such patients is modest. Lower-cost options
such as treadmill testing should therefore be used whenever
possible, and only the most abnormal results (described in
Section III.2) should be referred to angiography.
B. ECG/Chest X-Ray
Patients with chronic stable angina who have rest ECG
abnormalities are at greater risk than those with normal
ECGs (355). Evidence of $1 prior MI on ECG indicates
an increased risk for cardiac events. In fact, the presence of
Q waves in multiple ECG leads, often accompanied by an
R wave in lead V1 (posterior infarction), is frequently
associated with a markedly reduced LV ejection fraction, an
important determinant of the natural history of patients
with suspected atherosclerotic CHD (356). A “QRS score”
has been used to indicate the extent of old or new MI (357),
with the higher scores being associated with lower LV
ejection fractions and a poorer long-term prognosis. The
presence of persistent ST-T wave inversions, particularly in
leads V1 to V3 of the rest ECG, is associated with an
increased likelihood of future acute coronary events and a
poor prognosis (358–361). A decreased prognosis for pa-
tients with angina pectoris is also likely when the ECG
shows left bundle-branch block, bifascicular block (often left
anterior fascicular block plus right bundle-branch block),
second- or third-degree atrioventricular block, atrial fibril-
lation or ventricular tachyarrhythmias (362). The presence
of LV hypertrophy by ECG criteria in a patient with angina
pectoris is also associated with increased morbidity and
mortality (361,363).
On the chest roentgenogram, the presence of cardiomeg-
aly, an LV aneurysm or pulmonary venous congestion is
associated with a poorer long-term prognosis than that
which occurs in patients with a normal chest X-ray result.
The presence of left atrial enlargement, indicating a higher
likelihood of pulmonary venous congestion or mitral regur-
gitation, is also a negative prognostic factor.
As indicated previously, the presence of calcium in the
coronary arteries on chest X-ray or fluoroscopy in patients
with symptomatic CAD suggests an increased risk of
cardiac events (364). The presence and amount of coronary
artery calcification by EBCT also correlates to some extent
with the severity of CAD, but there is considerable patient
variation.
C. Noninvasive Testing
1. Resting LV Function
(Echocardiographic/Radionuclide Imaging)
Recommendations for Measurement of Rest LV
Function by Echocardiography or Radionuclide
Angiography in Patients With Chronic Stable Angina
Class I
1. Echocardiography or radionuclide angiography
(RNA) in patients with a history of prior MI,
pathologic Q waves or symptoms or signs sugges-
tive of heart failure to assess LV function. (Level of
Evidence: B)
2. Echocardiography in patients with a systolic mur-
mur suggesting mitral regurgitation to assess its
severity and etiology. (Level of Evidence: C)
3. Echocardiography or RNA in patients with com-
plex ventricular arrhythmias to assess LV function.
(Level of Evidence: B)
Class III
1. Routine periodic reassessment of stable patients for
whom no new change in therapy is contemplated.
(Level of Evidence: C)
2. Patients with a normal ECG, no history of MI and
no symptoms or signs suggestive of CHF. (Level of
Evidence: B)
Importance of Assessing LV Function
Most patients undergoing a diagnostic evaluation for
angina do not need an echocardiogram. However, in the
chronic stable angina patient who has a history of docu-
mented MI or Q waves on ECG, measurement of global
LV systolic function (e.g., ejection fraction) may be impor-
tant in choosing appropriate medical or surgical therapy and
making recommendations about activity level, rehabilitation
and work status (13,365). Similarly, in patients who, in
addition to chronic stable angina, have clinical signs or
symptoms of heart failure, cardiac imaging may be helpful in
establishing pathophysiologic mechanisms and guiding
therapy. For example, a patient with heart failure might
have predominantly systolic LV dysfunction, predominantly
diastolic dysfunction, mitral or aortic valve disease, some
combination of these abnormalities or a noncardiac cause
for symptoms. The best treatment of the patient can be
planned more rationally knowing the status of LV systolic
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and diastolic function (by echocardiography or radionuclide
imaging), valvular function, and pulmonary artery pressure
(by transthoracic echo-Doppler techniques).
Assessment of Global LV Function
Left ventricular global systolic function and volumes have
been well documented to be important predictors of prog-
nosis in patients with cardiac disease. In patients with
chronic ischemic heart disease, LV ejection fraction mea-
sured at rest by either echocardiography (352) or RNA
(96,352,365) is predictive of long-term prognosis; as LV
ejection fraction declines, mortality increases (352). A rest
ejection fraction of ,35% is associated with an annual
mortality rate .3% per year.
Current echocardiographic techniques permit a compre-
hensive assessment of LV size and function (366,367).
Two-dimensional echocardiographic LV ejection fraction
may be measured quantitatively or reported qualitatively (by
visual estimation) as increased; normal; or mildly, moder-
ately, or severely reduced. When performed by skilled
observers, visual estimation has been reported to yield
ejection fractions that correspond closely to those obtained
by angiography (368) or gated blood pool scanning (369). In
addition to measures of LV systolic function, echo-Doppler
characteristics of the pulsed Doppler transmitral velocity
pattern can help assess diastolic function (370), although its
independent prognostic value has not been established.
Left ventricular mass and wall thickness-to-chamber
radius ratio, as measured from echocardiographic images,
have both been shown to be independent of cardiovascular
morbidity and mortality (371–373). The LV mass can be
measured from two-dimensional or two-dimensionally di-
rected M-mode echocardiographic images.
Radionuclide ejection fraction may be measured at rest
using a gamma camera, a 99mTc tracer, and first-pass or
gated equilibrium blood pool angiography (13) or gated
SPECT perfusion imaging (257). Diastolic function can
also be assessed by radionuclide ventriculography (374,375).
It should be noted that LV ejection fraction and other
indexes of myocardial contractile performance are limited by
their dependence on loading conditions and heart rate
(146,376).
Although magnetic resonance imaging is less widely
disseminated, it may also be used to assess LV performance,
including ejection fraction (377).
LV Segmental Wall Motion Abnormalities
In patients with chronic stable angina and a history of
previous MI, segmental wall motion abnormalities can be
seen not only in the zone(s) of prior infarction but also in
areas with ischemic “stunning” or “hibernation” of myocar-
dium that is nonfunctional but still viable (143,148,151,378–
380). The sum of these segmental abnormalities reflects total
ventricular functional impairment, which may overestimate
true anatomic infarct size or radionuclide perfusion defect
(380). Thus, echocardiographically derived infarct size (143)
correlates only modestly with 201Tl perfusion defects (151),
peak creatine kinase levels (148,381), hemodynamic changes
(143) and pathologic findings (379). However, it does predict
the development of early (382) and late (383) complications
and mortality (143,384).
As mentioned previously (Sections II.C.3 and II.C.4),
recent developments in both echocardiography (tissue har-
monic imaging and intravenous contrast agents to assess the
endocardium) and myocardial perfusion imaging (gated
SPECT imaging to assess global and regional function)
should improve the ability of both techniques to assess LV
function.
Ischemic Mitral Regurgitation, LV Aneurysm, and LV
Thrombosis
In patients with chronic ischemic heart disease, mitral
regurgitation may result from global LV systolic dysfunction
(161), regional papillary muscle dysfunction (162), scarring
and shortening of the submitral chords (163), papillary
muscle rupture (164), or other causes. The presence, severity
and mechanism of mitral regurgitation can be reliably
detected by transthoracic imaging and Doppler echocardio-
graphic techniques (13). Potential surgical approaches also
can be defined. In addition, chronic stable angina patients
who have ischemic mitral regurgitation have a worse prog-
nosis than those without regurgitation.
In patients with chronic angina and concomitant heart
failure or significant ventricular arrhythmias, the presence or
absence of ventricular aneurysm can generally be established
by transthoracic echocardiography (385,386). When an
aneurysm is demonstrated, the function of the nonaneurys-
mal portion of the left ventricle is an important consider-
ation in choosing medical or surgical therapy (387).
Echocardiography is the definitive test for detecting
intracardiac thrombi (388–394). The LV thrombi are most
common in stable angina pectoris patients who have signif-
icant LV wall motion abnormalities.
In patients with anterior and apical infarctions (388,392–
394), the presence of LV thrombi denotes an increased risk
of both embolism (389) and death (391). In addition, the
structural appearance of a thrombus, which can be defined
by transthoracic (or transesophageal) echocardiography, has
some prognostic significance. Sessile, laminar thrombi rep-
resent less of a potential embolic risk than do pedunculated
and mobile thrombi (13).
2. Exercise Testing for Risk Stratification and
Prognosis
Recommendations for Risk Assessment and Prognosis
in Patients With an Intermediate or High Probability
of CAD
Class I
1. Patients undergoing initial evaluation. (Exceptions
are listed below in classes IIb and III.) (Level of
Evidence: B)
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2. Patients after a significant change in cardiac symp-
toms. (Level of Evidence: C)
Class IIb
1. Patients with the following ECG abnormalities:
a. Preexcitation (Wolff-Parkinson-White)
syndrome. (Level of Evidence: B)
b. Electronically paced ventricular rhythm.
(Level of Evidence: B)
c. More than 1 mm of ST depression at rest.
(Level of Evidence: B)
d. Complete left bundle-branch block. (Level
of Evidence: B)
2. Patients who have undergone cardiac catheteriza-
tion to identify ischemia in the distribution of a
coronary lesion of borderline severity. (Level of
Evidence: C)
3. Postrevascularization patients who have a signifi-
cant change in anginal pattern suggestive of isch-
emia. (Level of Evidence: C)
Class III
Patients with severe comorbidity likely to limit life
expectancy or prevent revascularization. (Level of
Evidence: C)
Risk Stratification for Death or MI: General
Considerations
Risk stratification with the exercise test does not take
place in isolation but as part of a process that includes other
data from the clinical examination and other laboratory
tests. Thus, the value of exercise testing for risk stratification
must be considered in light of what is added to what is
already known about the patient’s risk status. Most research
on exercise testing has concentrated on its relationship with
future survival and, to a lesser extent, freedom from MI.
The summary presented here is based on the “ACC/AHA
Guidelines for Exercise Testing” (14).
Risk Stratification With the Exercise Test
The risk of exercise testing in appropriately selected
candidates is extremely low, and thus the main argument for
not performing an exercise test is that the extra information
provided would not be worth the extra cost of obtaining that
information or the test might provide misinformation that
could lead to inappropriate testing or therapy.
Unless cardiac catheterization is indicated, symptomatic
patients with suspected or known CAD should usually
undergo exercise testing to assess the risk of future cardiac
events unless they have confounding features on the rest
ECG. Furthermore, documentation of exercise-induced
ischemia is desirable for most patients who are being
evaluated for revascularization (72,395).
The choice of initial stress test should be based on the
patient’s rest ECG, physical ability to perform exercise, local
expertise and available technologies. Patients with a normal
rest ECG constitute a large and important subgroup. Most
patients who present with angina for the first time have a
normal rest ECG (49). Such patients are very likely (92% to
96%) to have normal LV function (141,142,396) and
therefore an excellent prognosis (49). The exercise ECG has
a higher specificity in the absence of rest ST-T changes, LV
hypertrophy and digoxin.
Several studies have examined the incremental value of
exercise imaging procedures compared with the exercise
ECG in patients with a normal rest ECG who are not
taking digoxin (Table 19). In analyses (397,398) that
included clinical and exercise ECG parameters for the
prediction of left main or three-vessel disease, the modest
benefit of imaging does not appear to justify its cost, which
has been estimated at $20,550 per additional patient cor-
rectly classified (397). For the prediction of subsequent
cardiac events, four separate analyses have failed to demon-
strate incremental value. Mattera et al. (399) did find some
incremental value, but only for the prediction of hard and
soft events (including unstable angina) and only if the
exercise ECG was abnormal. They still favored a stepwise
strategy that used the exercise ECG as the initial test, like
that proposed by others (83,400).
For these reasons, the committee favored a stepwise
strategy in which the exercise ECG, and not stress imaging
procedures, is performed as the initial test in patients who
are not taking digoxin, have a normal rest ECG, and are
able to exercise. In contrast, a stress-imaging technique
should be used for patients with widespread rest ST depres-
sion (.1 mm), complete left bundle-branch block, ventric-
ular paced rhythm or preexcitation. Although exercise
capacity can be assessed in such patients, exercise-induced
ischemia cannot. Patients unable to exercise due to physical
limitations such as reduced exercise capacity, arthritis, am-
putations, severe peripheral vascular disease or severe
chronic obstructive pulmonary disease should undergo phar-
macologic stress testing in combination with imaging.
The primary evidence that exercise testing can be used to
estimate prognosis and assist in management decisions
consists of seven observational studies (354,355,401–405).
One of the strongest and most consistent prognostic mark-
ers is maximum exercise capacity. This measure is at least
partly influenced by the extent of rest LV dysfunction and
the amount of further LV dysfunction induced by exercise.
However, the relationship between exercise capacity and LV
function is complex, because exercise capacity is also affected
by age, general physical conditioning, comorbidities and
psychological state, especially depression (406). Exercise
capacity is measured by maximum exercise duration, maxi-
mum MET level achieved, maximum workload achieved,
maximum heart rate and double product. The specific
variable used to measure exercise capacity is less important
than including exercise capacity in the assessment. The
translation of exercise duration or workload into METs
provides a standard measure of performance regardless of
the type of exercise test or protocol used.
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A second group of prognostic markers is related to
exercise-induced ischemia. The ST-segment depression and
elevation (in leads without pathological Q waves and not in
aVR) best summarize the prognostic information related to
ischemia (401). Other variables are less powerful, including
angina, the number of leads with ST-segment depression,
the configuration of the ST depression (downsloping, hor-
izontal or upsloping), and the duration of ST deviation into
the recovery phase.
The Duke treadmill score combines this information and
provides a way to calculate risk (37,401). The Duke tread-
mill score equals the exercise time in minutes minus (53 the
ST-segment deviation, during or after exercise, in millime-
ters) minus (43 the angina index, which has a value of “0”
if there is no angina, “1” if angina occurs, and “2” if angina
is the reason for stopping the test). Among outpatients with
suspected CAD, the two thirds of patients with scores
indicating low risk had a four-year survival rate of 99%
(average annual mortality rate 0.25%), and the 4% who had
scores indicating high risk had a four-year survival rate of
79% (average annual mortality rate 5%) (see Table 20). The
score works well for both inpatients and outpatients, and
preliminary data suggest that the score works equally well
for men and women (37,409,410). Only a small number of
elderly patients have been studied, however. Comparable
scores have been developed by others (402).
Because of its simplicity, lower cost and widespread
familiarity with its performance and interpretation, the
standard exercise test is the most reasonable one to select for
men with a normal rest ECG who are able to exercise. The
Table 19. Studies Examining the Incremental Value of Exercise Imaging Studies for the Prediction of Severe CAD and Subsequent
Cardiac Events in Patients With a Normal Resting ECG*
First
Author Ref
Imaging
Modality N
End point
(Follow-up)
Clinical Variables
Forced into
Models
Statistical
Significance Clinical Impact
Gibbons (398) RNA 391 3V/LM Yes p , 0.01 Correct classifications
increased slightly from
60 to 63%.
Christian (397) SPECT Tl-201 411 3V/LM Yes p 5 ns (ROC)
p 5 0.02 (relaxed)
Net correct classifications
increased slightly from
43% to 46%; cost per
additional correct
classification 5
$20,550
Nallamothu (407) SPECT Tl-201 321 3V/LM No p 5 0.0001 Correct classification not
analyzed
Simari (408) RNA 265 D/MI/Rev
(51 months)
Yes p 5 0.18 Excellent event-free
survival in patients
with negative ECG or
RNA
Ladenheim (400) Planar Tl-201 1,451 D/MI/Rev
(12 months)
Yes p 5 0.28 Stepwise testing reduced
cost by 64%
Christian (397) SPECT Tl-201 267 D/MI/Rev
(34 months)
Yes p 5 ns Overall 4-year infarct-
free survival was
excellent at 95%
Mattera (399) SPECT Tl-201
or sestamibi
313 D/MI
(12 months)
No p 5 ns Only 1 hard event
Mattera (399) SPECT Tl-201
or sestamibi
313 D/MI/Rev/UA
(12 months)
No* p 5 ns
(Nl ECG vs.
Nl MPI)
p 5 0.04
(Abn ECG vs.
Abn MPI)
Stepwise testing (using
clinical variables)
reduced cost by 38%
ROC indicates receiver operator characteristic curve analysis; D 5 death; MI 5 myocardial infarction; Rev 5 revascularization (after 3 months, except for Mattera); UA 5
unstable angina; MPI 5 myocardial perfusion imaging. Patients taking digoxin were excluded from all studies except Ladenheim, where they were included if the ECG was
interpreted as normal.
*Not included in statistical model, but considered in stepwise strategy.
Table 20. Survival According to Risk Groups Based on Duke
Treadmill Scores
Risk Group (Score)
Percentage
of Total
Four-
Year
Survival
Annual
Mortality
(Percent)
Low ($ 15) 62 0.99 0.25
Moderate (210 to 14) 34 0.95 1.25
High (, 210) 4 0.79 5.0
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optimal testing strategy remains less well defined in women.
Until adequate data are available to resolve this issue, it is
reasonable to use exercise testing for risk stratification in
women.
Use of Exercise Test Results in Patient Management
The results of exercise testing may be used to titrate
medical therapy to the desired level of effectiveness. For
example, a normal heart rate response to exercise suggests
that the dose of beta-blocker should be increased. Testing
for this purpose should generally be performed with the
patient on medication. The other major management step
addressed by the exercise test is whether to proceed with
additional testing, which might lead to revascularization.
Proceeding with additional testing usually involves imag-
ing. Although both stress echocardiography and stress
SPECT perfusion imaging have been used after exercise
testing, only SPECT perfusion imaging has been studied in
patients divided into risk groups based on the Duke tread-
mill score (410). In patients with an intermediate-risk
treadmill score, imaging appears to be useful for further risk
stratification. In patients with a high-risk treadmill score,
imaging may identify enough low-risk patients who can
avoid cardiac catheterization to justify the cost of routine
imaging, but further study is required. Few patients (,5%)
who have a low-risk treadmill score will be identified as high
risk after imaging, and thus the cost of identifying these
patients argues against routine imaging (410).
Patients with a predicted average annual cardiac mortality
rate of #1% per year (low-risk score) can be managed
medically without the need for cardiac catheterization.
Patients with a predicted average annual cardiac mortality
rate $3% per year (high-risk score) should be referred for
cardiac catheterization. Patients with a predicted average
annual cardiac mortality rate of 1% to 3% per year
(intermediate-risk score) should have either cardiac cathe-
terization or an exercise imaging study. Those with known
LV dysfunction should have cardiac catheterization.
Recommendation for Exercise Testing in Patients
With Chest Pain >6 Months After Revascularization
Class IIb
Patients with a significant change in anginal pat-
tern suggestive of ischemia. (Level of Evidence: B)
Rationale
There are two postrevascularization phases. In the early
phase, the goal of exercise testing is to determine the
immediate result of revascularization. In the late phase,
which begins six months after revascularization and is the
focus of this discussion, the goal is to assist in the evaluation
and management of patients with chronic established CAD.
Exercise testing also may be helpful in guiding a cardiac
rehabilitation program and return-to-work decisions.
Exercise Testing After CABG
Exercise testing distinguishes cardiac from noncardiac
causes of chest pain, which is often atypical after surgery.
After CABG, the exercise ECG has a number of limita-
tions. Rest ECG abnormalities are frequent, and if an
imaging test is not incorporated into the study, more
attention must be paid to symptom status, hemodynamic
response, and exercise capacity. Because of these consider-
ations and the need to document the site of ischemia, stress
imaging tests are preferred for evaluating patients in this
group.
Exercise Testing After PTCA
Similar considerations apply to angioplasty patients. Re-
stenosis is more frequent, however. Although most resten-
osis occurs ,6 months after angioplasty, when these rec-
ommendations do not apply, restenosis does occur later.
The exercise ECG is an insensitive predictor of restenosis,
with sensitivities ranging from 40% to 55%, which are
significantly less than those with SPECT (12,411) or
exercise echocardiography (13,412). Because of these con-
siderations and the need to document the site of ischemia,
stress imaging tests are preferred for evaluating symptomatic
patients in this group.
Some authorities advocate routine testing for all patients
in the late phase after PTCA with either exercise ECGs or
stress imaging, as restenosis commonly induces silent isch-
emia. The rationale for this approach is that ischemia,
whether painful or silent, worsens prognosis (413,414). This
approach seems particularly attractive for high-risk patients,
for example, those with decreased LV function, multivessel
CAD, proximal left anterior descending artery disease,
previous sudden death, diabetes mellitus, hazardous occu-
pations and suboptimal PTCA results. If routine testing is
done, there are insufficient data to justify a particular
frequency of testing after angioplasty. The alternative ap-
proach, which the committee labeled class IIb because the
prognostic benefit of controlling silent ischemia needs to be
proved, is to selectively evaluate only patients with a
significant change in anginal pattern.
3. Stress Imaging Studies (Radionuclide and
Echocardiography)
Recommendations for Cardiac Stress Imaging as the
Initial Test for Risk Stratification of Patients With
Chronic Stable Angina Who Are Able to Exercise
Class I
1. Exercise myocardial perfusion imaging or exercise
echocardiography to identify the extent, severity
and location of ischemia in patients who do not
have left bundle-branch block or an electronically
paced ventricular rhythm and have either an abnor-
mal rest ECG or are using digoxin. (Level of
Evidence: B)
2127JACC Vol. 33, No. 7, 1999 Gibbons et al.
June 1999:2092–197 ACC/AHA/ACP-ASIM Chronic Stable Angina Guidelines
2. Dipyridamole or adenosine myocardial perfusion
imaging in patients with left bundle-branch block
or electronically paced ventricular rhythm. (Level of
Evidence: B)
3. Exercise myocardial perfusion imaging or exercise
echocardiography to assess the functional signifi-
cance of coronary lesions (if not already known) in
planning PTCA. (Level of Evidence: B)
Class IIb
1. Exercise or dobutamine echocardiography in pa-
tients with left bundle-branch block. (Level of Ev-
idence: C)
2. Exercise, dipyridamole, adenosine myocardial per-
fusion imaging or exercise or dobutamine echocar-
diography as the initial test in patients who have a
normal rest ECG and who are not taking digoxin.
(Level of Evidence: B)
Class III
1. Exercise myocardial perfusion imaging in patients
with left bundle-branch block. (Level of Evidence:
C)
2. Exercise, dipyridamole, adenosine myocardial per-
fusion imaging or exercise or dobutamine echocar-
diography in patients with severe comorbidity likely
to limit life expectation or prevent revasculariza-
tion. (Level of Evidence: C)
Recommendations for Cardiac Stress Imaging as the
Initial Test for Risk Stratification of Patients With
Chronic Stable Angina Who Are Unable to Exercise
Class I
1. Dipyridamole or adenosine myocardial perfusion
imaging or dobutamine echocardiography to iden-
tify the extent, severity and location of ischemia in
patients who do not have left bundle-branch block
or electronically paced ventricular rhythm. (Level of
Evidence: B)
2. Dipyridamole or adenosine myocardial perfusion
imaging in patients with left bundle-branch block
or electronically paced ventricular rhythm. (Level of
Evidence: B)
3. Dipyridamole or adenosine myocardial perfusion
imaging or dobutamine echocardiography to assess
the functional significance of coronary lesions (if
not already known) in planning PTCA. (Level of
Evidence: B)
Class IIb
Dobutamine echocardiography in patients with left
bundle-branch block. (Level of Evidence: C)
Class III
Dipyridamole or adenosine myocardial perfusion
imaging or dobutamine echocardiography in pa-
tients with severe comorbidity likely to limit life
expectation or prevent revascularization. (Level of
Evidence: C)
Available Stress Imaging Approaches
Stress imaging studies in which radionuclide myocardial
perfusion imaging techniques or two-dimensional echocar-
diography at rest and during stress are useful for risk
stratification and determination of the most beneficial
management strategy for patients with chronic stable angina
(415–417). Whenever possible, treadmill or bicycle exercise
should be used as the most appropriate form of stress
because it provides the most information concerning patient
symptoms, cardiovascular function and hemodynamic re-
sponse during usual forms of activity (14). In fact, the
inability to perform a bicycle or exercise treadmill test is in
itself a negative prognostic factor for patients with chronic
CAD.
In patients who cannot perform an adequate amount of
bicycle or treadmill exercise, various types of pharmacologic
stress are useful for risk stratification (12,13,217,418). The
selection of the type of pharmacologic stress will depend on
specific patient factors such as the patient’s heart rate and
blood pressure, the presence or absence of bronchospastic
disease, the presence of left bundle-branch block or a
pacemaker and the likelihood of ventricular arrhythmias.
Pharmacologic agents are often used to increase cardiac
workload as a substitute for treadmill or bicycle exercise or to
cause an increase in overall coronary blood flow (224,225). For
the former effect, adrenergic-stimulating drugs (such as dobut-
amine or arbutamine) are usually used, and for the latter effect,
vasodilating agents (such as dipyridamole or adenosine) are
generally used (12,13,217,224,225,418) (see Section II.C.4).
Radionuclide imaging has played a major role in risk
stratification of patients with CAD. Either planar (three
conventional views) or SPECT (multiple tomographic slices
in three planes) imaging with 201Tl or 99mTc perfusion
tracers with images obtained at stress and during rest
provide important information about the severity of func-
tionally significant CAD (180 –188,191,192,199,204,
205,419).
More recently, stress echocardiography has been used for
assessing patients with chronic stable angina; thus, the
amount of prognostic data obtained with this approach is
somewhat limited. Nevertheless, the presence or absence of
inducible myocardial wall motion abnormalities has useful
predictive value in patients undergoing exercise or pharma-
cologic stress echocardiography. A negative stress echocar-
diography study denotes a low cardiovascular event rate
during follow-up (420–428).
Important Findings on Stress Perfusion Studies for Risk
Stratification
Normal poststress thallium scan results are highly predic-
tive of a benign prognosis even in patients with known
coronary disease (12). A collation of 16 studies involving
3,594 patients followed up for a mean of 29 months
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indicated a rate of cardiac death and MI of 0.9% per year
(429), nearly as low as that of the general population (430).
In a recent prospective study of 5,183 consecutive patients
who underwent myocardial perfusion studies during stress
and later at rest, patients with normal scans were at low risk
(,0.5% per year) for cardiac death and MI during 642 6
226 days of mean follow-up, and rates of both outcomes
increased significantly with worsening scan abnormalities
(431). The presence of a normal stress myocardial perfusion
scan indicates such a low likelihood of significant CAD that
coronary arteriography is usually not indicated as a subse-
quent test. Although the published data are limited, the
single exception would appear to be patients with high-risk
treadmill scores and normal images (431).
The number, extent, and site of abnormalities on stress
myocardial perfusion scintigrams reflect the location and
severity of functionally significant coronary artery stenoses.
Lung uptake of 201Tl on postexercise or pharmacologic
stress images is an indicator of stress-induced global LV
dysfunction and is associated with pulmonary venous hy-
pertension in the presence of multivessel CAD (432–435).
Transient poststress ischemic LV dilation also correlates
with severe two- or three-vessel CAD (436–439). Several
studies have suggested that SPECT may be more accurate
than planar imaging for determining the size of defects,
detecting coronary and particularly left circumflex CAD and
localizing abnormalities in the distribution of individual
coronary arteries (180,204,419). However, more false-
positive results are likely to result from photon attenuation
during SPECT imaging (12).
The number, size, and location of perfusion abnormal-
ities, the amount of lung uptake of 201Tl on poststress
images, and the presence or absence of poststress isch-
emic LV dilation can be combined to maximize the
recognition of high-risk patients, including those with
multivessel disease, left main CAD and disease of the
proximal portion of the left anterior descending coronary
artery (LAD). Incremental prognostic information from
the results of stress myocardial perfusion imaging can
determine the likelihood of subsequent important cardiac
events. The number of transient perfusion defects,
whether provoked by exercise or pharmacologic stress, is
a reliable predictor of subsequent cardiac death or non-
fatal MI (180,419,440 – 447). The number of stenotic
coronary arteries may be less predictive than the number
of reversible perfusion defects (440 – 450). The magni-
tude of the perfusion abnormality was the single most
prognostic indicator in a study that demonstrated inde-
pendent and incremental prognostic information from
SPECT 201Tl scintigraphy compared with that obtained
from clinical, exercise treadmill and catheterization data
(451). As indicated previously, increased lung uptake of
thallium induced by exercise or pharmacologic stress is
associated with a high risk for cardiac events (12,452).
Information concerning both myocardial perfusion and
ventricular function at rest may be helpful in determining
the extent and severity of coronary disease (181,183,453).
This combined information can be obtained by performing
two separate exercise tests (e.g., stress perfusion scintigraphy
and stress RNA) or combining the studies after one exercise
test (e.g., first-pass RNA with 99mTc-based agents followed
by perfusion imaging or perfusion imaging using gating).
However, an additional benefit of the greater information
provided by combined myocardial perfusion and ventricular
function exercise testing has not been shown in clinical
outcome or prognostic studies (12). Thus, one determina-
tion of LV function at rest and one measure of exercise/
pharmacologic stress-induced myocardial perfusion or exer-
cise ventricular function, but not both, are appropriate (12).
The prognostic value of stress myocardial perfusion imaging
in chronic stable angina is summarized in Table 21 (studies
with .100 patients, who did not have recent MI, and that
included both positive and negative perfusion images).
Application of Myocardial Perfusion Imaging to Specific
Patient Subsets
Patients With a Normal Rest ECG. Myocardial perfusion
imaging has little advantage over the less expensive treadmill
exercise test in this subset of patients. Three separate studies
(402,404,405) have demonstrated little (if any) incremental
value of myocardial perfusion imaging in the initial evalu-
ation of such patients. As mentioned previously (Section
III.2), many such patients will have low-risk treadmill scores
and will not require further evaluation.
Concomitant Use of Drugs. As mentioned previously (Sec-
tions II.2 and II.4), beta-blockers (and other anti-ischemic
drugs) should be withheld for four to five half-lives before
testing. However, even if these drugs are continued, most
high-risk patients will usually still be identified (14). Ni-
trates may also decrease the extent of perfusion defects or
even convert abnormal exercise scan results to normal results
(462).
Women, the Elderly, or Obese Patients. The treadmill
ECG test is less accurate for the diagnosis of CHD in
women who have a lower pretest likelihood than men (194).
However, the sensitivity of thallium perfusion scans may be
lower in women than men (194,245). Artifacts due to breast
attenuation, usually manifest in the anterior wall, can be an
important consideration in the interpretation of women’s
scans, especially when 201Tl is used as a tracer (12). As
mentioned previously, 99mTc sestamibi may be preferable to
201Tl scintigraphy for determining prognosis as well as
diagnosing CAD in women with large breasts or breast
implants (248).
Although many elderly patients can perform an exercise
test, some are unable to do so because of physical impair-
ment. Pharmacologic stress imaging is an appropriate op-
tion for risk stratification in such patients. Very obese
patients constitute a specific problem because most imaging
tables used for SPECT have weight-bearing limits (usually
300 to 450 lb) that preclude imaging very heavy subjects.
These subjects can still be imaged by planar scintigraphy
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(12). Obese patients often have suboptimal perfusion im-
ages, especially with thallium-201 because of the marked
photon attenuation by soft tissue. In these patients, tech-
netium sestamibi is probably the most appropriate and
should provide images of better quality than 201Tl.
Left Bundle-Branch Block. As mentioned previously (Sec-
tion II.4), pharmacologic stress perfusion imaging is pref-
erable to exercise perfusion imaging in patients with left
bundle-branch block. Recently, 245 patients with left
bundle-branch block underwent SPECT imaging with
201Tl (n 5 173) or 99mTc sestamibi (n 5 72) during
dipyridamole (n 5 153) or adenosine (n 5 92) stress testing
(463). Patients with a large, severe fixed defect, a large
reversible defect or cardiac enlargement and either increased
pulmonary uptake (thallium) or decreased ejection fraction
(sestamibi) (n 5 20) were classified as high-risk patients.
The rest were classified as low risk. The three-year overall
survival rate was 57% in the high-risk group compared with
87% in the low-risk group (p 5 0.001). Patients with a
low-risk scan had an overall survival rate that was not
Table 21. Prognostic Value of Stress Myocardial Imaging in Definite or Suspected Chronic Stable Angina
Author Test No.
Patient
Population
Avg
f/u
(mo.)
%
Abn
Test
Event
%
Pos.
Pred.
Value
%
Neg.
Pred.
Value
%
Relative
Risk Events
Ladenheim
1986 (441)
Tl-201
(planar)
ETT
1689 CAD
symptoms
12 50 4.4 7.5 98.7 10.6 Death, MI,
CABG
Pollock 1992
(454)
Tl-201
(planar)
ETT
501 Suspected
CAD
52.8 N/A 18.5 N/A N/A 2.2 Death or MI
Machecourt
1994 (455)
Tl-201
(SPECT)
ETT or
Dyp.
1929 Angina,
prior MI,
CABG,
PTCA
33 63 5.2 3.8 99.4 9.1 Death or MI
Marie 1995
(456)
Tl-201
(SPECT)
ETT
217 Suspected
CAD
70 N/A 13.47 N/A N/A 1.04 Death or MI
Kaul 1988
(444)
Tl-201
(planar)
ETT
299 Suspected
CAD
55.2 50 30 41.0 81.22 2.20 Death, MI
or CABG
Hachamovitch
1998 (431)
Tl-201 1
(SPECT)
sestamibi,
ETT, or
adenosine
5183 Suspected
CAD
21.4 43 5.3 5.3
(per
yr)
99.2
(per
yr)
6.5 Death or MI
Geleijnse
1996 (457)
Sestamibi
(SPECT)
dobutamine
392 CAD,
Suspected
CAD
22 67 11 16 98.5 14.5 Death or MI
Kamal 1994
(458)
Tl-201
(SPECT)
adenosine
177 CAD 22 83 8 9.5 100 ` Death or MI
Stratmann
1994 (459)
Sestamibi
(SPECT)
dipyrida-
mole
534 Suspected
CAD
13 66.5 11 15.4 98.3 8.4 Death or MI
Stratmann
1994 (460)
Sestamibi
(SPECT)
exercise
521 Stable
angina
13 60.5 4.6 7.3 99.5 13.8 Death or MI
Iskandrian
1988 (443)
Tl-201
(planar)
exercise
404 Suspected
CAD,
age .60
25 54.7 4 7.7 99.5 14.1 Death or MI
Iskandrian
1985 (461)
Tl-201
(planar)
exercise
743 Suspected
CAD
13 46 2.7 4.4 98.8 3.5 Death or MI
CAD indicates coronary artery disease; MI 5 myocardial infarction; ETT 5 exercise treadmill test; CABG 5 coronary artery bypass graft surgery; SPECT 5 single photon
emission computed tomography; Dyp 5 dipyridamole; PTCA 5 percutaneous transluminal coronary angioplasty.
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significantly different from that of the U.S.-matched pop-
ulation (p 5 0.86). The value of pharmacologic perfusion
imaging for prognostication was confirmed in three other
studies (464–466), which included .300 patients followed
for a mean of nearly three years. Normal dipyridamole or
adenosine scans were associated with a low cardiac event
rate; large defects and increased pulmonary uptake were
associated with a high cardiac event rate.
After Coronary Angiography. Myocardial perfusion imag-
ing is useful in planning revascularization procedures be-
cause it demonstrates whether a specific coronary stenosis is
associated with the stress-induced perfusion abnormality
(12). Myocardial perfusion imaging is particularly helpful in
determining the functional importance of single or multiple
stenoses when PTCA is targeted to the “culprit lesion,” that
is, the ischemia-provoking stenosis (12,463,467–469).
After Myocardial Revascularization. Myocardial perfusion
imaging can be useful in several situations after coronary
bypass surgery. In patients with ST-T wave abnormalities at
rest, recurrent myocardial ischemia during stress can be
better evaluated by exercise scintigraphy than ECG tread-
mill testing. In addition, approximately 30% have an abnor-
mal ECG response on treadmill exercise testing early after
bypass surgery (470); these patients can be assessed for
potential and incomplete revascularization and the extent of
myocardium affected. Patients with initial negative postop-
erative treadmill test results that later become positive
usually have progressive ischemia due to either graft closure
or progression of disease in the native circulation (471).
Myocardial perfusion scintigraphy can be useful in deter-
mining the location, extent and severity of such ischemia
(12). Its prognostic value has been demonstrated both early
(472) and late (473–475) after CABG.
After Exercise Testing. In patients who perform a treadmill
exercise test that is not associated with an adequate exercise
effort necessary to risk-stratify the patient appropriately, a
repeat exercise test with thallium scintigraphy or a myocar-
dial perfusion imaging test with pharmacologic stress may
give a better indication of the presence or absence of
high-risk coronary disease (14).
Important Findings on Stress Echocardiography for Risk
Stratification
Stress echocardiography is both sensitive and specific for
detecting inducible myocardial ischemia in patients with
chronic stable angina (13) (see Section II.C.4). Compared
with standard exercise treadmill testing, stress echocardiog-
raphy provides an additional clinical value for detecting and
localizing myocardial ischemia. The results of stress echo-
cardiography may provide important prognostic value. Sev-
eral studies indicate that patients at low, intermediate and
high risk for cardiac events can be stratified on the presence
or absence of inducible wall motion abnormalities on stress
echocardiography testing. A positive stress echocardio-
graphic study can be useful in determining the location and
severity of inducible ischemia, even in a patient with a high
pretest likelihood that disease is present. A negative stress
echocardiographic evaluation predicts a low risk for future
cardiovascular events (420–428).
However, the value of a negative study compared with a
negative thallium study must be further documented be-
cause there are less follow-up data compared with radionu-
clide imaging. Recently, McCully et al. (476) assessed the
outcomes of 1,325 patients who had normal exercise echo-
cardiograms with overall and cardiac event-free survival as
end points. Cardiac events included cardiac death, nonfatal
MI, and coronary revascularization. The event-free survival
rates were 99.2% at one year, 97.8% at two years, and 97.4%
at three years. Table 22 summarizes the prognostic value of
stress echocardiography from the literature (studies with
.100 patients who did not have recent MI and that
included both positive and negative echocardiograms). The
presence of ischemia on the exercise echocardiogram is
independent and incremental to clinical and exercise data in
predicting cardiac events in both men and women
(477,478).
The prognosis is not benign in patients with a positive
stress echocardiographic study. In this subset, morbid or
fatal cardiovascular events are more likely, but the overall
event rates are rather variable. Hence, the cost-effectiveness
of using routine stress echocardiographic testing to establish
prognosis is uncertain.
In general, patients with a positive ECG response to
treadmill stress testing but no inducible wall motion abnor-
mality on stress echocardiography have a very low rate of
adverse cardiovascular events during follow-up (13,420,421),
albeit higher than in patients with negative ECG results as
well. However, the number of patients followed up after
both stress ECG and stress echocardiography is relatively
small, and there has been no breakdown into groups with
various METs achieved during ECG treadmill testing and
with different risks according to the treadmill score (see
Section II.C.2).
In patients with a significant clinical suspicion of CAD,
stress echocardiography is appropriate for risk stratification
when standard exercise testing is likely to be suboptimal
(14). A variety of methods can be used to induce stress.
Treadmill stress echocardiography may have lowered sensi-
tivity if there is a significant delay from the end of exercise
to the acquisition of postexercise images. Dobutamine stress
echocardiography has substantially higher sensitivity than
vasodilator stress echocardiography for detecting coronary
stenoses (13,224,225,479). Sensitivity can also be dimin-
ished if all myocardial segments are not adequately visual-
ized.
Application of Stress Echocardiography to Specific Patient
Subsets
Women, the Elderly, and Obese Patients. There are some
recent data concerning the usefulness of stress echocardiog-
raphy in women compared with men. Two studies by
Marwick and associates (129,479) define the predictive
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value of exercise echocardiography as an independent pre-
dictor of cardiac events in women with known or suspected
CAD. Symptom-limited exercise echocardiography was
performed in 508 consecutive women (55 6 10 years)
between 1989 and 1993 (129), with a follow-up of 41 6 10
months. Cardiac events occurred in 7% of women, and
exercise echocardiography provided key prognostic informa-
tion incremental to clinical and exercise testing data with a
Cox proportional hazard model. In another group of
women, the specificity of exercise echocardiography for
indicating CAD and potential risk exceeded that of exercise
electrocardiography (80 6 3% vs. 64 1 3%, p 5 0.05) and
was a more cost-effective approach (129). Although these
data are promising, the committee thought that in most
women, ECG treadmill testing is still the first choice for
detecting high-risk inducible myocardial ischemia.
The echocardiographic window and the number of myo-
cardial segments detected during exercise or dobutamine
echocardiography are often suboptimal in very obese pa-
tients and many elderly patients who have chronic obstruc-
tive lung disease and a suboptimal echocardiographic win-
dow. As mentioned previously (Section II.C.3), tissue
harmonic imaging and contrast echocardiography should
improve detection of the endocardium.
Left Bundle-Branch Block. Like exercise myocardial per-
fusion imaging studies, the significance of stress-induced
echocardiography wall motion abnormalities in patients
with left bundle-branch block is unreliable (13). During
either exercise or dobutamine stimulation, abnormal con-
traction of the intraventricular septum has been a frequent
occurrence in patients with left bundle-branch block who do
not have underlying disease of the LAD.
After Coronary Angiography. Echocardiographic studies
may help in planning revascularization procedures by dem-
onstrating the functional significance of a given coronary
stenosis. This may be of particular value in determining the
need for PTCA, especially when the degree of angiographic
stenosis is of uncertain physiologic significance or when
multiple lesions are present (13).
After Revascularization. When symptoms persist or recur
$6 months after CABG, echocardiographic testing can be
useful. Abnormal baseline ECG findings after cardiac sur-
gery are common, and postbypass patients frequently have
abnormal ECG responses on standard treadmill testing.
When symptoms of ischemia suggest incomplete revascu-
larization, stress echocardiography studies may demonstrate
the location and severity of residual ischemia. When symp-
toms recur after initial relief and stress echocardiogram
Table 22. Prognostic Value of Stress Echocardiography in Definite or Suspected Coronary Heart Disease (Studies With n . 100,
Not Recent MI, Both Positive/Negative Echocardiograms)
Author Test No.
Patient
Population
Avg
f/u
(mo.)
%
Abn
Test
Event
%
Pos.
Pred.
Value
%
Neg.
Pred.
Value
%
Relative
Risk Events
Krivokapich
1993 (421)
TME 360 Suspected CAD 12 18 14 34 92 4.3 MI, death,
CABG or
PTCA
Severi 1994
(423)
DIP 429 Suspected CAD 38 63 35 N/A N/A 2.9 Death, MI,
revascularization
Coletta 1995
(424)
DIP 268 CAD 16 17 5 61 98 25.4 Death or MI
Kamaran 1995
(427)
DSE 210 Suspected CAD,
CAD
8 30 16 48 97 16 Death or MI
Williams 1996
(425)
DSE 108 CAD, LVEF,
,40%
16 43 26 66 90 3.51 Death, MI, late
revascularization
Marcovitz 1996
(428)
DSE 291 Suspected CAD,
CAD
15 70 11 15 98 7.5 Death or MI
Heupler 1997
(479)
TME 508 Women with
suspected
CAD
41 19 17 47 92 9.8 Death, MI or
revascularization
Marwick 1997 TME 463 Suspected 44 40 17 60 81 6.47* Death, MI, UA
(480) CAD, 3.05†
CAD
Chuah 1998
(481)
DSE 860 Suspected CAD,
CAD
24 31 10 14 96 3.5 Death or MI
f/u 5 follow-up; nl 5 no chest pain; TME 5 treadmill echocardiogram; MI 5 myocardial infarction; DIP 5 dipyridamole echocardiogram; SBE 5 supine bicycle ergometry;
CAD 5 known or suspected coronary artery disease; DSE 5 dobutamine stress echocardiogram; ECG 5 electrocardiogram; CP 5 chest pain (suspected coronary artery disease);
CHF 5 congestive heart failure; EF 5 ejection fraction. Events include cardiac death, myocardial infarction, revascularization (in some series), and unstable angina requiring
hospitalization (in some series).
*Echo ischemia. †Echo scar. Modified from reference (13) with permission.
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demonstrates inducible ischemia, either graft closure or the
development of new coronary artery obstructive lesions is
likely (482).
After Treadmill Exercise Testing. As with stress myocardial
perfusion imaging, stress echocardiography may provide
additional information in patients unable to perform appro-
priate exercise on the treadmill and in those who have an
intermediate risk determined by ECG criteria during exer-
cise testing (13).
D. Coronary Angiography and Left Ventriculography
The availability of potent but expensive strategies to
reduce the long-term risk of CAD mandates that the
patients most likely to benefit, namely those at increased
risk, be identified. This effort poses a significant challenge to
both the cardiovascular specialist and primary-care physi-
cian (41,134,333,483–486). It is important to recognize
that the science of risk prediction is only now evolving, and
in the case of coronary atherosclerosis methods of identify-
ing vulnerable plaques, the precursors of coronary events, are
lacking (41,134,333,485–487).
Assessment of cardiac risk and decisions regarding fur-
ther testing usually begin with simple, repeatable, and
inexpensive assessments of history and physical examination
and extend to noninvasive or invasive testing, depending on
outcome. Clinical risk factors are in general additive, and a
crude estimate of one-year mortality can be obtained from
these variables. An index has been developed that is the sum
of the age plus a score based on symptoms plus comorbidity
(diabetes, peripheral vascular disease, cerebrovascular dis-
ease, prior MI) (485). It is important to note that one-year
mortality rates of patients without severe comorbidity who
have stable, progressive and unstable angina are similar
(range 1.3% to 1.7%), showing the limited predictive value
of symptom severity alone (485). Patients with mild anginal
symptoms may have severe coronary disease (Fig. 6)
(41,333,485), which is detectable only with noninvasive or
invasive testing. LV dysfunction is a powerful determinant
of long-term survival in patients with chronic stable angina
pectoris (96,488). It may be inferred from extensive Q-wave
formation on ECG or history of CHF or measured nonin-
vasively by echocardiography, radionuclide techniques or
contrast angiography at the time of coronary angiography.
The coexistence of significant LV dysfunction and chronic
stable angina constitutes increased risk and warrants careful
further evaluation.
Risk stratification of patients with chronic stable angina
by stress testing with exercise or pharmacologic agents has
been shown to permit identification of groups of patients
with low, intermediate, or high risk of subsequent cardiac
events (12–14,37) (see Sections III.B and III.C). Although
one recent study (431) suggested that myocardial perfusion
imaging can identify patients who are at low risk of death
but increased risk of nonfatal MI, the major current focus of
noninvasive risk stratification is on subsequent patient
mortality. The rationale is to identify patients in whom
coronary angiography and subsequent revascularization
might improve survival. Such a strategy can be effective only
if the patient’s prognosis on medical therapy is sufficiently
poor that it can be improved.
Previous experience in the randomized trials of CABG
demonstrated that patients randomized to initial CABG
had a lower mortality rate than those treated with medical
therapy only if they were at substantial risk (489). Low-risk
patients who did not have a lower mortality rate with
CABG had a five-year survival rate of about 95% with
medical therapy. This is equivalent to an annual mortality
rate of 1%. As a result, coronary angiography to identify
patients whose prognosis can be improved is inappropriate
when the estimated annual mortality rate is #1%. In
contrast, patients with a survival advantage with CABG,
such as those with three-vessel disease, have an annual
mortality rate $3%. Coronary angiography is appropriate
for patients whose mortality risk is in this range.
Noninvasive test findings that identify high-risk patients
are listed in Table 23. Patients identified as high risk are
generally referred for coronary arteriography independent of
their symptomatic status. When appropriately used, nonin-
vasive tests are less costly than coronary angiography and
have an acceptable predictive value for adverse events
(12–14,37,485). This is most true when the pretest proba-
bility of severe CAD is low. When the pretest probability of
severe CAD is high, direct referral for coronary angiography
without noninvasive testing has been shown to be most
cost-effective (see Section III.A) as the total number of tests
is reduced (335).
Coronary Angiography for Risk Stratification in
Patients With Chronic Stable Angina
Recommendations
Class I
1. Patients with disabling (Canadian Cardiovascular
Society [CCS] classes III and IV) chronic stable
angina despite medical therapy. (Level of Evidence:
B)
2. Patients with high-risk criteria on noninvasive test-
ing (Table 23) regardless of anginal severity. (Level
of Evidence: B)
3. Patients with angina who have survived sudden
cardiac death or serious ventricular arrhythmia.
(Level of Evidence: B)
4. Patients with angina and symptoms and signs of
CHF. (Level of Evidence: C)
5. Patients with clinical characteristics that indicate a
high likelihood of severe CAD. (Level of Evidence:
C)
Class IIa
1. Patients with significant LV dysfunction (ejection
fraction <45%), CCS class I or II angina, and
demonstrable ischemia but less than high-risk cri-
teria on noninvasive testing. (Level of Evidence: C)
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2. Patients with inadequate prognostic information
after noninvasive testing. (Level of Evidence: C)
Class IIb
1. Patients with CCS class I or II angina, preserved
LV function (ejection fraction >45%), and less than
high-risk criteria on noninvasive testing. (Level of
Evidence: C)
2. Patients with CCS class III or IV angina, which
with medical therapy improves to class I or II.
(Level of Evidence: C)
3. Patients with CCS class I or II angina but intoler-
ance (unacceptable side effects) to adequate medical
therapy. (Level of Evidence: C)
Class III
1. Patients with CCS class I or II angina who respond
to medical therapy and who have no evidence of
ischemia on noninvasive testing. (Level of Evidence:
C)
2. Patients who prefer to avoid revascularization.
(Level of Evidence: C)
Risk Stratification With Coronary Angiography
Coronary angiography, the traditional gold standard for
clinical assessment of coronary atherosclerosis, has limita-
tions. Coronary angiography is not a reliable indicator of the
functional significance of a coronary stenosis and is insen-
sitive in detection of a thrombus (an indicator of disease
activity) (203,490). More important, coronary angiography
is ineffective in determining which plaques have character-
istics likely to lead to acute coronary events, that is, the
vulnerable plaque with a large lipid core, thin fibrous cap
and increased macrophages (491–494). Serial angiographic
studies performed before and after acute events and early
after MI suggest that plaques resulting in unstable angina
and MI commonly produced ,50% stenosis before the
acute event and were therefore angiographically “silent”
(495,496).
Despite these limitations of coronary angiography, the
extent and severity of coronary disease and LV dysfunction
identified on angiography are the most powerful clinical
predictors of long-term outcome (41,134,485,497,498).
Several prognostic indexes have been used to relate disease
severity to the risk of subsequent cardiac events; the simplest
and most widely used is the classification of disease into
one-vessel, two-vessel, three-vessel, or left main coronary
artery disease (96,499–501). In the CASS registry of
medically treated patients, the 12-year survival rate of
patients with normal coronary arteries was 91% compared
with 74% for those with one-vessel disease, 59% for those
with two-vessel disease, and 40% for those with three-vessel
disease (p , 0.001) (488). The effect of LV dysfunction on
survival was quite dramatic. In the CASS registry, the
12-year survival rate of patients with ejection fractions in the
range of 50% to 100%, 35% to 49%, and ,35% were 73%,
54%, and 21%, respectively (p , 0.0001) (488). The
importance of proximal coronary stenoses over distal lesions
was recognized, and a “jeopardy score” was developed in
which the prognostic significance of lesions was weighed as
a function of lesion location (502). Recent angiographic
studies indicate that a direct correlation also exists between
the angiographic severity of coronary disease and the
amount of angiographically insignificant plaque buildup
elsewhere in the coronary tree. These studies suggest that
the higher mortality rate of patients with multivessel disease
may occur because they have more mildly stenotic or
nonstenotic plaques that are potential sites for acute coro-
nary events than those with one-vessel disease (503).
Whether new technology such as magnetic resonance im-
aging and EBCT scanning will provide incremental prog-
nostic value by identifying and quantifying plaque and its
components remains to be determined (504).
For many years, it has been known that patients with
severe stenosis of the left main coronary artery have a poor
prognosis when treated medically. In a hierarchical prog-
Table 23. Noninvasive Risk Stratification
High-Risk (greater than 3% annual mortality rate)
1. Severe resting left ventricular dysfunction (LVEF , 35%)
2. High-risk treadmill score (score # 211)
3. Severe exercise left ventricular dysfunction (exercise LVEF
, 35%)
4. Stress-induced large perfusion defect (particularly if
anterior)
5. Stress-induced multiple perfusion defects of moderate size
6. Large, fixed perfusion defect with LV dilation or increased
lung uptake (thallium-201)
7. Stress-induced moderate perfusion defect with LV dilation
or increased lung uptake (thallium-201)
8. Echocardiographic wall motion abnormality (involving
greater than two segments) developing at low dose of
dobutamine (#10 mg/kg/min) or at a low heart rate
(,120 beats/min)
9. Stress echocardiographic evidence of extensive ischemia
Intermediate Risk (1%–3% annual mortality rate)
1. Mild/moderate resting left ventricular dysfunction (LVEF
5 35% to 49%)
2. Intermediate-risk treadmill score (211 , score , 5)
3. Stress-induced moderate perfusion defect without LV
dilation or increased lung intake (thallium-201)
4. Limited stress echocardiographic ischemia with a wall
motion abnormality only at higher doses of dobutamine
involving less than or equal to two segments
Low-Risk (less than 1% annual mortality rate)
1. Low-risk treadmill score (score $5)
2. Normal or small myocardial perfusion defect at rest or
with stress*
3. Normal stress echocardiographic wall motion or no change
of limited resting wall motion abnormalities during stress*
*Although the published data are limited, patients with these findings will probably
not be at low risk in the presence of either a high-risk treadmill score or severe resting
left ventricular dysfunction (LVEF , 35%).
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nostic index developed recently, patients with severe left
main coronary artery stenosis were given a prognostic
weight of 100 and patients with no angiographic disease a
weight of 0 (501). A gradient of risk existed between these
extremes, with three-, two-, and one-vessel disease having
decreasing risk. The presence of severe proximal LAD
disease significantly reduces the survival rate. The five-year
survival rate with three-vessel disease plus .95% proximal
LAD stenosis was reported to be 59% compared with
three-vessel disease without LAD stenosis of 79% (Table
24). A nomogram for predicting the five-year survival rate
has been developed that incorporates clinical history, phys-
ical examination, coronary angiography and LV ejection
fraction (see Fig. 8). The importance of considering clinical
factors and especially LV function in estimating the risk of
a given coronary angiographic finding is illustrated by
comparing the predicted five-year survival rate of 65-year-
old men with stable angina, three-vessel disease, and normal
ventricular function with that of 65-year-old men with
stable angina, three-vessel disease, heart failure, and an
ejection fraction of 30%. The five-year survival rate for the
former is 93%, whereas patients with the same characteris-
tics but heart failure and reduced ejection fraction had a
predicted survival rate of only 58% (501).
An additional but less quantifiable benefit of coronary
angiography and left ventriculography derives from the
ability of experienced angiographers to integrate the two
studies. Coronary artery lesion characteristics (e.g., stenosis
severity, length, complexity, presence of thrombus) as well
as the number of lesions posing jeopardy to regions of
contracting myocardium, possible role of collaterals and
mass of jeopardized viable myocardium may afford some
insight into the consequences of subsequent vessel occlu-
sion. For example, a patient with a noncontracting inferior
or lateral wall and severe proximal stenosis of a very large
LAD would be at substantial risk of developing cardiogenic
shock if the LAD occluded. This integration of coronary
angiography and left ventriculography permits the best
estimate of the potential benefit of revascularization strate-
gies discussed below.
Patients With Previous CABG
Patients who have previously undergone CABG are a
particularly heterogeneous group with respect to the ana-
tomic basis of ischemia and its implications for subsequent
morbidity and mortality. Progression of native CAD is not
uncommon, but more frequently saphenous vein graft attri-
tion or the development of obstructive atherosclerotic vein
graft lesions account for late recurrence of chronic stable
angina. Saphenous vein graft lesions represent a particularly
unstable form of atherosclerosis, which is prone to rapid
progression and thrombotic occlusion (505–508). Conse-
quently, a low threshold for angiographic evaluation is
recommended for patients who develop chronic stable
angina .5 years after surgery, especially when ischemia is
noninvasively documented in the distribution of a vein graft,
the LAD is supplied by a vein graft, or multiple vein grafts
are present. The outcome of patients with vein graft disease
can be improved by reoperation (509,510), and in some
patients, symptoms can be relieved by percutaneous
catheter-based strategies (511).
IV. TREATMENT
A. Pharmacologic Therapy
Recommendations for Pharmacotherapy to Prevent MI
and Death and Reduce Symptoms
Class I
1. Aspirin in the absence of contraindications. (Level
of Evidence: A)
2. Beta-blockers as initial therapy in the absence of
contraindications in patients with prior MI. (Level
of Evidence: A)
3. Beta-blockers as initial therapy in the absence of
contraindications in patients without prior MI.
(Level of Evidence: B)
4. Calcium antagonists* or long-acting nitrates as
initial therapy when beta-blockers are contraindi-
cated. (Level of Evidence: B)
5. Calcium antagonists* or long-acting nitrates in
combination with beta-blockers when initial treat-
ment with beta-blockers is not successful. (Level of
Evidence: B)
6. Calcium antagonists* and long-acting nitrates as a
substitute for beta-blockers if initial treatment with
beta-blockers leads to unacceptable side effects.
(Level of Evidence: C)
*Short-acting dihydropyridine calcium antagonists should be avoided.
Table 24. CAD Prognostic Index
Extent of CAD
Prognostic
Weight
(0–100)
5-Year
Survival
Rate
(%)*
1-vessel disease, 75% 23 93
.1-vessel disease, 50% to 74% 23 93
1-vessel disease, $95% 32 91
2-vessel disease 37 88
2-vessel disease, both $95% 42 86
1-vessel disease, $95% proximal LAD 48 83
2-vessel disease, $95% LAD 48 83
2-vessel disease, $95% proximal LAD 56 79
3-vessel disease 56 79
3-vessel disease, $95% in at least 1 63 73
3-vessel disease, 75% proximal LAD 67 67
3-vessel disease, $95% proximal LAD 74 59
*Assuming medical treatment only. CAD 5 coronary artery disease; LAD 5 left
anterior descending coronary artery. From Califf RM, Armstrong PW, Carver JR, et
al: Task Force 5. Stratification of patients into high-, medium- and low-risk
subgroups for purposes of risk factor management. J Am Coll Cardiol 1996;27:964–
1047.
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7. Sublingual nitroglycerin or nitroglycerin spray for the
immediate relief of angina. (Level of Evidence: C)
8. Lipid-lowering therapy in patients with docu-
mented or suspected CAD and LDL cholesterol
>130 mg/dL, with a target LDL of <100 mg/dL.
(Level of Evidence: A)
Class IIa
1. Clopidogrel when aspirin is absolutely contraindi-
cated. (Level of Evidence: B)
2. Long-acting nondihydropyridine calcium antago-
nists* instead of beta-blockers as initial therapy.
(Level of Evidence: B)
3. Lipid-lowering therapy in patients with docu-
mented or suspected CAD and LDL cholesterol
100 to 129 mg/dL, with a target LDL of 100
mg/dL. (Level of Evidence: B)
Class IIb
Low-intensity anticoagulation with warfarin in addi-
tion to aspirin. (Level of Evidence: B)
Class III
1. Dipyridamole. (Level of Evidence: B)
2. Chelation therapy. (Level of Evidence: B)
Overview of Treatment
The treatment of stable angina has two major purposes.
The first is to prevent MI and death and thereby increase
the “quantity” of life. The second is to reduce symptoms of
angina and occurrence of ischemia, which should improve
the quality of life.
Therapy directed toward preventing death has the highest
priority. When two different therapeutic strategies are
equally effective in alleviating symptoms of angina, the
therapy with a definite or very likely advantage in preventing
death should be recommended. For example, coronary
artery bypass surgery is the preferred therapy for patients
with significant left main CAD because it prolongs life.
However, in many patients with mild angina, one-vessel
CAD, and normal LV function, medical therapy, coro-
nary angioplasty and coronary artery bypass surgery are all
reasonable options. The choice of therapy often depends
on the clinical response to initial medical therapy, al-
though some patients may prefer coronary revasculariza-
tion. Patient education, cost-effectiveness and patient
preference are important components in this decision-
making process.
The section on pharmacologic therapy considers treat-
ments to prevent MI and death first; antianginal and
anti-ischemic therapy to alleviate symptoms, reduce isch-
emia, and improve quality of life are considered in a
second section. Pharmacologic therapy directed toward
prevention of MI and death has expanded greatly in
recent years with the emergence of evidence that dem-
onstrates the efficacy of lipid-lowering agents for this
purpose. For that reason, the committee has chosen to
discuss lipid-lowering drugs in two sections of these
guidelines: briefly in the following section on pharmaco-
logical therapy and in more detail in the later section on
risk factor reduction. The committee believes that the
emergence of such medical therapy for prevention of MI
and death represents a new treatment paradigm that
should be recognized by all healthcare professionals
involved in the care of patients with stable angina.
Figure 8. Nomogram for prediction of five-year survival from clinical, physical examination and cardiac catheterization findings. Asymp 5
asymptomatic; CAD 5 coronary artery disease; MI 5 myocardial infarction; and Symp 5 symptomatic. From Califf RM, Armstrong PW,
Carver JR, et al: Task Force 5. Stratification of patients into high-, medium- and low-risk subgroups for purposes of risk factor
management. J Am Coll Cardiol 1996;27:964–1047.
*Short-acting dihydropyridine calcium antagonists should be avoided.
2136 Gibbons et al. JACC Vol. 33, No. 7, 1999
ACC/AHA/ACP-ASIM Chronic Stable Angina Guidelines June 1999:2092–197
Pharmacotherapy to Prevent MI and Death
Antiplatelet Agents
Aspirin exerts an antithrombotic effect by inhibiting
cyclo-oxygenase and synthesis of platelet thromboxane A2.
The use of aspirin in .3,000 patients with stable angina was
associated with a 33% (on average) reduction in the risk of
adverse cardiovascular events (512,513). In patients with
unstable angina, aspirin decreases the short and long-term
risk of fatal and nonfatal MI (514,515). In the Physicians’
Health Study (516), aspirin (325 mg), given on alternate
days to asymptomatic persons, was associated with a de-
creased incidence of MI.
In the Swedish Angina Pectoris Aspirin Trial (SAPAT)
(517) in patients with stable angina, the addition of 75 mg
of aspirin to sotalol resulted in a 34% reduction in primary
outcome events of MI and sudden death and a 32% decrease
in secondary vascular events.
Ticlopidine is a thienopyridine derivative that inhibits
platelet aggregation induced by adenosine diphosphate and
low concentrations of thrombin, collagen, thromboxane A2,
and platelet activating factor (518,519). It also reduces
blood viscosity due to reduction in plasma fibrinogen and an
increase in red cell deformability (520). Ticlopidine de-
creases platelet function in patients with stable angina but,
unlike aspirin, has not been shown to decrease adverse
cardiovascular events (521,522). It may, however, induce
neutropenia and, albeit infrequently, thrombotic thrombo-
cytopenic purpura (TTP).
Clopidogrel, also a thienopyridine derivative, is chemi-
cally related to ticlopidine but appears to possess a greater
antithrombotic effect than ticlopidine (523). Clopidogrel
prevents adenosine diphosphate-mediated activation of
platelets by selectively and irreversibly inhibiting the bind-
ing of adenosine diphosphate (ADP) to its platelet receptors
and thereby affecting ADP-dependent activation of the GP
IIb-IIIa complex. In a randomized trial that compared
clopidogrel with aspirin in patients with previous MI, stroke
and peripheral vascular disease (i.e., at risk of ischemic
events), clopidogrel appeared to be slightly more effective
than aspirin in decreasing the combined risk of MI, vascular
death or ischemic stroke (524). However, no further studies
have been performed to confirm the efficacy of clopidogrel
in patients with stable angina.
Dipyridamole is a pyrimido-pyrimidine derivative that
exerts vasodilatory effects on coronary resistance vessels and
also has antithrombotic effects. Dipyridamole increases
intracellular platelet cyclic adenosine monophosphate (cyclic
AMP) by inhibiting the enzyme phosphodiesterase, activat-
ing the enzyme adenylate cyclase, and inhibiting uptake of
adenosine from vascular endothelium and erythrocytes
(525). Increased plasma adenosine is associated with vaso-
dilation. Because even the usual oral doses of dipyridamole
can enhance exercise-induced myocardial ischemia in pa-
tients with stable angina (526), it should not be used as an
antiplatelet agent.
Aspirin 75 to 325 mg daily should be used routinely in all
patients with acute and chronic ischemic heart disease with
or without manifest symptoms in the absence of contrain-
dications.
Antithrombotic Therapy
Disturbed fibrinolytic function such as elevated tissue
plasminogen activator antigen (tPA-ag), high plasminogen
activator inhibitor (PAI-1), and low tPA-ag responses after
exercise has been found to be associated with an increased
risk of subsequent cardiovascular deaths in patients with
chronic stable angina (527), providing the rationale for
long-term antithrombotic therapy. In small placebo-
controlled studies among patients with chronic stable an-
gina, daily subcutaneous administration of low-molecular-
weight heparin decreased the fibrinogen level, which was
associated with improved clinical class and exercise time to
1-mm ST depression and peak ST depression (528). How-
ever, the clinical experience of such therapy is extremely
limited. The efficacy of newer antiplatelet and antithrom-
botic agents such as glycoprotein IIb/IIIa inhibitors and
recombinant hirudin in the management of patients with
chronic stable angina has not been established (529). Low-
intensity oral anticoagulation with warfarin (international
normalized ratio [INR] 1.47) has been shown to decrease
the risk of ischemic events (coronary death and fatal and
nonfatal MI) in a randomized trial of patients with risk
factors for atherosclerosis but without symptoms of angina
(530). This benefit was incremental to that provided by
aspirin.
Lipid-Lowering Agents
Earlier lipid-lowering trials with the use of bile acid
sequestrant (cholestyramine), fibric acid derivatives (gemfi-
brozil and clofibrate), or niacin reported reductions in total
cholesterol of 6% to 15%. The pooled data from these
studies also suggested that every 1% reduction in total
cholesterol could reduce coronary events by 2% (531).
Angiographic trials have addressed the effects of lipid-
lowering therapy on anatomic changes of the coronary
atherosclerotic plaques. Active treatment was associated
with less progression, more stabilization, and more regres-
sion of these plaque lesions and decreased incidence of
clinical events. A meta-analysis (532) of 37 trials demon-
strated that treatment-mediated reductions in cholesterol
are significantly associated with the observed reductions in
CHD mortality and total mortality rates.
Recent clinical trials have documented that LDL-
lowering agents can decrease the risk of adverse ischemic
events in patients with established CAD. In the Scandina-
vian Simvastatin Survival Study (4S) (533), treatment with
an HMG-CoA reductase inhibitor in patients with docu-
mented CAD (including stable angina) with a baseline total
cholesterol between 212 and 308 mg/dL was associated with
30% to 35% reductions in both mortality rate and major
coronary events. In the Cholesterol And Recurrent Events
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(CARE) study (534), in both men and women with
previous MI and total plasma cholesterol levels ,240
mg/dL (mean 209) and LDL-cholesterol levels of 115 to
174 mg/dL (mean 139), treatment with an HMG-CoA
reductase inhibitor (statin) was associated with a 24%
reduction in risk for fatal or nonfatal MI. These clinical
trials indicate that in patients with established CAD,
including chronic stable angina, lipid-lowering therapy
should be recommended even in the presence of mild to
moderate elevations of LDL cholesterol.
Antianginal and Anti-ischemic Therapy
Antianginal and anti-ischemic drug therapy consists of
beta-adrenoreceptor blocking agents (beta-blockers), cal-
cium antagonists, and nitrates. Other classes of drugs, such
as ACE inhibitors, amiodarone, “metabolic agents,” and
nonconventional therapy, also have been used in certain
subsets of patients with stable angina, but their clinical
effectiveness has not been confirmed.
BETA-BLOCKERS. Mechanism of Action. Activation of
beta-receptors is associated with an increase in heart rate,
acceleration of conduction through the atrioventricular
(AV) node, and increased contractility. Inhibition of beta-
receptors is associated with a reduction in inotropic state
and sinus rate and slowing of AV conduction. Some
beta-blockers have partial agonist activity, also called intrin-
sic sympathomimetic activity, and may not decrease heart
rate and blood pressure at rest.
The decrease in heart rate, contractility and arterial
pressure with beta-blockers is associated with decreased
myocardial oxygen demand. A reduction in heart rate also
increases diastolic perfusion time, which may enhance LV
perfusion. Although beta-blockers have the potential to
increase coronary vascular resistance by the formation of
cyclic AMP, the clinical relevance of this pharmacodynamic
effect remains uncertain. A marked slowing of heart rate
may increase LV diastolic wall tension, which may increase
myocardial oxygen demand; the concomitant use of nitrates
can offset these potentially deleterious effects of beta-
blockers.
Clinical Effectiveness. Various types of beta-blocker are
available for treatment of hypertension and angina. The
pharmacokinetic and pharmacodynamic effects of these
agents are summarized in Table 25. All beta-blockers
appear to be equally effective in angina pectoris. In patients
with chronic stable exertional angina, these agents decrease
the heart rate-blood pressure product during exercise, and
the onset of angina or the ischemic threshold during
exercise is delayed or avoided (535,536). In the treatment of
stable angina, it is conventional to adjust the dose of
beta-blockers to reduce heart rate at rest to 55 to 60
beats/min. In patients with more severe angina, heart rate
can be reduced to ,50 beats/min, provided that there are no
symptoms associated with bradycardia and heart block does
not develop. In patients with stable exertional angina,
beta-blockers limit the increase in heart rate during exercise,
which ideally should not exceed 75% of the heart rate
response associated with onset of ischemia. Beta-blockers
with additional vasodilating properties have also been found
effective in stable angina (537–539). Agents with combined
alpha- and beta-adrenergic antagonist properties have also
been found effective in the management of chronic stable
angina (540,541). Beta-blockers are clearly effective in
controlling exercise-induced angina (542,543). Controlled
studies comparing beta-blockers with calcium antagonists
have reported equal efficacy in controlling stable angina
(544–547). In patients with postinfarction stable angina and
those who require antianginal therapy after revasculariza-
tion, treatment with beta-blockers appears to be effective in
controlling symptomatic and asymptomatic ischemic epi-
sodes (548). In elderly patients with hypertension without
manifest CAD, beta-blockers as first-line therapy were
reported to be ineffective in preventing cardiovascular mor-
tality and all-cause mortality compared with diuretics.
Table 25. Properties of Beta-Blockers in Clinical Use
Drugs Selectivity
Partial
Agonist
Activity Usual Dose for Angina
Propranolol None No 20–80 mg twice daily
Metoprolol b1 No 50–200 mg twice daily
Atenolol b1 No 50–200 mg/day
Nadolol None No 40–80 mg/day
Timolol None No 10 mg twice daily
Acebutolol b1 Yes 200–600 mg twice daily
Betaxolol b1 No 10–20 mg/day
Bisoprolol b1 No 10 mg/day
Esmolol (intravenous) b1 No 50–300 mg/kg/min
Labetalol* None Yes 200–600 mg twice daily
Pindolol None Yes 2.5–7.5 mg 3 times daily
*Labetalol is a combined alpha- and b-blocker.
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However, beta-blockers are still the anti-ischemic drug of
choice in elderly patients with stable angina (549).
Beta-blockers are frequently combined with nitrates for
treatment of chronic stable angina. Nitrates tend to increase
sympathetic tone and may cause reflex tachycardia, which is
attenuated with the concomitant use of beta-blockers. The
potential increase in LV volume and end-diastolic pressure
and wall tension associated with decreased heart rate with
beta-blockers is counteracted by the concomitant use of
nitroglycerin. Thus, combination therapy with nitrates and
beta-blockers appears to be more effective than nitrates or
beta-blockers alone (550,551). Beta-blockers may also be
combined with calcium antagonists. For combination ther-
apy, slow-release dihydropyridines or new-generation, long-
acting dihydropyridines are the calcium antagonists of
choice (552–556). The tendency to develop tachycardia with
these calcium antagonists is counteracted by the concomi-
tant use of beta-blockers. Beta-blockers should be combined
with verapamil and diltiazem with caution, because extreme
bradycardia or AV block may occur. When beta-blockers
are added to high-dose diltiazem or verapamil, marked
fatigue may also result.
In patients with pure vasospastic angina (Prinzmetal
angina) without fixed obstructive lesions, beta-blockers are
ineffective and may increase the tendency to induce coronary
vasospasm from unopposed alpha-receptor activity (557);
they should therefore not be used.
Patient Outcomes. Beta-blockers have been shown in
many randomized trials to improve the survival rate of
patients with recent MI. These agents have also been shown
in several large randomized trials to improve the survival
rate and prevent stroke and CHF in patients with hyper-
tension (558). The effects of beta-blockers in patients with
stable angina without prior MI or hypertension have been
investigated in a few small randomized control trials (Table
26).
In the Total Ischemic Burden European Trial (TIBET)
(559), the combination of atenolol and nifedipine produced
a nonsignificant trend toward a lower rate of cardiac death,
nonfatal MI and unstable angina. There was no difference
between atenolol and nifedipine. The Angina Prognosis
Study in Stockholm (APSIS) (560) reported no difference
between metoprolol and verapamil treatment in patients
with chronic stable angina in relation to mortality, cardio-
vascular end points and measures of quality of life. In the
Atenolol Silent Ischemia Trial (ASIST) (413), patients with
documented CAD and mild angina (CCS class I or II) were
treated with 100 mg atenolol daily; the number and mean
duration of ischemic episodes detected by 48 h of ambula-
tory ECG monitoring were decreased after four weeks of
therapy compared with placebo. After one year, fewer
patients in the atenolol group experienced the combined
end point of death, ventricular tachycardia and fibrillation,
MI, hospitalization, aggravation of angina or revasculariza-
tion (413). The atenolol-treated patients had a longer time
until their first adverse event. In patients with stable angina, Ta
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the effects of bisoprolol (a vasodilator beta-blocker) and
nifedipine on transient myocardial ischemia were studied in
a prospective randomized controlled trial Total Ischemic
Burden Bioprolol Study (TIBBS) (561). In this study, 330
patients with stable angina pectoris and a positive exercise
test with ST-segment depression and $2 episodes of
transient myocardial ischemia during 48 h of ambulatory
ECG monitoring were randomized to either 10 mg biso-
prolol once daily or 20 mg slow-release nifedipine twice
daily for four weeks. The doses were then doubled for an
additional four weeks. Both bisoprolol and nifedipine re-
duced the number and duration of ischemic episodes in
patients with stable angina. However, bisoprolol was more
effective than nifedipine. In the International Multicenter
Angina Exercise Study (IMAGE) (562), the efficacy of
metoprolol alone, nifedipine alone, and the combination of
metoprolol and nifedipine were assessed in patients with
stable angina pectoris. In this study, 280 patients #75 years
old with stable angina for $6 months and a positive exercise
test were randomized to receive 200 mg metoprolol daily or
20 mg nifedipine twice daily for 6 weeks after a 2-week
placebo period. The patients were then randomized to the
addition of the second drug or placebo for four more weeks.
Both metoprolol and nifedipine were effective as mono-
therapy in increasing exercise time, although metoprolol was
more effective than nifedipine (562). The combination
therapy also increased the exercise time compared with
either drug alone.
Contraindications. The absolute cardiac contraindications
for the use of beta-blockers are severe bradycardia, preex-
isting high degree of AV block, sick sinus syndrome and
severe, unstable LV failure (mild CHF may actually be an
indication from beta-blockers) (563). Asthma and broncho-
spastic disease, severe depression, and peripheral vascular
disease are relative contraindications. Most diabetic patients
will tolerate beta-blockers, although these drugs should be
used cautiously in patients who require insulin.
Side Effects. Fatigue, inability to perform exercise, leth-
argy, insomnia, nightmares, worsening claudication and
impotence are frequently experienced side effects. The
mechanism of fatigue is not clear. During exercise, the total
maximal work achievable is reduced by approximately 15%
with long-term therapy and may increase the sense of
fatigue (564). The average incidence of impotence is about
1%; however, lack of or inadequate erection has been
observed in #26% of patients (565). Changes in quality of
life have not been systematically studied in patients with
chronic stable angina treated with beta-blockers.
CALCIUM ANTAGONISTS. Mechanisms of Action. These
agents reduce the transmembrane flux of calcium via the
calcium channels. There are three types of voltage-
dependent calcium channel: L type, T type, or N type. They
are categorized according to whether they are characteristi-
cally large in conductance, transient in duration of opening,
or neuronal in distribution (566). The pharmacodynamics of
calcium antagonists are summarized in Table 27.
All calcium antagonists exert a negative inotropic effect.
In smooth muscle, calcium ions also regulate the contractile
mechanism, and calcium antagonists reduce smooth muscle
tension in the peripheral vascular bed, which is associated
with vasodilation.
Calcium antagonists, including the newer, second-
generation vasoselective dihydropyridine agents and nondi-
hydropyridine drugs such as verapamil and diltiazem, de-
crease coronary vascular resistance and increase coronary
blood flow. All of these agents cause dilation of the
epicardial conduit vessels and the arteriolar resistance ves-
sels. Dilation of the epicardial coronary arteries is the
principal mechanism of the beneficial effect of calcium
antagonists for relieving vasospastic angina. Calcium antag-
onists also decrease myocardial oxygen demand primarily by
reduction of systemic vascular resistance and arterial pres-
sure. The negative inotropic effect of calcium antagonists
also decreases the myocardial oxygen requirement. How-
ever, the negative inotropic effect varies considerably with
different types of calcium antagonist. Among dihydropyri-
dines, nifedipine probably exerts the most pronounced
negative inotropic effect, and newer-generation, relatively
vasoselective dihydropyridines such as amlodipine and felo-
dipine exert much less of a negative inotropic effect. The
new T-channel blocker mibefradil also appears to exert a
less negative inotropic effect (567,568). However, mibefradil
has been withdrawn from clinical use because of adverse
drug interactions and is not discussed further in this
document. Diltiazem and verapamil can reduce heart rate by
slowing the sinus node or decreasing ventricular response in
patients with atrial flutter and fibrillation due to reduction
in AV conduction. Calcium antagonists are therefore useful
for treatment of both demand and supply ischemia (569–
575).
Calcium Antagonists in Chronic Stable Angina. Random-
ized clinical trials comparing calcium antagonists and beta-
blockers have demonstrated that calcium antagonists are
generally equally as effective as beta-blockers in relieving
angina (Fig. 9) and improving exercise time to onset of
angina or ischemia (Fig. 10). The clinical effectiveness of
calcium antagonists was evident with both dihydropyridine
and nondihydropyridine agents and various dosing regi-
mens.
Calcium Antagonists in Vasospastic Angina. In patients
with vasospastic (Prinzmetal) angina, calcium antagonists
have been shown to be effective in reducing the incidence of
angina. Short-acting nifedipine, diltiazem, and verapamil all
appeared to completely abolish the recurrence of angina in
approximately 70% of patients; in another 20% of patients,
the frequency of angina was reduced substantially (576–
579). A randomized placebo-controlled trial has also been
performed with the use of newer, vasoselective, long-acting
dihydropyridine amlodipine in the management of patients
with vasospastic angina (580). In this study, 52 patients with
well documented vasospastic angina were randomized to
receive either amlodipine or placebo. The rate of anginal
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episodes decreased significantly with amlodipine treatment
compared with placebo, and the intake of nitroglycerin
tablets showed a substantial reduction.
Patient Outcomes. Retrospective case control studies re-
port that in patients with hypertension, treatment with
immediate-acting nifedipine, diltiazem and verapamil was
associated with increased risk of MI by 31%, 63% and 61%,
respectively (581). A meta-analysis of 16 trials that used
immediate-release and short-acting nifedipine in patients
with MI and unstable angina reported a dose-related influ-
ence on excess mortality (582). However, further analysis of
the published reports has failed to confirm an increased risk
of adverse cardiac events with calcium antagonists
(583,584). Furthermore, slow-release or long-acting vaso-
selective calcium antagonists have been reported to be
effective in improving symptoms and decreasing the risk of
adverse cardiac events (585). However, in the Appropriate
Blood Pressure Control in Diabetes (ABCD) study (586),
the use of nisoldipine, a relatively short-acting dihydropyr-
idine calcium antagonist, was associated with a higher
incidence of fatal and nonfatal MI compared with enalapril,
an ACE inhibitor. In an earlier trial of patients with stable
angina, nisoldipine was not effective in relieving angina
compared with placebo. Furthermore, larger doses tended to
increase the incidence of adverse events (587). These data
indicate that relatively short-acting dihydropyridine calcium
antagonists have the potential to enhance the risk of adverse
cardiac events and should be avoided. In contrast, long-
acting calcium antagonists, including slow-release and long-
acting dihydropyridines and nondihydropyridines, are effec-
tive in relieving symptoms in patients with chronic stable
angina. They should be used in combination with beta-
blockers when initial treatment with beta-blockers is not
successful or as a substitute for beta-blockers when initial
treatment leads to unacceptable side effects. However, their
use is not without potential hazard, as demonstrated by the
FACET trial (588), in which amlodipine was associated
with a higher incidence of cardiovascular events than fosi-
nopril, an ACE inhibitor.
Contraindications. In general, overt decompensated heart
failure is a contraindication for the use of calcium antago-
nists, although new-generation vasoselective dihydropyri-
dines (i.e., amlodipine, felodipine) are tolerated by patients
with reduced LV ejection fraction. Bradycardia, sinus node
dysfunction, and AV nodal block are contraindications for
the use of heart rate-modulating calcium antagonists. A
long QT interval is a contraindication for the use of
mibefradil and bepridil.
Side Effects. (589–591) (Table 27). Hypotension, depres-
sion of cardiac function and worsening heart failure may
Table 27. Properties of Calcium Antagonists in Clinical Use
Drugs Usual Dose
Duration
of
Action Side Effects
Dihydropyridines
Nifedipine Immediate release:
30–90 mg daily orally
Short Hypotension, dizziness,
flushing, nausea,
constipation, edema
Slow release:
30–180 mg orally
Amlodipine 5–10 mg qd Long Headache, edema
Felodipine 5–10 mg qd Long Headache, edema
Isradipine 2.5–10 mg bid Medium Headache, fatigue
Nicardipine 20–40 mg tid Short Headache, dizziness,
flushing, edema
Nisoldipine 20–40 mg qd Short Similar to nifedipine
Nitrendipine 20 mg qd or bid Medium Similar to nifedipine
Miscellaneous
Bepridil 200–400 mg qd Long Arrhythmias, dizziness,
nausea
Diltiazem Immediate release:
30–80 mg 4 times daily
Short Hypotension, dizziness,
flushing, bradycardia,
edema
Slow release:
120–320 mg qd
Long
Verapamil Immediate release:
80–160 mg tid
Short Hypotension, myocardial
depression, heart failure,
edema, bradycardia
Slow release:
120–480 mg qd
Long
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occur during long-term treatment with any calcium antag-
onist. Peripheral edema and constipation are recognized
side effects of all calcium antagonists. Headache, flushing,
dizziness and nonspecific central nervous system symptoms
may also occur. Bradycardia, AV dissociation, AV block,
and sinus node dysfunction may occur with heart rate-
modulating calcium antagonists. Bepridil can induce poly-
morphous ventricular tachycardia associated with an in-
creased QT interval (592).
Combination Therapy With Calcium Antagonists. In gen-
eral, in combination with beta-blockers, calcium antagonists
produce greater antianginal efficacy in patients with stable
angina (552–556). In the IMAGE trial (562), the combi-
nation of metoprolol and nifedipine was effective in reduc-
ing the incidence of ischemia as well as improving exercise
tolerance compared with either drug alone. In the TIBBS
trial (561), the combination of bisoprolol and nifedipine was
effective in reducing the number and duration of ischemic
episodes in patients with stable angina. In the Circadian
Anti-ischemic Program in Europe (CAPE) trial (593), the
effect of one daily dose of amlodipine on the circadian
pattern of myocardial ischemia in patients with stable
Figure 9. Beta-blockers versus calcium antagonists: angina relief.
Figure 10. Beta-blockers versus calcium antagonists: exercise time to 1-mm ST depression.
2142 Gibbons et al. JACC Vol. 33, No. 7, 1999
ACC/AHA/ACP-ASIM Chronic Stable Angina Guidelines June 1999:2092–197
angina pectoris was assessed (593). In this randomized,
double-blind, placebo-controlled, multicenter trial, 315
men, aged 35 to 80 years, with stable angina, $3 attacks of
angina per week, and $4 ischemic episodes during 48 h of
ambulatory ECG monitoring were randomized to receive
either 5 or 10 mg amlodipine per day or placebo for 8 weeks.
Amlodipine was used in addition to regular antianginal
therapy. There was a substantial reduction in the frequency
of both symptomatic and asymptomatic ischemic episodes
with the use of amlodipine. The long-acting, relatively
vasoselective dihydropyridine calcium antagonists enhance
antianginal efficacy in patients with stable angina when
combined with beta-blockers (594–596). Maximal exercise
time and work time to angina onset are increased and
subjective indexes, including anginal frequency and nitro-
glycerin tablet consumption, decrease.
NITROGLYCERIN AND NITRATES. Mechanisms of Action.
Nitrates are endothelium-independent vasodilators that
produce beneficial effects by both reducing the myocardial
oxygen requirement and improving myocardial perfusion
(597,598). The reduction in myocardial oxygen demand and
consumption results from the reduction of LV volume and
arterial pressure primarily due to reduced preload. A reduc-
tion in central aortic pressure can also result from improved
nitroglycerin-induced central arterial compliance. Nitro-
glycerin also exerts antithrombotic and antiplatelet effects in
patients with stable angina (599). A reflex increase in
sympathetic activity, which may increase heart rate and
contractile state, occurs in some patients. In general, how-
ever, the net effect of nitroglycerin and nitrates is a reduc-
tion in myocardial oxygen demand.
Nitrates dilate large epicardial coronary arteries and
collateral vessels. The vasodilating effect on epicardial cor-
onary arteries with or without atherosclerotic CAD is
beneficial in relieving coronary vasospasm in patients with
vasospastic angina. As nitroglycerin decreases myocardial
oxygen requirements and improves myocardial perfusion,
these agents are effective in relieving both demand and
supply ischemia.
Clinical Effectiveness. In patients with exertional stable
angina, nitrates improve exercise tolerance, time to onset of
angina, and ST-segment depression during the treadmill ex-
ercise test. In combination with beta-blockers or calcium
antagonists, nitrates produce greater antianginal and anti-
ischemic effects in patients with stable angina (564,566,600–
605).
The properties of commonly used preparations available
for clinical use are summarized in Table 28. Sublingual
nitroglycerin tablets or nitroglycerin spray are suitable for
immediate relief of effort or rest angina and can also be used
Table 28. Nitroglycerin and Nitrates in Angina
Compound Route Dose Duration of Effect
Nitroglycerin Sublingual tablets 0.3–0.6 mg up to 1.5 mg 11⁄2–7 min
Spray 0.4 mg as needed Similar to sublingual
tablets
Ointment 2% 6 3 6 in., 15 3
15 cm 7.5–40 mg
Effect up to 7 h
Transdermal 0.2–0.8 mg/h every 12 h 8–12 h during
intermittent
therapy
Oral sustained
release
2.5 mg–13 mg 4–8 h
Buccal 1–3 mg 3 times daily 3–5 h
Intravenous 5–200 mg/min Tolerance in 7–8 h
Isosorbide Sublingual 2.5–15 mg Up to 60 min
Dinitrate Oral 5–80 mg, 2–3 times daily Up to 8 h
Spray 1.25 mg daily 2–3 min
Chewable 5 mg 2–21⁄2 h
Oral slow release 40 mg 1–2 daily Up to 8 h
Intravenous 1.25–5.0 mg/h Tolerance in 7–8 h
Ointment 100 mg/24 h Not effective
Isosorbide Oral 20 mg twice daily 12–24 h
Mononitrate 60–240 mg once daily
Pentaerythritol
Tetranitrate
Sublingual 10 mg as needed Not known
Erythritol Sublingual 5–10 mg as needed Not known
Tetranitrate Oral 10–30 3 times daily Not known
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for prophylaxis to avoid ischemic episodes when used several
minutes before planned exercise. As treatment to prevent
the recurrence of angina, long-acting nitrate preparations
such as isosorbide dinitrate, mononitrates, transdermal ni-
troglycerin patches and nitroglycerin ointment are used. All
long-acting nitrates, including isosorbide dinitrates and
mononitrates, appear to be equally effective when a sufficient
nitrate-free interval is provided (606,607).
Contraindications. Nitroglycerin and nitrates are relatively
contraindicated in hypertrophic obstructive cardiomyopa-
thy, because in these patients, nitrates can increase LV
outflow tract obstruction and severity of mitral regurgitation
and can precipitate presyncope or syncope. In patients with
severe aortic valve stenosis, nitroglycerin should be avoided
because of the risk of inducing syncope. However, nitro-
glycerin can be used for relief of angina.
The interaction between nitrates and sildenafil is discussed
in detail elsewhere (608). The coadministration of nitrates and
sildenafil significantly increases the risk of potentially life-
threatening hypotension. Patients who take nitrates should be
warned of the potentially serious consequences of taking
sildenafil within the 24-h interval after taking a nitrate prep-
aration, including sublingual nitroglycerin.
Side Effects. The major problem with long-term use of
nitroglycerin and long-acting nitrates is development of
nitrate tolerance (609). Tolerance develops not only to
antianginal and hemodynamic effects but also to platelet
antiaggregatory effects (610). The mechanism for develop-
ment of nitrate tolerance still remains unclear. The de-
creased availability of sulfhydryl (SH) radicals, activation of
the renin-angiotensin-aldosterone system, an increase in
intravascular volume due to an altered transvascular Starling
gradient, and generation of free radicals with enhanced
degradation of nitric oxide have been proposed. The con-
current administration of an SH donor such as SH contain-
ing ACE inhibitors, acetyl or methyl cysteine (611) and
diuretics has been suggested to reduce the development of
nitrate tolerance. Concomitant administration of hydral-
azine has also been reported to reduce nitrate tolerance.
However, for practical purposes, less frequent administra-
tion of nitroglycerin with an adequate nitrate-free interval (8
to 12 h) appears to be the most effective method of
preventing nitrate tolerance (553). The most common side
effect during nitrate therapy is headache. Sometimes the
headaches abate during long-term nitrate therapy even
when antianginal efficacy is maintained. Patients may de-
velop hypotension and presyncope or syncope (554,555).
Rarely, sublingual nitroglycerin administration can produce
bradycardia and hypotension, probably due to activation of
the Bezold Jarish reflex.
OTHER ANTIANGINAL AGENTS AND THERAPIES. Mol-
sidomine, a sydnonimine which has pharmacological prop-
erties similar to those of nitrates, has been shown to be
beneficial in the management of symptomatic patients with
chronic stable angina (612). Nicorandil, a potassium chan-
nel activator, also has pharmacologic properties similar to
those of nitrates and may be effective in treatment of stable
angina (613–615). Metabolic agents such as trimetazidine,
ranolazine, and L-carnitine have been observed to produce
antianginal effects in some patients (616–619). Bradycardic
agents such as alindine and zatebradin have been used for
treatment of stable angina (620,621), but their efficacy has
not been well documented (622,623). Angiotensin convert-
ing enzyme inhibitors have been investigated for treatment
of stable angina, but their efficacy has not been established
(624,625). The serotonin antagonist ketanserin appears not
to be an effective antianginal agent (626). Labetalol, a beta-
and alpha-adrenoreceptor blocking agent, has been shown
to produce beneficial antianginal effects (620,627). Nonse-
lective phosphodiesterase inhibitors such as theophylline
and trapidil have been reported to produce beneficial anti-
anginal effects (621,628). Fantofarone, a calcium antagonist,
exerts an inhibitory effect on the sinus node and decreases
heart rate. Like other calcium antagonists, it is a potent
peripheral and coronary vasodilator. In controlled studies,
its beneficial antianginal effects in patients with chronic
stable angina have been observed (629). Further studies,
however, will be required to determine the efficacy of these
newer antianginal drugs.
Chelation therapy and acupuncture have not been found
to be effective to relieve symptoms and are not recom-
mended for treatment of chronic stable angina. Although
several small observational studies have suggested benefit
from enhanced external counterpulsation (630,631), the
available evidence does not support a recommendation for
its use. The standard use of antibiotics is also not recom-
mended.
Choice of Pharmacologic Therapy in Chronic Stable
Angina
The primary consideration in the choice of pharmacological
agents for treatment of angina should be to improve prognosis.
Aspirin and lipid-lowering therapy have been shown to reduce
the risk of death and nonfatal MI in both primary and
secondary prevention trials. These data strongly suggest that
cardiac events will also be reduced among patients with chronic
stable angina, an expectation corroborated by direct evidence in
small, randomized trials with aspirin.
Beta-blockers also reduce cardiac events when used as
secondary prevention in postinfarction patients and re-
duce mortality and morbidity among patients with hy-
pertension. On the basis of their potentially beneficial
effects on morbidity and mortality, beta-blockers should
be strongly considered as initial therapy for chronic stable
angina. They appear to be underused (632). Diabetes
mellitus is not a contraindication to their use. Nitrates
have not been shown to reduce mortality with acute MI
or in patients with CAD. Immediate-release or short-
acting dihydropyridine calcium antagonists have been
reported to increase adverse cardiac events. However,
long-acting or slow-release dihydropyridines, or nondi-
hydropyridines, have the potential to relieve symptoms in
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patients with chronic stable angina without enhancing
the risk of adverse cardiac events. No conclusive evidence
exists to indicate that either long-acting nitrates or
calcium antagonists are superior for long-term treatment
for symptomatic relief of angina. The committee believed
that long-acting calcium antagonists are often preferable
to long-acting nitrates for maintenance therapy because
of their sustained 24-h effects. However, the patient’s and
treating physician’s preferences should always be consid-
ered.
Special Clinical Situations
Newer-generation, vasoselective, long-acting dihydropyr-
idine calcium antagonists such as amlodipine or felodipine
can be used in patients with depressed LV systolic function.
In patients who have sinus node dysfunction, rest bradycar-
dia, or AV block, beta-blockers or heart rate-modulating
calcium antagonists should be avoided. In patients with
insulin-dependent diabetes, beta-blockers should be used
with caution because they can mask hypoglycemic symp-
toms. In patients with mild peripheral vascular disease, there
is no contraindication for use of beta-blockers or calcium
antagonists. However, in patients with severe peripheral
vascular disease with ischemic symptoms at rest, it is
desirable to avoid beta-blockers, and calcium antagonists are
preferred. In patients with hypertrophic obstructive cardio-
myopathy, the use of nitrates and dihydropyridine calcium
antagonists should be avoided. In these patients, beta-
blockers or heart rate-modulating calcium antagonists may
be useful. In patients with severe aortic stenosis, all vasodi-
lators, including nitrates, should be used cautiously because
of the risk of inducing hypotension and syncope. Associated
conditions that influence the choice of therapy are summa-
rized in Table 29.
Patients with angina may have other cardiac conditions,
e.g., CHF, that will require other special treatment, such as
diuretics and ACE inhibitors. These issues are covered in
other ACC/AHA guidelines.
B. Definition of Successful Treatment and Initiation of
Treatment
Successful Treatment
Definition of Successful Treatment of Chronic Stable
Angina
The treatment of chronic stable angina has two comple-
mentary objectives: to reduce the risk of mortality and
morbid events and reduce symptoms. From the patient’s
perspective, it is often the latter that is of greater concern.
The cardinal symptom of stable CAD is anginal chest pain
or equivalent symptoms such as exertional dyspnea. Often
the patient suffers not only from the discomfort of the
symptom itself but also from accompanying limitations on
activities and the associated anxiety that the symptoms may
produce. Uncertainty about prognosis may be an additional
source of anxiety. For some patients, the predominant
symptoms may be palpitations or syncope that are caused by
arrhythmias or fatigue, edema or orthopnea caused by heart
failure.
Because of the variation in symptom complexes among
patients and patients’ unique perceptions, expectations and
preferences, it is impossible to create a definition of treat-
ment success that is universally accepted. For example, given
an otherwise healthy, active patient, the treatment goal may
be complete elimination of chest pain and a return to
vigorous physical activity. Conversely, an elderly patient with
more severe angina and several coexisting medical problems
may be satisfied with a reduction in symptoms that enables
performance of only limited activities of daily living.
The committee agreed that for most patients, the goal of
treatment should be complete, or nearly complete, elimina-
tion of anginal chest pain and return to normal activities and
a functional capacity of CCS class I angina. This goal
should be accomplished with minimal side effects of ther-
apy. This definition of successful therapy must be modified
in light of the clinical characteristics and preferences of each
patient.
Initial Treatment
The initial treatment of the patient should include all the
elements in the following mnemonic:
In constructing a flow diagram to reflect the treatment
process, the committee thought that it was clinically helpful
to divide the entire treatment process into two parts: 1)
antianginal treatment and 2) education and risk factor
modification. The assignment of each treatment element to
one of these two subdivisions is self-evident, with the
possible exception of aspirin. Given the fact that aspirin
clearly reduces the risk of subsequent heart attack and death
but has no known benefit in preventing angina, the com-
mittee thought that it was best assigned to the education
and risk factor component, as reflected in the flow diagram.
All patients with angina should receive a prescription for
sublingual nitroglycerin and education about its proper use.
It is particularly important for patients to recognize that this
is a short-acting drug with no known long-term conse-
quences so that they will not be reluctant to use it.
If the patient’s history has a prominent feature of rest and
nocturnal angina suggesting vasospasm, initiation of therapy
with long-acting nitrates or calcium antagonists is appro-
priate.
A 5 Aspirin and Antianginal therapy
B 5 Beta-blocker and Blood pressure
C 5 Cigarette smoking and Cholesterol
D 5 Diet and Diabetes
E 5 Education and Exercise
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As mentioned previously, medications or conditions that
are known to provoke or exacerbate angina must be recog-
nized and treated appropriately. On occasion, angina may
resolve with appropriate treatment of these conditions. If so, no
further antianginal therapy is required. Usually, anginal symp-
toms improve but are not relieved by the treatment of such
conditions, and further therapy should then be initiated.
The committee favored the use of a beta-blocker as initial
therapy in the absence of contraindications. The evidence
for this approach is strongest in the presence of prior MI,
for which this class of drugs has been shown to reduce
mortality. Because these drugs have also been shown to
reduce mortality in the treatment of isolated hypertension,
the committee favored their use as initial therapy even in the
absence of prior MI.
If serious contraindications with beta-blockers exist, un-
acceptable side effects occur with their use, or angina persists
despite their use, calcium antagonists should then be ad-
ministered.
If serious contraindications to calcium antagonists exist,
unacceptable side effects occur with their use, or angina
persists despite their use, long-acting nitrate therapy should
then be prescribed.
At any point, on the basis of coronary anatomy, severity
of anginal symptoms and patient preferences, it is reason-
able to consider evaluation for coronary revascularization.
As discussed in the revascularization section, certain cate-
gories of patients, a minority of the total group, have a
demonstrated survival advantage with revascularization.
However, for most patients, for whom no demonstrated
Table 29. Recommended Drug Therapy (Calcium Antagonist vs. Beta-Blocker) in Patients With Angina and Associated Conditions
Condition
Recommended Treatment
(and Alternative) Avoid
Medical Conditions
Systemic hypertension Beta-blockers (calcium antagonists)
Migraine or vascular headaches Beta-blockers (verapamil or diltiazem)
Asthma or chronic obstructive pulmonary
disease with bronchospasm
Verapamil or diltiazem Beta-blockers
Hyperthyroidism Beta-blockers
Raynaud’s syndrome Long-acting slow-release calcium antagonists Beta-blockers
Insulin-dependent diabetes mellitus Beta-blockers (particularly if prior myocardial
infarction) or long-acting slow-release calcium
antagonists
Non-insulin-dependent diabetes mellitus Beta blockers or long-acting slow-release calcium
antagonists
Depression Long-acting slow-release calcium antagonists Beta-blockers
Mild peripheral vascular disease Beta-blockers or calcium antagonists
Severe peripheral vascular disease with rest
ischemia
Calcium antagonists Beta-blockers
Cardiac Arrhythmias and Conduction Abnormalities
Sinus bradycardia Long-acting slow-release calcium antagonists
that do not decrease heart rate
Beta-blockers, diltiazem,
verapamil
Sinus tachycardia (not due to heart failure) Beta-blockers
Supraventricular tachycardia Verapamil, diltiazem, or beta-blockers
Atrioventricular block Long-acting slow-release calcium antagonists
that do not slow A-V conduction
Beta-blockers, verapamil,
diltiazem
Rapid atrial fibrillation (with digitalis) Verapamil, diltiazem, or beta-blockers
Ventricular arrhythmias Beta blockers
Left Ventricular Dysfunction
Congestive heart failure
Mild (LVEF $ 40%) Beta-blockers
Moderate to severe (LVEF , 40%) Amlodipine or felodipine (nitrates) Verapamil, diltiazem
Left-sided valvular heart disease
Mild aortic stenosis Beta-blockers
Aortic insufficiency Long-acting slow-release dihydropyridines
Mitral regurgitation Long-acting slow-release dihydropyridines
Mitral stenosis Beta-blockers
Hypertrophic cardiomyopathy Beta-blockers, non-dihydropyridine calcium
antagonist
Nitrates, dihydropyridine
calcium antagonists
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survival advantage is associated with revascularization, med-
ical therapy should be attempted before angioplasty or
surgery is considered. The extent of the effort that should be
undertaken with medical therapy obviously depends on the
individual patient. In general, the committee thought that
low-risk patients should be treated with at least two, and
preferably all three, available classes of drugs before medical
therapy is considered a failure.
C. Education of Patients With Chronic Stable Angina
Because the presentation of ischemic heart disease is
often dramatic and because of impressive recent technolog-
ical advances, healthcare providers tend to focus on diag-
nostic and therapeutic interventions, often overlooking crit-
ically important aspects of high-quality care. Chief among
these neglected areas is the education of patients. In the
1995 National Ambulatory Medical Care Survey (666),
counseling about physical activity and diet occurred during
only 19% and 23%, respectively, of general medical visits.
This shortcoming was observed across specialties, including
cardiology, internal medicine and family practice.
Effective education is critical to enlisting patients’ full and
meaningful participation in therapeutic and preventive ef-
forts and in allaying their natural concerns and anxieties.
This in turn is likely to lead to a patient who not only is
better informed and more satisfied with his or her care but
who is also able to achieve a better quality of life and
improved survival (667–669).
Patient education should be viewed as a continuous
process that ought to be part of every patient encounter. It
is a process that must be individualized so that information
is presented at appropriate times and in a manner that is
readily understandable. It is frequently advisable to address
patients’ overriding concerns initially, for example, their
short-term prognosis. In directly addressing worrisome
issues, it is possible to put patients more at ease and make
them more receptive to addressing other issues, such as
modification of risk factors. This is true even when the
short-term prognosis cannot be fully addressed until addi-
tional testing has been conducted.
It is also essential to recognize that adequate education is
likely to lead to better adherence to medication regimens
and programs for risk factor reduction. Even brief sugges-
tions from a physician about exercise or smoking cessation
can have a meaningful effect (670,671). Moreover, an
informed patient will be better able to understand treatment
decisions and express preferences that are an important
component of the decision-making process (672).
Principles of Patient Education
A thorough discussion of the philosophies of and ap-
proaches to patient education is beyond the scope of this
section. There are several useful reviews on this topic,
including several that focus on ischemic heart disease
(673–675). It has been demonstrated that well-designed
educational programs can improve patients’ knowledge and
in some instances has been shown to improve outcomes
(676). These approaches form the basis for commonly used
educational programs, such as those conducted before
CABG (677) and after MI (678,679). A variety of princi-
ples should be followed to help ensure that educational
efforts are successful.
1. Assess the patient’s baseline understanding. This
serves not only to help establish a starting point for
education but also helps to engage the patient.
Healthcare providers are often surprised at the idio-
syncratic notions that patients have about their own
medical conditions and therapeutic approaches
(680,681).
2. Elicit the patient’s desire for information. Adults
prefer to set their own agendas, and they learn better
when they can control the flow of information.
3. Use epidemiologic and clinical evidence. As clinical
decision making becomes increasingly based on scien-
tific evidence, it is reasonable to share that evidence
with patients. Epidemiologic data can assist in formu-
lating an approach to patient education. In many
patients, for example, smoking reduction/cessation is
likely to confer a greater reduction in risk than
treatment of modestly elevated lipid levels; thus,
smoking should be addressed first. Scientific evidence
can help persuade patients about the effectiveness of
various interventions.
4. Use ancillary personnel and professional patient edu-
cators when appropriate. One reason that physicians
often fail to perform adequate patient education is that
the time available for a patient encounter is con-
strained, and education must be performed along with
a long list of other tasks. Reimbursement for educa-
tional activities is poor. Furthermore, physicians are
not trained to be effective health educators, and many
feel uncomfortable in this role. Fortunately, in many
settings, trained health educators, such as those spe-
cializing in diabetes or cardiac disease, are available.
Personnel from related disciplines such as physical
therapy, nutrition, pharmacology, and so forth also
have much to offer patients with ischemic heart disease
(682).
5. Use professionally prepared resources when available.
A vast array of informational materials and classes are
available to assist with patient education. These ma-
terials include books, pamphlets and other printed
materials, audiotapes and videotapes, computer soft-
ware, and most recently, sites on the World Wide
Web. The latter source is convenient for medical
personnel and patients with access to personal com-
puters. The AHA, for example, maintains a Web site
(http://www.americanheart.org) that presents detailed
and practical dietary recommendations, information
about physical activity, and a thorough discussion of
heart attacks and CPR. There also are links to other
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Web sites, such as the National Cholesterol Education
Program. For patients who do not have access to a
computer, work stations can be set up in the clinic or
physician’s office, relevant pages can be printed or
patients can be referred to hospital or public libraries.
6. Develop a plan with the patient. It is necessary to
convey a great deal of information to patients about
their condition. It is advisable to hold discussions over
time, taking into consideration many factors, which
include the patient’s level of sophistication and prior
educational attainment, language barriers, relevant
clinical factors and social support. For example, it
might be counterproductive to attempt to coax a
patient into simultaneously changing several behav-
iors, such as smoking, diet, exercise and taking (and
purchasing) multiple new medications. Achieving op-
timal adherence often requires problem solving with
the patient. To improve compliance with medications,
the healthcare provider may need to spend time
understanding the patient’s schedule and suggesting
strategies such as placing pill containers by the tooth-
brush or purchasing a watch with multiple alarms to
serve as reminders.
7. Involve family members in educational efforts. It is
advisable and often necessary to include family mem-
bers in educational efforts. Many topics such as dietary
changes require the involvement of the person who
actually prepares the meals. Efforts to encourage
smoking cessation or weight loss or increase physical
activity may be enhanced by enlisting the support of
family members who can reinforce messages and may
themselves benefit from participation.
8. Remind, repeat, and reinforce. Almost all learning
deteriorates without reinforcement. At regular inter-
vals, the patients’ understanding should be reassessed,
and key information should be repeated as warranted.
Patients should be congratulated for progress even
when their ultimate goals are not fully achieved. Even
though the patient who has reduced his or her use of
cigarettes from two packs to one pack per day has not
quit smoking, that 50% reduction in exposure is
important and may simply represent a milestone on
the path to complete cessation.
Information for Patients
There is a great deal of information that patients with
ischemic heart disease want to and should learn. This
information falls into the categories listed in the following
section.
General Aspects of Ischemic Heart Disease
PATHOLOGY AND PATHOPHYSIOLOGY. Patients vary in the
level of detail they want to know about ischemic heart
disease. Because therapy for angina is closely tied to the
underlying pathophysiology, an understanding of these
derangements and the effects of medications or interven-
tions often helps patients to comply with therapy. Patients
are often interested in learning about their own coronary
anatomy and its relationship to cardiac events (683).
RISK FACTORS. It is useful to review the important known
risk factors.
COMPLICATIONS. Some patients may want to know about
the potential complications of ischemic heart disease, such
as unstable angina, MI, heart failure, arrhythmia and
sudden cardiac death.
Patient-Specific Information
PROGNOSIS. Most patients are keenly interested in under-
standing their own risk of complications, especially in the
short term. To the extent possible, it is useful to provide
numerical estimates for risk of infarction or death from
cardiovascular events because many patients assume that
their short-term prognosis is worse that it actually is.
TREATMENT. Patients should be informed about their
medications, including mechanisms of action, method of
administration, and potentially adverse effects. It is helpful
to be as specific as possible and to tie this information in
with discussions of pathophysiology. For example, it can be
explained that aspirin reduces platelet aggregation and
prevents clot formation or that beta-blockers reduce myo-
cardial oxygen demand. Patients should be carefully in-
structed about how and when to take their medications. For
example, they should be told exactly when to take sublingual
nitrates (i.e., immediately when pain begins or before
stressful activity), how often (i.e., three times spaced five
minutes apart if pain persists) and to sit down before taking
the medication. Complete explanations of other tests and
interventions should also be provided.
PHYSICAL ACTIVITY. The healthcare provider should have
an explicit discussion with all patients about any limitations
on physical activity. For most patients, this will consist of
reassurance about their ability to continue normal activities,
including sexual relations (684). Patients in special circum-
stances, for example, those who engage in extremely stren-
uous activity or have a high-risk occupation, may require
special counseling. As mentioned previously, men with
impotence who are considering the use of sildenafil should
be warned of the potentially serious consequences of using
both sildenafil and nitrates within 24 h of one another
(608).
RISK FACTOR REDUCTION. It is essential that individual risk
factors be reviewed with every patient. To engage patients in
an effective program of behavioral change that will lessen
the probability of subsequent cardiovascular events, a clear
understanding of their relevant risk factors is required. The
greatest emphasis should be placed on modifiable factors,
beginning with those that have the greatest potential for
reducing risk or are most likely to be favorably influenced.
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For example, for an obese smoker, a greater initial reduction
in risk would likely be realized through attention to smoking
cessation than by pursuit of significant weight reduction.
CONTACTING THE MEDICAL SYSTEM. It is critically impor-
tant that all patients and their families be clearly instructed
about how and when to seek medical attention. In many
communities, a major obstacle to effective therapy for acute
coronary events is the failure of patients to promptly activate
the emergency medical system (685,686). Patients should be
given an action plan that covers 1) prompt use of aspirin and
nitroglycerin if available, 2) how to access emergency
medical services, and 3) location of the nearest hospital that
offers 24-h emergency cardiovascular care. Reviewing the
description of possible symptoms of myocardial infarction
and the action plan in simple, understandable terms at each
visit is extremely important. Discussions with patients and
family members should emphasize the importance of acting
promptly.
OTHER INFORMATION. In individual circumstances, special
counseling is warranted. One quarter million people with
ischemic heart disease die suddenly each year (687). For this
reason, in many patients, CPR training for family members
is advisable. Although some may find this anxiety-
provoking, others appreciate having the potential to inter-
vene constructively and not feel helpless if cardiac arrest
occurs (688). Patients and their families should also be
counseled when a potentially heritable condition such as
familial hypercholesterolemia is responsible for premature
coronary disease.
In summary, patient education requires a substantial
investment in time by primary-care providers and specialists
using an organized and thoughtful approach. The potential
rewards for patients are also substantial in terms of im-
proved quality of life, satisfaction, and adherence to medical
therapy. As a result, many should also have improved
physical function and survival.
D. Coronary Disease Risk Factors and Evidence That
Treatment Can Reduce the Risk for Coronary Disease
Events
Recommendations for Treatment of Risk Factors
Class I
1. Treatment of hypertension according to Joint Na-
tional Conference VI guidelines. (Level of Evidence:
A)
2. Smoking cessation therapy. (Level of Evidence: B)
3. Management of diabetes. (Level of Evidence: C)
4. Exercise training program. (Level of Evidence: B)
5. Lipid-lowering therapy in patients with docu-
mented or suspected CAD and LDL cholesterol
>130 mg/dL, with a target LDL of <100 mg/dL.
(Level of Evidence: A)
6. Weight reduction in obese patients in the presence
of hypertension, hyperlipidemia, or diabetes melli-
tus. (Level of Evidence: C)
Class IIa
Lipid-lowering therapy in patients with documented
or suspected CAD and LDL cholesterol 100 to 129
mg/dL, with a target LDL <100 mg/dL. (Level of
Evidence: B)
Class IIb
1. Hormone replacement therapy in postmenopausal
women in the absence of contraindications. (Level
of Evidence: B)
2. Weight reduction in obese patients in the absence
of hypertension, hyperlipidemia or diabetes melli-
tus. (Level of Evidence: C)
3. Folate therapy in patients with elevated homocys-
teine levels. (Level of Evidence: C)
4. Vitamin C and E supplementation. (Level of Evi-
dence: B)
5. Identification and appropriate treatment of clinical
depression. (Level of Evidence: C)
6. Intervention directed at psychosocial stress reduc-
tion. (Level of Evidence: C)
Class III
1. Chelation therapy. (Level of Evidence: C)
2. Garlic. (Level of Evidence: C)
3. Acupuncture. (Level of Evidence: C)
Categorization of Coronary Disease Risk Factors
The 27th Bethesda Conference proposed the following
categorization of CAD risk factors based both on the
strength of evidence for causation and the evidence that risk
factor modification can reduce risk for clinical CAD events
(688). Of note, evidence of benefit from treating these risk
factors comes from observational studies and clinical trials.
Secondary prevention trials providing evidence of benefit
from risk factor modification are identified, but rarely have
such trials been limited to patients with chronic stable
angina. Consequently, recommendations about risk factor
treatment in patients with chronic stable angina are based
largely on inference from primary and secondary interven-
tion studies.
Category
I. Risk factors clearly associated with an increase in
coronary disease risk for which interventions
have been shown to reduce the incidence of
coronary disease events.
II. Risk factors clearly associated with an increase in
coronary disease risk for which interventions are
likely to reduce the incidence of coronary disease
events.
III. Risk factors clearly associated with an increase in
coronary disease risk for which interventions
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might reduce the incidence of coronary disease
events.
IV. Risk factors associated with an increase in coro-
nary disease risk but which cannot be modified or
the modification of which would be unlikely to
change the incidence of coronary disease events.
Risk Factors for Which Interventions Have Been
Shown to Reduce the Incidence of Coronary Disease
Events
Category I risk factors must be identified and, when
present, treated as part of an optimal secondary prevention
strategy in patients with chronic stable angina (see Fig. 11).
They are common in this patient population and readily
amenable to modification, and their treatment can have a
favorable effect on clinical outcome. For these reasons, they
are discussed in greater detail than other risk factors.
Cigarette Smoking
The evidence that cigarette smoking increases the risk
for cardiovascular disease events is based primarily on
observational studies, which have provided overwhelming
support for such an association (690). The 1989 Surgeon
General’s report concluded, on the basis of case-control
and cohort studies, that smoking increased cardiovascular
disease mortality by 50% (691). A dose-response rela-
tionship has been reported between cigarettes smoked
and cardiovascular disease risk in men (692) and women
(693), with relative risks approaching 5.5 for fatal car-
diovascular disease events among heavy smokers com-
pared with nonsmokers (693). Smoking also amplifies the
effect of other risk factors, thereby promoting acute
cardiovascular events (694). Events related to thrombus
formation, plaque instability and arrhythmias are all
influenced by cigarette smoking. A smoking history
should be obtained in all patients with coronary disease as
part of a stepwise strategy aimed at smoking cessation
(Table 30).
The 1990 Surgeon General’s report (695) summarized
clinical data which strongly suggest that smoking cessation
reduces the risk of cardiovascular events. Prospective cohort
studies show that the risk of MI declines rapidly in the first
several months after smoking cessation. Patients who con-
tinue to smoke after acute MI have an increase in the risk of
reinfarction and death; the increase in risk of death has
ranged from 22% to 47%. Smoking also has been implicated
in coronary bypass graft atherosclerosis and thrombosis.
Continued smoking after bypass grafting is associated with
a two-fold increase in the relative risk of death and an
increase in nonfatal MI and angina.
Randomized clinical trials of smoking cessation have not
been performed in patients with chronic stable angina.
Three randomized smoking cessation trials have been per-
formed in a primary prevention setting (696–698). Smok-
ing cessation was associated with a reduction of 7% to 47%
in cardiac event rates in these trials. The rapidity of risk
reduction after smoking cessation is consistent with the
known adverse effects of smoking on fibrinogen levels (699)
and platelet adhesion (700). Other rapidly reversible effects
of smoking include increased blood carboxyhemoglobin
levels, reduced HDL cholesterol (701), and coronary artery
vasoconstriction (702).
Patients with symptomatic coronary disease form the
group most receptive to treatment directed to smoking
cessation. Taylor and coworkers (703) have shown that
#32% of patients will stop smoking at the time of a cardiac
event and that this rate can be significantly enhanced to 61%
by a nurse-managed smoking cessation program. New
behavioral and pharmacologic approaches to smoking ces-
sation are available for use by trained healthcare profession-
als (703). Few physicians are adequately trained in smoking-
cessation techniques. Identification of experienced allied
healthcare professionals who can implement smoking ces-
sation programs for patients with coronary disease is a
priority. The importance of a structured approach cannot be
overemphasized. The rapidity and magnitude of risk reduc-
tion, as well as the other health-enhancing benefits of
smoking cessation, argue for the incorporation of smoking
cessation in all programs of secondary prevention of coro-
nary disease.
LDL Cholesterol
Total cholesterol level has been linked to the develop-
ment of CAD events with a continuous and graded relation,
beginning at levels of ,180 mg/dL (704,705). Most of this
risk is due to LDL cholesterol. Evidence linking LDL
cholesterol and CAD is derived from extensive epidemio-
logic, laboratory and clinical trial data. Epidemiologic stud-
ies indicate a 2% to 3% increase in risk for coronary events
per 1% increase in LDL-cholesterol level (706). Measure-
ment of LDL cholesterol is warranted in all patients with
coronary disease.
Evidence that LDL cholesterol plays a causal role in the
pathogenesis of atherosclerotic coronary disease comes from
randomized, controlled clinical trials of lipid-lowering ther-
apy. Several primary and secondary prevention trials have
shown that LDL-cholesterol lowering is associated with a
reduced risk of coronary disease events. Earlier lipid-
lowering trials used bile-acid sequestrants (cholestyramine),
fibric acid derivatives (gemfibrozil and clofibrate) or niacin
in addition to diet. The reduction in total cholesterol in
these early trials was 6% to 15% and was accompanied by a
consistent trend toward a reduction in fatal and nonfatal
coronary events. In seven of the early trials, the reduction in
coronary events was statistically significant. Although the
pooled data from these studies suggested that every 1%
reduction in total cholesterol could reduce coronary events
by 2%, the reduction in clinical events was 3% for every 1%
reduction in total cholesterol in studies lasting $5 years.
Angiographic trials, for which a much smaller number of
participants are required, provide firm evidence linking
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cholesterol reduction to favorable trends in coronary anat-
omy. In virtually all studies, the active treatment groups
experienced less progression, more stabilization of lesions,
and more regression than the control groups. More impor-
tantly, these trends toward more favorable coronary anat-
omy were linked to reductions in clinical events. A meta-
Figure 11. Guide to comprehensive risk reduction for patients with coronary and other vascular disease. ACE 5 angiotensin-converting
enzyme; AHA 5 American Heart Association; CHF 5 congestive heart failure; HDL 5 high-density lipoprotein; LDL 5 low-density
lipoprotein; LV 5 left ventricular; MI 5 myocardial infarction; and TG 5 triglycerides. *National High Blood Pressure Education
Program and National Cholesterol Education Program recommend new blood pressure levels that should trigger treatment: ,130/85, life
changes (plus medications when diabetes, CHF or renal failure are present); #140/90, life changes and medications. This figure has been
updated to reflect this new information and the use of clopidogrel as an alternative to aspirin when the latter is contraindicated. Adapted
from Smith et al. (716).
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analysis (707) of .2,000 participants in 14 trials suggests
that both LDL and HDL were important contributors to
the beneficial effects.
The most recent studies of lipid-lowering therapy involve
the HMG-CoA reductase inhibitors. A reduction in clinical
events has been demonstrated in both primary and second-
ary prevention settings. Among the most conclusive second-
ary prevention trials to evaluate the effects of cholesterol
lowering on clinical events were 4S (533) and CARE (534).
In the 4S trial, mean changes with simvastatin in total
cholesterol (225%), LDL cholesterol (235%), and HDL
cholesterol (18%) were statistically significant. These
changes in blood lipids were associated with reductions of
30% to 35% in both mortality rate and major coronary
events. Reductions in clinical events were noted in patients
with LDL-cholesterol levels in the lower quartiles at base-
line, women, and patients .60 years old. The study also
demonstrated that long-term (five-year) administration of
an HMG-CoA reductase-inhibiting drug was safe and
there was no increase in non-CHD death. In the CARE
study, 4,159 patients (3,583 men and 576 women) with
prior MI who had plasma total cholesterol levels ,240
mg/dL (mean 209) and LDL-cholesterol levels of 115 to
174 mg/dL (mean 139) were randomized to receive prava-
statin or placebo. Active treatment was associated with a
24% reduction in risk (95% CI interval, 9% to 36%; p 5
0.003) for nonfatal MI or a fatal coronary event.
The clinical trial data indicate that in patients with
established coronary disease, including chronic stable angina
pectoris, dietary intervention and treatment with lipid-
lowering medications should not be limited to those with
extreme values. The benefits of lipid-lowering therapy were
evident in patients in the lowest baseline quartile of LDL
cholesterol (modest elevations) in 4S and in those with
minimal elevation of LDL-cholesterol level in the CARE
study. These trials establish the benefits of aggressive
lipid-lowering treatment for the most coronary disease
patients, even when LDL cholesterol is within a range
considered acceptable for patients in a primary prevention
setting. For patients with established coronary disease,
nonpharmaceutical treatment should be initiated when
LDL cholesterol is .100 mg/dL, and drug treatment is
warranted when LDL cholesterol is .130 mg/dL. The goal
of treatment is an LDL-cholesterol level #100 mg/dL.
Finally, despite LDL-cholesterol reduction, arterio-
graphic progression continues in many patients with coro-
nary disease. Arteriographic trials demonstrate continued
coronary lesion progression in 25% to 60% of subjects even
with the most aggressive LDL-cholesterol lowering. Max-
imum benefit may require management of other lipid
abnormalities (elevated triglycerides, low HDL cholesterol)
and treatment of other atherogenic risk factors.
Hypertension
Data from numerous observational studies indicate a
continuous and graded relation between blood pressure and
cardiovascular disease risk (708,709). A meta-analysis by
MacMahon and colleagues (710) of nine prospective, ob-
servational studies involving .400,000 subjects showed a
strongly positive relationship between both systolic and
diastolic blood pressure and CHD; the relationship was
linear without a threshold effect and showed a relative risk
that approached 3.0 at the highest pressures.
Hypertension probably predisposes patients to coronary
events both as a result of the direct vascular injury caused by
increases in blood pressure and its effects on the myocar-
dium, including increased wall stress and myocardial oxygen
demand.
The first and second Veterans Affairs Cooperative studies
(711,712) were the first to definitively demonstrate the
benefits of hypertension treatment. A meta-analysis of 17
randomized trials of therapy in .47,000 patients confirmed
the beneficial effects of hypertension treatment on cardio-
vascular disease risk (713). More recent trials in older
patients with systolic hypertension have underscored the
benefits to be derived from blood pressure lowering in the
elderly. A recent meta-analysis found that the absolute
reduction of coronary events in older subjects (2.7/1,000
person-years) was more than twice as great as that in
younger subjects (1.0/1,000 person-years) (714). This find-
ing contrasts with clinical practice, in which hypertension
often is less aggressively treated in older persons.
Table 30. Smoking Cessation for the Primary Care Clinician
Strategy 1. Ask—systematically identify all tobacco users at
every visit
● Implement an office-wide system that ensures that, for
EVERY patient at EVERY clinic visit, tobacco-use status
is queried and documented.
Strategy 2. Advise—strongly urge all smokers to quit
● In a clear, strong, and personalized manner, urge every
smoker to quit.
Strategy 3. Identify smokers willing to make a quit attempt
● Ask every smoker if he or she is willing to make a quit
attempt at this time.
Strategy 4. Assist—aid the patient in quitting
● Help the patient with a quit plan.
● Encourage nicotine replacement therapy or bupropion
except in special circumstances.
● Give key advice on successful quitting.
● Provide supplementary materials.
Strategy 5. Arrange—schedule follow-up contact
● Schedule follow-up contact, either in person or via
telephone.
Modified from Fiore MC, Bailey WC, Cohen JJ, et al. Smoking Cessation. Clinical
Practice Guideline Number 18. AHCPR Publication No. 96-0692. Rockville, MD:
Agency for Health Care Policy and Research, Public Health Service, U.S. Department
of Health and Human Services, 1996.
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Clinical trial data on the effects of blood pressure lower-
ing in hypertensive patients with established coronary dis-
ease are lacking. Nevertheless, blood pressure should be
measured in all patients with coronary disease.
Hypertension Treatment
The National High Blood Pressure Education Program
Joint National Committee on Prevention, Detection, Eval-
uation, and Treatment of High Blood Pressure (21) recently
recommended a system for categorizing levels of blood
pressure and risk classes. Hypertension is present when the
average blood pressure is $140 mm Hg systolic or
$90 mm Hg diastolic. High normal blood pressure is
present when the systolic blood pressure is 130 to
139 mm Hg or diastolic pressure is 85 to 89 mm Hg. The
level of blood pressure and the concomitant presence of risk
factors, coexisting cardiovascular disease, or evidence of
target-organ damage are used in the classification of blood
pressure severity and to guide treatment. Coronary disease,
diabetes, LV hypertrophy, heart failure, retinopathy and
nephropathy are indicators of increased cardiovascular dis-
ease risk. The target of therapy is a reduction in blood
pressure to ,130 mm Hg systolic and ,85 mm Hg
diastolic in patients with coronary disease and coexisting
diabetes, heart failure or renal failure and ,140/90 mm Hg
in the absence of these coexisting conditions.
Hypertensive patients with chronic stable angina are at
high risk for cardiovascular disease morbidity and mortality.
The benefits and safety of hypertension treatment in such
patients have been established (715,716). Treatment begins
with nonpharmacologic means. When lifestyle modifica-
tions and dietary alterations adequately reduce blood pres-
sure, pharmacologic intervention may be unnecessary. The
modest benefit of antihypertensive therapy for coronary
event reduction in clinical trials may underestimate the
efficacy of this therapy in hypertensive patients with estab-
lished coronary disease because in general, the higher the
absolute risk of the population, the greater the magnitude of
response to therapy.
Lowering the blood pressure too rapidly, especially when
it precipitates reflex tachycardia and sympathetic activation,
should be avoided. Blood pressure should be lowered to
,140/90 mm Hg, and even lower blood pressure is desir-
able if angina persists. When pharmacologic treatment is
necessary, beta-blockers or calcium channel antagonists may
be especially useful in patients with hypertension and angina
pectoris; however, short-acting calcium antagonists should
not be used (581,582,717). In patients with chronic stable
angina who have had a prior MI, beta-blockers without
intrinsic sympathomimetic activity should be used because
they reduce the risk for subsequent MI or sudden cardiac
death. Use of ACE inhibitors is also recommended in
hypertensive patients with angina in whom LV systolic
dysfunction is present to prevent subsequent heart failure
and mortality (715). If beta-blockers are contraindicated
(e.g., the presence of asthma) or ineffective in controlling
blood pressure or angina symptoms, verapamil or diltiazem
should be considered because they have been shown to
modestly reduce cardiac events and mortality after non–Q-
wave MI and after MI with preserved LV function
(1,718,719).
Finally, the risk of hypertension cannot be taken in
isolation. This risk is unevenly distributed and closely
related to the magnitude and number of coexisting risk
factors, including hyperlipidemia, diabetes and smoking
(720).
LV Hypertrophy
Left ventricular hypertrophy (LVH) is the response of the
heart to chronic pressure or volume overload. Its prevalence
and incidence are higher with increasing levels of blood
pressure (721). Epidemiologic studies have implicated LVH
as a risk factor for development of MI, CHF and sudden
death (722,723). Its association with increased risk has been
described in hospital and clinic-based studies (373,724,725)
and population studies (371,372,726). Left ventricular hy-
pertrophy has also been shown to predict outcome in
patients with established CAD (727).
There is a growing body of evidence in hypertensive
patients that LVH regression can occur in response to
pharmacologic and nonpharmacologic (728,729) antihyper-
tensive treatment. Recent data suggest that regression of
LVH can reduce the cardiovascular disease burden associ-
ated with this condition. A report from the Framingham
Heart Study found that subjects who demonstrated ECG
evidence of LVH regression were at a substantially reduced
risk for a cardiovascular event (50) compared with subjects
who did not. Studies are needed to definitively establish the
direct benefits of LVH regression. There are no clinical
trials of LVH regression in patients with chronic stable
angina.
Thrombogenic Factors
Coronary artery thrombosis is a trigger of acute MI.
Aspirin has been documented to reduce risk for CHD
events in both primary and secondary prevention settings
(730). A number of prothrombotic factors have been iden-
tified and can be quantified (731). In the Physicians’ Health
Study, men in the top quartile of C-reactive protein values
had three times the risk of MI and two times the risk of
ischemic stroke compared with men with the lowest quartile
values (732). The reduction in risk of MI associated with
the use of aspirin was directly related to the level of
C-reactive protein.
Elevated plasma fibrinogen levels predict CAD risk in
prospective observational studies (733). The increase in risk
related to fibrinogen is continuous and graded (734). In the
presence of hypercholesterolemia, a high fibrinogen level
increases CHD risk .6 times (735), whereas a low fibrin-
ogen level is associated with reduced risk, even in the
presence of high total cholesterol levels (736). Elevated
triglycerides, smoking and physical inactivity are all associ-
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ated with increased fibrinogen levels. Exercise and smoking
cessation appear to favorably alter fibrinogen levels, as do
fibric acid-derivative drugs. Reducing fibrinogen levels
could lower coronary disease risk by improving plasma
viscosity and myocardial oxygen delivery and diminishing
the risk of thrombosis (731). Anticoagulant or antiplatelet
therapy may reduce the hazards associated with an elevated
fibrinogen level even though these agents do not lower the
fibrinogen level itself.
Several studies support an association between platelet
function and vascular disease, a finding consistent with the
known role of platelets in thrombosis, which is a precipitant
of acute CAD events (731). Measures of platelet hyperag-
gregability, including the presence of spontaneous platelet
aggregation (737) and increased platelet aggregability in-
duced by conventional stimuli (738), provide evidence of an
association between platelet aggregability and an increased
risk for CAD events in both cohort and cross-sectional
studies. This may explain the proved benefits of aspirin
therapy in both primary and secondary prevention settings.
Other potential thrombogenic/hemostatic risk factors in-
clude factor VII, plasminogen activator inhibitor-1 (PAI-1),
tPA, von Willebrand factor, protein C and antithrombin III
(731,739). It is probable that anticoagulants can affect several
of these factors, partially explaining their influence on decreas-
ing CAD risk in certain secondary prevention settings.
Risk Factors for Which Interventions Are Likely to
Reduce the Incidence of Coronary Disease Events
Diabetes Mellitus
Diabetes, which is defined as a fasting blood sugar .126
mg/dL (740), is present in a significant minority of adult
Americans. Data supporting an important role of diabetes
mellitus as a risk factor for cardiovascular disease come from
a number of observational settings. This is true for both type
I, insulin-dependent diabetes mellitus (IDDM), and type II,
noninsulin-dependent diabetes mellitus (NIDDM). Ath-
erosclerosis accounts for 80% of all diabetic mortality
(741–743), with coronary disease alone responsible for 75%
of total atherosclerotic deaths. In persons with type I
diabetes, coronary mortality is increased three- to ten-fold;
in patients with type II diabetes, risk for coronary mortality
is two-fold in men and four-fold in women. The National
Cholesterol Education Program estimates that 25% of all
heart attacks in the U.S. occur in patients with diabetes
(744,745). Diabetes is associated with a poor outcome in
patients with established coronary disease, even after angio-
graphic and other clinical characteristics are considered. For
example, diabetic persons in the CASS registry experienced
a 57% increase in the hazard of death after controlling for
other known risk factors (746).
Although better metabolic control in persons with type I
diabetes has been shown to lower the risk for microvascular
complications (741,747–749), there is a paucity of data on
the benefits of tighter metabolic control in type I or type II
diabetes with regard to reducing risk for coronary disease in
either primary or secondary prevention settings. At present,
it is worthwhile to pursue strict glycemic control in diabetic
persons with chronic stable angina with the belief that this
will provide benefits with regard to microvascular compli-
cations and also may reduce risk for other cardiovascular
disease complications. However, convincing data from clin-
ical trials are lacking. The long-standing controversy regard-
ing the potentially adverse effects of oral hypoglycemic
agents persists (750).
The common coexistence of other modifiable factors in
the diabetic patient contributes to increased coronary dis-
ease risk, and they must be managed aggressively (751,752).
These risk factors include hypertension, obesity and in-
creased LDL-cholesterol levels. In addition, elevated tri-
glyceride levels and low HDL-cholesterol levels are com-
mon in persons with diabetes.
HDL Cholesterol
Observational studies and clinical trials have documented
a strong inverse association between HDL cholesterol and
CAD risk. It has been estimated that a 1-mg/dL decline in
HDL cholesterol is associated with a 2% to 3% increase in
risk for coronary disease events (753). This inverse relation
is observed in men and women and among asymptomatic
persons as well as patients with established coronary disease.
Low levels of HDL cholesterol are often observed in
persons with adverse risk profiles (obesity, diabetes, smok-
ing, high levels of LDL cholesterol and triglycerides and
physical inactivity). Although low levels of HDL are clearly
associated with increased risk for CHD and there is good
reason to conclude that such a relation is causal (e.g.,
biological plausibility), it has been difficult to demonstrate
that raising HDL lowers CHD risk. No completed trial has
been able to address the efficacy of raising HDL cholesterol
alone; drugs that raise HDL also lower LDL cholesterol or
triglyceride levels. The National Cholesterol Education
Program Adult Treatment Panel II has defined a low
HDL-cholesterol level as ,35 mg/dL (754). Patients with
established coronary disease and low HDL cholesterol are at
high risk for recurrent events and should be targeted for
aggressive nonpharmacologic treatment (dietary modifica-
tion, weight loss, physical exercise) and, when appropriate,
drug treatment directed at the entire lipid profile. Nicotinic
acid and fibrates can raise HDL levels appreciably, as do
HMG-CoA reductase inhibitors and estrogen replacement
therapy to a lesser degree. The benefits of lowering LDL
levels in coronary disease patients who have low HDL
cholesterol and LDL levels ,130 mg/dL have not been
established, nor have the benefits of raising HDL levels in
such persons.
Obesity
Obesity is a common condition associated with increased
risk for coronary disease and mortality (755,756). Obesity is
associated with and contributes to other coronary disease
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risk factors, including high blood pressure, glucose intoler-
ance, low HDL cholesterol, and elevated triglyceride levels.
Hence, much of the increased CAD risk associated with
obesity is mediated by these risk factors. It is likely that for
obese patients with coronary disease, weight reduction can
reduce risk for future coronary events because weight
reduction will bring about improvements in these other
modifiable risk factors. Because of the increased myocardial
oxygen demand imposed by obesity and the demonstrated
effects of weight loss on other coronary disease risk factors,
weight reduction is indicated in all obese patients with
chronic stable angina. Referral to a dietitian is often
necessary to maximize the likelihood of success of a dietary
weight loss program. No clinical trials have specifically
examined the effect of weight loss on risk for coronary
disease events.
Physical Inactivity
The evidence and recommendations presented here are
based heavily on previously published documents, particu-
larly the 27th Bethesda Conference on risk factor manage-
ment (23), the AHCPR/NHLBI clinical practice guideline
on cardiac rehabilitation (24), and the AHA scientific
statement on exercise (757). Interested readers are referred
to those documents for more detailed discussions of the
evidence and organizational issues regarding performance of
exercise training. Although this section focuses on the
effects of exercise training, it is important to recognize that
such training is usually incorporated into a multifactorial
risk factor reduction effort, which includes smoking cessa-
tion, lipid management, and hypertension treatment, all of
which were covered in previous sections. Many of the
studies performed in the literature have tested multifactorial
intervention rather than exercise training alone. The evi-
dence presented here therefore assumes that exercise train-
ing is incorporated into such a multifactorial program
whenever possible.
A large portion of the published evidence regarding
exercise training focuses on post-MI or postcoronary revas-
cularization patients. Although it is attractive to apply this
evidence to patients with stable angina, such an extrapola-
tion is not appropriate, as most patients with stable angina
have not suffered an MI or undergone coronary revascular-
ization, and patients with MI are more likely to have
three-vessel or left main coronary artery disease and a more
adverse short-term prognosis. This section therefore focuses
on published data from patients with stable angina and, for
the most part, will exclude data derived from patients with
previous MI or coronary revascularization. The single ex-
ception is the subsection on safety issues, as the committee
thought that the risk of exercise training in patients with
stable angina should be no greater than that in patients with
recent MI who have been studied extensively.
Any discussion of exercise training must acknowledge
that it will not only usually be incorporated into a multi-
factorial intervention program but will have multiple effects.
It is biologically difficult to separate the effects of exercise
training from the multiple secondary effects that it may have
on confounding variables. For example, exercise training
may lead to changes in patient weight, sense of well-being
and antianginal medication. These effects will be clear
confounders in interpreting the impact of exercise training
on exercise tolerance, patient symptoms, and subsequent
cardiac events. This presentation will assume that the
primary and secondary effects of exercise training are closely
intertwined and will make no effort to distinguish them.
Effects of Exercise Training on Exercise Tolerance,
Symptoms, and Psychological Well-Being
Multiple randomized, controlled trials comparing exer-
cise training with a “no-exercise” control group have dem-
onstrated a statistically significant improvement in exercise
tolerance for the exercise group versus the control group.
These data, which are summarized in Table 31, are remark-
able for several features. First, they are remarkably consis-
tent (eight of nine studies with positive results; the single
exception studied disabled patients) despite small sample
sizes, multiple different outcome variables, and variable
length of follow-up (24 days to 4 years). Four of the nine
studies incorporated exercise training into a multifactorial
intervention; five tested exercise training alone. A variety of
different settings were used, including outpatient rehabili-
tation centers, home rehabilitation monitoring, and a resi-
dential unit. The major limitation of the published evidence
is that it is based almost exclusively on male patients. Six of
the nine studies (705,758–762) enrolled male patients
exclusively. Two studies did not provide data about the
gender of the patients enrolled (763,764). The largest study
of 300 patients (765) enrolled only 41 women. Thus, there
is relatively little evidence from randomized trials to confirm
the efficacy of exercise training in female patients. Obser-
vational studies (766–768) have suggested that women
benefit at least as much as men.
Given the consistently positive effect of exercise training
on exercise capacity, it is not surprising that it also results in
an improvement in symptomatology. However, the number
of randomized trials demonstrating this point in patients
with stable CHD is far fewer. As shown in Table 32, the
three published randomized trials (758,769,770) have en-
rolled ,250 patients. Two of the three studies (758,770)
demonstrated a statistically significant decrease in patient
symptoms, but one did not (769). The overall magnitude of
these effects was modest.
Four randomized trials have examined the potential
benefit of exercise training on objective measures of isch-
emia (Table 32). One study used ST-segment depression on
ambulatory monitoring, and three used exercise myocardial
perfusion imaging with 201Tl. Three of the four studies
(759,763,770) demonstrated a reduction in objective mea-
sures of ischemia in those patients randomized to the
exercise group compared with the control group. The last
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study (705) reported a significant decrease in ST depression
during exercise but not in the exercise thallium defect or
thallium redistribution. Although it is not specifically dem-
onstrated in these studies, the threshold for ischemia is
likely to increase with exercise training, as training reduces
the heart rate-blood product at a given submaximal exercise
workload.
There is a widespread belief among cardiac rehabilitation
professionals that exercise training improves patients’ sense
of well-being. Although multiple randomized trials have
used a variety of instruments to measure significant differ-
ences in various psychological outcomes between the exer-
cise group and the control group, these trials have been
conducted in patients following MI. Given the underlying
biologic differences outlined above and the well-
documented effects of MI on patients’ sense of well-being,
these results are not easily extrapolated to patients with
stable angina. A single nonrandomized trial compared
multifactorial intervention (including exercise and psycho-
logical intervention) in 60 treated patients with 60 control
patients (771). Follow-up was performed three months
later. There was a significant reduction in disability scores,
an improvement in well-being scores, and an improvement
in positive affect scores in the intervention group. Thus, the
evidence supporting an improvement in psychological pa-
rameters with exercise training in patients with stable angina
is very limited.
Lipid Management and Disease Progression
Multiple randomized trials have examined the potential
benefit of exercise training in the management of lipids
(Table 33). Some of these trials have examined exercise
training alone; others have studied exercise training as part
of a multifactorial intervention. Again, the majority of
subjects studied have been male. Of the 1,827 patients
studied, only 52 were women. Most studies had a follow-up
of one year. One study used a 24-day follow-up. Two other
studies used much longer follow-ups of 39 months and 4
years, respectively. Most studies have found a statistically
Table 31. Randomized Controlled Trials Examining the Effects of Exercise Training on Exercise Capacity in Patients With
Stable Angina
First
Author Reference N Men (%) Setting Intervention F/U Outcome
Ornish (763) 46 N/A Res M 24 d 1 ex. tolerance
Froelicher (758) 146 100 OR E 1 yr 1 ex. tolerance
1 O2 consumption
May (764) 121 N/A OR E 10–12 mos. 1 O2 consumption
1 max HR-BP
Sebrechts (759) 56 100 OR E 1 year 1 ex. duration
Oldridge (760) 22 100 OR/H E 3 mos. 1 O2 consumption
Schuler (705) 113 100 OR M 1 year 1 work capacity
1 max HR-BP
Hambrecht (761) 88 100 Hosp/H M 1 year 1 O2 consumption
1 ex. duration
Fletcher (762) 88 100 H E 6 mos. NS (ex. duration or
Disabled O2 consumption)
Haskell (765) 300 86 H M 4 yrs. 1 ex. tolerance
Res 5 Residential facility; OR 5 Outpatient rehab; H 5 home; Hosp 5 Hospital; M 5 Multifactorial; E 5 Exercise training only;15 Statistically significant increase favoring
intervention; NS 5 No significant difference between groups; N/A 5 Not available.
Table 32. Randomized Controlled Trials Examining the Effects of Exercise Training on Symptoms and Objective Measures
of Ischemia
First
Author Reference N Men (%) Inter F/U Symptoms Objective Ischemia
Froelicher (758) 146 100 E 1 year 2 2 thallium ischemia score
Sebrechts (759) 56 100 E 1 year — 1 thallium uptake
Ornish (763) 48 N/A M 1 year NS —
Todd (770) 40 100 E 1 year 2 2 ST depression (ambulatory
monitor)
Schuler (705) 113 100 M 1 year — 2 ST depression (exercise)
NS (exercise thallium defect or
redistribution)
NS 5 No significant difference;1 5 Statistically significant increase favoring intervention group;2 5 Statistically significant decrease favoring intervention group; N/A 5 Not
available; Inter 5 Intervention; M 5 Multifactorial; E 5 Exercise training only.
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significant reduction in total cholesterol and LDL choles-
terol (where reported) favoring the intervention group, but
this finding has not been totally uniform. One larger, older
study (772) did not show a significant reduction in choles-
terol in the treatment group along with one more recent
small study (773). Five of the seven studies that reported the
results of intervention on triglycerides found a significant
reduction favoring the treatment group. Two studies of 88
and 48 patients, respectively, did not (761,762). The results
of intervention on HDL cholesterol have been far less
impressive. Only one study (765) reported a statistically
significant increase in HDL cholesterol favoring the treat-
ment group. Four others (705,761,762,774) have not found
any difference between the control and treatment groups.
One study found a decrease in HDL cholesterol in the
treatment group. The preponderance of evidence clearly
suggests that exercise training is beneficial and associated
with a reduction in total cholesterol, LDL cholesterol, and
triglycerides compared with controlled therapy but has little
effect on HDL cholesterol. However, it must be recognized
that exercise training alone is unlikely to be sufficient in
patients with a true lipid disorder.
Not surprisingly, this reduction in lipids has been asso-
ciated with less disease progression according to angio-
graphic follow-up. Four of the randomized trials of lipid
management, all involving multifactorial intervention, per-
formed follow-up angiography to assess disease progression.
Three of the studies performed follow-up angiography at
one year; the remaining study performed angiographic
follow-up at four years. All the studies demonstrate signif-
icantly less disease progression and more disease regression
in the intervention group.
Although exercise training has a beneficial effect on disease
progression, it has not been associated with any consistent
changes in cardiac hemodynamic measurements (775–777),
LV systolic function (778–780), or coronary collateral circula-
tion (763). In patients with heart failure and decreased LV
function, exercise training does produce favorable changes in
the skeletal musculature (781), but there has not been a
consistent effect on LV dysfunction (782,783).
Safety and Mortality
Physicians and patients are sometimes concerned about
the safety of exercise training in patients with underlying
coronary disease. Two major surveys of rehabilitation pro-
grams have been conducted to determine the rates of
cardiovascular events based on questionnaire responses. One
study of 30 programs in North America covering the period
of 1960 to 1977 (780) found a nonfatal cardiac arrest rate of
1/32,593 patient-hours of exercise and a nonfatal MI rate of
1/34,600 patient-hours of exercise. A more recent study of
142 U.S. cardiac programs from 1980 to 1984 (784)
reported an even lower nonfatal MI rate of 1/294,000
patient-hours. Thus, there is clearly a very low rate of
serious cardiac events during cardiac rehabilitation.
These survey data are supported by the results of ran-
domized trials following MI. As indicated earlier, the commit-
tee believed that these data can be appropriately extrapolated to
patients with stable angina, because it is unlikely that patients
with stable angina are at greater risk than those who are
post-MI. Fifteen randomized control trials, 10 of which
involved exercise as the major intervention and 5 of which used
exercise as part of a multifactorial intervention, reported no
statistically significant differences in the rates of reinfarction
comparing patients in the intervention group with those in the
control group (24). These randomized data clearly support the
safety of exercise training. It is important to recognize that
recent clinical practice, including acute reperfusion therapy for
MI, the use of beta-blockers and ACE inhibitors after MI, and
the aggressive use of revascularization, has probably further
reduced the risk of exercise training compared with the
previously reported literature.
Given its effects on lipid management and disease pro-
gression, it is attractive to hypothesize that exercise training
Table 33. Randomized Controlled Trials Examining the Effects of Exercise Training on Lipids and Angiographic Progression
First
Author Ref N Men (%) Inter F/U Chol HDL LDL Tri
Angio
Progression/
Regression
Plavsic (786) 483 100 E 6/12 mos. * — — — —
Oberman (772) 651 100 E 1 yr. NS — — 2 —
Ornish (763) 46 89 M 24 days 2 2 — 2 —
Ornish (769) 48 88 M 1 yr. 2 NS 2 NS 2
Nikolaus (773) 45 100 E 1 yr. NS — — 2 —
Schuler (705) 92 100 E 1 yr. 2 NS 2 2 2
Watts (774) 74 100 M 39 mos. 2 NS 2 — —
Hambrecht (761) 88 100 E 1 yr. 2 NS 2 NS 2
Haskell (765) 300 86 M 4 yr. 2 1 2 2 2
1827
(52 female)
*No statistics reported.
2 5 Statistically significant decrease favoring intervention;1 5 Statistically significant increase favoring intervention; Angio 5 Angiographic; E 5 Exercise training only;
Inter 5 Intervention; m 5 Multifactorial; NS 5 No significant difference between groups; Tri 5 Triglycerides.
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will reduce the subsequent risk of cardiac events. However,
only one clinical trial has examined the influence of exercise
training on subsequent cardiac events in patients with stable
angina. Haskell et al. (765) enrolled 300 patients with stable
angina, including some who were postrevascularization, in a
four-year follow-up study comparing multifactorial inter-
vention with usual care. The cardiac event rate in the study
was low. There were 3 cardiac deaths in the usual-care
group and 2 in the intervention group as well as 10 nonfatal
MIs in the usual-care group and 4 in the intervention group.
When cardiac events initiating hospitalization, including
death, MI, PTCA and CABG, were tabulated, there was a
total of 25 events in the intervention group and 44 in the
usual-care group (risk ratio 0.61; p 5 0.05). However, the
cardiac event rate was not a primary a priori end point of the
study. Although these data suggest a favorable effect of
exercise training on patient outcome, they are clearly not
definitive. In contrast, several meta-analyses of randomized
trials in patients with previous MI have shown a 20% to
30% reduction in cardiac deaths with exercise training
(678,785) but no reduction in nonfatal MI.
Postmenopausal Status
Both estrogenic and androgenic hormones produced by the
ovary are protective against the development of atherosclerotic
cardiovascular disease. When hormonal production decreases
in the perimenopausal period over several years, the risk of
CAD rises in postmenopausal women. By age 75, the risk of
atherosclerotic cardiovascular disease among men and women
is equal. Women have an accelerated risk of developing CAD
if they experience an early menopause or abrupt onset of
menopause through surgical removal or chemotherapeutic
ablation of the ovaries. Loss of estrogen and onset of meno-
pause result in an increase in LDL cholesterol, a small decrease
in HDL cholesterol, and therefore an increased ratio of total to
HDL cholesterol (787).
Postmenopausal estrogen replacement has been proposed
for both primary and secondary prevention of CAD in
women. Prospective studies of the effects of estrogen ad-
ministration on cardiac risk factors demonstrate an increase
in HDL cholesterol and a decrease in LDL cholesterol
(788–791). Other effects of estrogen replacement include a
decrease in the likelihood of thrombosis (788,791) and
several positive physiologic effects on the vascular smooth
muscle and the endothelium.
Numerous epidemiologic studies have been conducted to
assess the influence of estrogen replacement therapy on the
primary prevention of CAD in postmenopausal women
(792–794). The Nurses’ Health Study reported a relative
risk of 0.56 for MI or death in current users of estrogen and
a 0.83 relative risk for those women who had ever used
estrogen replacement therapy. Other beneficial health ef-
fects of estrogen replacement therapy include prevention of
osteoporosis and subsequent wrist and hip fractures and
amelioration of menopausal symptoms (e.g., vasomotor
instability, vaginal dryness, mood swings). Studies of the
efficacy of estrogen replacement therapy in women with
established CAD are limited (795–798).
However, the first published randomized trial of estrogen
plus progestin therapy in postmenopausal women with
known CAD did not show any reduction in cardiovascular
events over four years of follow-up (799), despite an 11%
lower LDL cholesterol level and a 10% higher HDL-
cholesterol level in those women receiving hormone replace-
ment therapy. In addition, women receiving hormone re-
placement therapy had higher rates of thromboembolic
events and gallbladder disease. Among women who received
hormone replacement therapy, there was a trend toward
lower late cardiovascular event rates, suggesting that addi-
tional studies now in progress may reveal a longer-term
effect of hormone replacement therapy. Other randomized
trials of hormone replacement therapy in primary and
secondary prevention of CAD in postmenopausal women
are being conducted, and their results will become available
over the next several years.
Risk Factors for Which Interventions Might Reduce
the Incidence of Coronary Disease Events
Psychosocial Factors
The evidence and recommendations presented here are
based heavily on previously published documents, including
the 27th Bethesda Conference on Risk Factor Management
(23) and the AHCPR/NHLBI clinical practice guideline on
cardiac rehabilitation (24). More detailed discussions of the
complex issues involved are available in those documents.
Education, counseling, and behavioral interventions are
important elements of a multifactorial risk factor reduction
effort directed at smoking cessation, lipid management and
hypertension treatment, as previously mentioned. The evi-
dence presented here therefore assumes that appropriate
multifactorial intervention has been initiated in those areas
and considers the specific application of similar broad-based
efforts to reduce stress and address other psychological
problems.
Most of the published evidence on stress management
focuses on patients who are post-MI or postrevasculariza-
tion. The extrapolation of the findings from such patient
populations to patients with stable angina is questionable.
Patients with MI are further along in the natural history of
CAD, and the occurrence of MI may have itself altered
their psyche, creating psychological problems or a difference
in their overall response to general life stresses. Unfortu-
nately, the published data regarding stress management in
patients with stable angina are quite limited.
EVIDENCE LINKING STRESS AND PSYCHOLOGICAL FACTORS TO
CAD. A variety of psychological factors, particularly type A
personality, have been associated with the development of
clinically apparent CAD (800,801). Epidemiologic evidence
linking such psychological factors to CAD has not always
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been consistent (802–805). Psychological stress, depression,
anger and hostility (806,807) may be even more closely
associated with coronary risk. More recently, studies have
focused more specifically on measures of hostility, which
appears to have a more powerful influence on coronary
disease outcome than other psychosocial factors (808,809).
TREATMENT DIRECTED AT STRESS REDUCTION AND PSYCHO-
LOGICAL WELL-BEING. A number of randomized trials in-
volving post-MI patients have shown that interventions
designed to reduce stress can reduce recurrent cardiac events
by 35% to 75% (810–812). The trials were generally small
and used a wide variety of different approaches, including
relaxation training, behavior modification and psychosocial
support. Other psychological outcomes were also improved
by intervention (24). However, for the reasons indicated
above, it is not evident whether such results apply to patients
with stable angina.
Two studies on stress management are potentially appli-
cable to patients with stable angina. One was a small,
nonrandomized trial of three weeks of relaxation training in
association with a cardiac exercise program (813). Anxiety,
somatization and depression scores were all lower in the
treatment than the control group. More recently, Blumen-
thal et al. (814) examined the effects of a four-month
program of exercise or stress management training in 107
patients with CAD and documented ischemia. Forty pa-
tients were assigned to a nonrandom, usual-care comparison
group. The remaining patients were randomized to either
exercise or stress management. The stress-management
program included patient education, instruction in specific
skills to reduce the components of stress, and biofeedback
training. During follow-up of 38 6 17 months, there was a
significant reduction in overall cardiac events in the stress-
management group compared with the nonrandom usual-
care group. However, virtually all the events consisted of
CABG or angioplasty. The exercise group had an event rate
that was not statistically significantly different from either of
the other groups. The predominance of revascularization
events could potentially reflect a change in patient prefer-
ence for revascularization as a result of education.
DEPRESSION AND ANXIETY. Many patients with CAD have
depression or anxiety related to their disease that may be
severe enough to benefit from short-term psychological
treatment (815,816). Identification and treatment of de-
pression should therefore be incorporated into the clinical
management of patients with stable angina. The safety of
pharmacologic therapy for depression in patients with isch-
emic heart disease is under investigation.
Triglycerides
Triglyceride levels are predictive of CHD risk in a variety
of observational studies and clinical settings (817). Much of
the association of triglycerides with CHD risk is related to
other factors, including diabetes, obesity, hypertension, high
LDL cholesterol and low HDL cholesterol (818). In addi-
tion, hypertriglyceridemia is often found in association with
abnormalities in hemostatic factors (819).
Nonpharmacologic management of high triglycerides
consists of weight loss, reduction in alcohol consumption for
those in whom this mechanism may be causal, smoking
cessation and physical activity. Drugs that can lower triglycer-
ides include nicotinic acid, fibrate derivatives, and to a lesser
degree HmG CoA reductase inhibitors. It is not clear whether
treatment directed at high triglyceride levels will reduce risk for
initial or recurrent CHD events. Data from the Helsinki Study
(820) indicated that among patients with elevated non-HDL
cholesterol, treatment with gemfibrozil reduced risk for CHD
events. This reduction in risk may be linked to the effects of
treatment on lipid components other than triglyceride level.
A 1992 consensus development conference defined tri-
glycerides of 200 to 400 mg/dL as “borderline high,” 400 to
1000 mg/dL as “high,” and .1000 mg/dL as “very high”
(821). The National Cholesterol Education Program Adult
Treatment Panel II provides guidance for the management
of elevated triglyceride levels (754).
Lipoprotein(a)
Lipoprotein(a) (Lp[a]) is a lipoprotein particle that has been
linked to CHD risk in observational studies (822,823). Lp(a)
levels are largely genetically determined (822). Elevated Lp(a)
levels are found in 15% to 20% of patients with premature
CHD (824). Among conventional lipid agents, only niacin
taken in high doses lowers Lp(a) levels (822). No prospective
intervention trial has specifically studied the effect of Lp(a)
lowering on risk of recurrent coronary disease events.
Homocysteine
Increased homocysteine levels are associated with increased
risk of CAD, peripheral arterial disease and carotid disease
(825–828). Although elevated homocysteine levels can oc-
cur as a result of inborn errors of metabolism such as
homocystinuria, homocysteine levels can also be increased
by deficiencies of vitamin B6, vitamin B12, and folate, which
commonly occur in older persons (829,830). More than
20% of the older subjects evaluated by the Framingham
Heart Study population had elevated homocysteine levels
(829). In patients with coronary disease and elevated ho-
mocysteine levels, supplementation with vitamins B6, B12,
and folic acid is relatively inexpensive and will usually lower
homocysteine levels. Clinical trials are needed to determine
whether such treatment is beneficial.
Oxidative Stress
Extensive laboratory data indicate that oxidation of LDL
cholesterol promotes and accelerates the atherosclerosis
process (831,832). Observational studies have documented
an association between dietary intake of antioxidant vita-
mins (vitamin C, vitamin E, and beta carotene) and reduced
risk for CHD (833).
Clinical trial evidence is incomplete regarding the poten-
tial benefits of supplementation with antioxidant vitamins.
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A Finnish study (834) failed to show a reduction in CHD
risk among middle-aged male smokers who received either
beta carotene or vitamin E. In the Cambridge Heart
Antioxidant Study (CHAOS) (835), dietary supplementa-
tion with vitamin E in patients with established ischemic
heart disease reduced risk for nonfatal MI by 77% (CI 89%
to 53%). In contrast, secondary analysis revealed a slight
excess of cardiovascular deaths in the actively treated group
(118%, p 5 0.61). Clinical trial data are not available to
support vitamin C supplementation in patients with CHD.
Probucol is a lipid-lowering drug with antioxidant prop-
erties. In a recent clinical trial, patients with coronary disease
undergoing angioplasty were treated with placebo, probucol, or
multivitamins (beta carotene, vitamin E, and vitamin C). A
reduction in restenosis was observed only with probucol (836).
In the PQRST trial, however, treatment with probucol had no
effect on femoral artery atherosclerosis (837).
Although dietary supplementation with antioxidants or a
diet rich in foods with antioxidant potential, especially
vitamin E, may be of benefit to patients with chronic stable
angina, the benefits are still unresolved.
Consumption of Alcohol
Observational studies have repeatedly shown an inverse
relation of moderate alcohol intake (approximately 1 to 3
drinks daily) to risk of CHD events (838–840). Excessive
alcohol intake can promote many other medical problems that
can outweigh its beneficial effects on CHD risk. Although
some studies have suggested an association of wine consump-
tion with a reduction in CHD risk that is greater than that
observed for beer or spirits, this issue is unresolved.
The benefits of moderate alcohol consumption may be
mediated through the effects of alcohol on HDL choles-
terol. An alternative mechanism is the potentially beneficial
effects of flavonoids. In the Zutphen Study (841), flavonoid
consumption was inversely related to mortality from CHD,
with risk in the lowest tertile of intake less than half that of
the highest tertile. In contrast, in the Physicians’ Health
Study (842), the association of flavonoid intake to risk for
MI was not significant. Clinical trials are lacking on the
effect of alcohol intake on CHD risk.
Risk Factors Associated With Increased Risk but That
Cannot Be Modified or the Modification of Which
Would Be Unlikely to Change the Incidence of
Coronary Disease Events
Advancing age, male gender and a positive family history
of premature CHD are nonmodifiable risk factors for CHD
that exert their influence on CHD risk to a large extent
through other modifiable risk factors noted above. The
National Cholesterol Education Program defines a family
history of premature CHD as definite MI or sudden death
before the age of 55 years in a father or other male
first-degree relative or before the age of 65 in a mother or
other female first-degree relative (20).
Many other risk factors for CHD have been proposed
(843), and many more will be in the future. At present, there
is little evidence that modification of risk factors other than
those covered in categories I through III above will reduce
risk for initial or recurrent CHD events.
Other Proposed Therapies
Diet
Diet is an important contributor to multiple other risk
factors discussed above, including LDL- and HDL-
cholesterol levels, blood pressure, obesity, impaired glucose
tolerance and antioxidant and vitamin intake. Conse-
quently, dietary modification can promote a favorable CHD
risk profile by affecting multiple risk pathways. Dietary
therapy has been assessed in seven randomized clinical trials
performed in CHD patients. Several early trials (844–846)
failed to demonstrate beneficial effects of diet on CHD risk.
Of the later trials (704,847–849), three demonstrated sta-
tistically significant reductions in cardiac mortality rate
associated with dietary therapy ranging from 32% to 66%
(704,847,849). These low-fat diets were high in fiber and
antioxidant-rich foods (704), monounsaturated fat (849), or
fish (847).
Some studies have found an inverse association between
fish consumption and CHD risk (850). Meta-analyses of
clinical trials have suggested that restenosis after coronary
angioplasty may be reduced by fish oils (851,852); however,
the results are inconclusive. Additional well-designed trials
are needed.
There are no randomized trials of garlic therapy in
patients with stable angina. However, garlic has been
evaluated as a treatment for two risk factors of coronary
artery disease (hypertension and hypercholesterolemia [Ta-
ble 34]). Two meta-analyses of garlic therapy for treatment
of hypercholesterolemia and hypertension were published in
the early 1990s (853,854). These suggested a small benefit
with garlic therapy. More recently, two rigorous studies of
garlic as a treatment for hypercholesterolemia have found no
measurable effect (855,856). The current evidence does not
suggest that there is a clinically significant benefit in
cholesterol reduction or blood-pressure lowering with garlic
therapy.
Therapies That Have Not Been Shown to Reduce Risk for
Coronary Disease Events
There is no evidence to support the use of chelation therapy
to treat atherosclerotic cardiovascular disease. Four random-
ized clinical trials in patients with atherosclerotic cardiovas-
cular disease (intermittent claudication) found no evidence
of a beneficial effect of chelation therapy on progression of
disease or clinical outcome (858). These results, combined
with the potential for harm from chelation therapy, indicate
that chelation therapy has no role in the treatment of
chronic stable angina.
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E. Revascularization for Chronic Stable Angina
Recommendations for Revascularization With PTCA
(or Other Catheter-Based Techniques) and CABG in
Patients With Stable Angina*
Class I
1. CABG for patients with significant left main cor-
onary disease. (Level of Evidence: A)
2. CABG for patients with three-vessel disease. The
survival benefit is greater in patients with abnormal
LV function (ejection fraction <50%). (Level of
Evidence: A)
3. CABG for patients with two-vessel disease with
significant proximal left anterior descending CAD
and either abnormal LV function (ejection fraction
<50%) or demonstrable ischemia on noninvasive
testing. (Level of Evidence: A)
4. PTCA for patients with two- or three-vessel disease
with significant proximal left anterior descending
CAD, who have anatomy suitable for catheter-
based therapy, normal LV function and who do not
have treated diabetes. (Level of Evidence: B)
5. PTCA or CABG for patients with one- or two-
vessel CAD without significant proximal left ante-
rior descending CAD but with a large area of viable
myocardium and high-risk criteria on noninvasive
testing. (Level of Evidence: B)
6. CABG for patients with one- or two-vessel CAD
without significant proximal left anterior descend-
ing CAD who have survived sudden cardiac death
or sustained ventricular tachycardia. (Level of Evi-
dence: C)
7. In patients with prior PTCA, CABG or PTCA for
recurrent stenosis associated with a large area of
viable myocardium or high-risk criteria on nonin-
vasive testing. (Level of Evidence: C)
8. PTCA or CABG for patients who have not been
successfully treated by medical therapy (see text)
and can undergo revascularization with acceptable
risk. (Level of Evidence: B)
Class IIa
1. Repeat CABG for patients with multiple saphenous
vein graft stenoses, especially when there is significant
stenosis of a graft supplying the LAD. It may be
appropriate to use PTCA for focal saphenous vein
graft lesions or multiple stenoses in poor candidates
for reoperative surgery. (Level of Evidence: C)
2. Use of PTCA or CABG for patients with one- or
two-vessel CAD without significant proximal LAD
disease but with a moderate area of viable myocar-
dium and demonstrable ischemia on noninvasive
testing. (Level of Evidence: B)
3. Use of PTCA or CABG for patients with one-
vessel disease with significant proximal LAD dis-
ease. (Level of Evidence: B)
Class IIb
1. Compared with CABG, PTCA for patients with
two- or three-vessel disease with significant proxi-
mal left anterior descending CAD, who have anat-
omy suitable for catheter-based therapy, and who
have treated diabetes or abnormal LV function.
(Level of Evidence: B)
2. Use of PTCA for patients with significant left main
coronary disease who are not candidates for CABG.
(Level of Evidence: C)
3. PTCA for patients with one- or two-vessel CAD
without significant proximal left anterior descend-
ing CAD who have survived sudden cardiac death
or sustained ventricular tachycardia. (Level of Evi-
dence: C)
Class III
1. Use of PTCA or CABG for patients with one- or
two-vessel CAD without significant proximal left
*Note: PTCA is used in these recommendations to indicate PTCA or other
catheter-based techniques, such as stents, atherectomy and laser therapy.
Table 34. Randomized Trials and Meta-Analyses of Garlic Therapy for Risk Treatment of Risk Factors
Author Year Study Type Patients
Daily Dose &
Preparation Effect of Garlic
Hypercholesterolemia
Berthold (855) 1998 RCT 25* 10 mg steam
distilled oil
No difference in multiple measures
Isaacsohn (856) 1998 RCT 40 900 mg powder No difference in multiple measures
Jain (857) 1993 RCT 42 900 mg powder Reduction in LDL of 11% vs. 3% for
placebo
Warshafsky (853) 1993 Meta-analysis 5 trials 1⁄2–1 clove per day Reduction in total cholesterol of 95 mg/dL
Hypertension
Silagy (854) 1994 Meta-analysis 8 trials 600–900 mg powder Small reduction in systolic and diastolic
BP
RCT indicates randomized controlled trial.
*Cross-over study.
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anterior descending CAD, who have mild symp-
toms that are unlikely due to myocardial ischemia
or who have not received an adequate trial of
medical therapy and
a. Have only a small area of viable myocar-
dium or
b. Have no demonstrable ischemia on non-
invasive testing. (Level of Evidence: C)
2. Use of PTCA or CABG for patients with border-
line coronary stenoses (50% to 60% diameter in
locations other than the left main coronary artery)
and no demonstrable ischemia on noninvasive test-
ing. (Level of Evidence: C)
3. Use of PTCA or CABG for patients with insignif-
icant coronary stenosis (<50% diameter). (Level of
Evidence: C)
4. Use of PTCA in patients with significant left main
coronary artery disease who are candidates for
CABG. (Level of Evidence: B)
There are currently two well-established revascularization
approaches to treatment of chronic stable angina caused by
coronary atherosclerosis. One is coronary artery bypass
grafting (CABG), in which segments of autologous arteries
or veins are used to reroute blood around relatively long
segments of the proximal coronary artery. The other is
percutaneous transluminal coronary angioplasty (PTCA), a
technique that uses catheter-borne mechanical or laser
devices to open a (usually) short area of stenosis from within
the coronary artery. Since the introduction of bypass surgery
in 1967 and PTCA in 1977, it has become clear that both
strategies can contribute to the effective treatment of pa-
tients with chronic stable angina, and both have weaknesses.
A major problem in trying to assess the role of these invasive
treatments is that demonstration of their effectiveness re-
quires long-term follow-up. Although these long-term
follow-up studies are being accomplished, treatments have
changed, usually for the better.
Revascularization is also potentially feasible with trans-
thoracic (laser) myocardial revascularization. However, this
technique, which is still in its infancy, is primarily used as an
alternative when neither CABG nor PTCA is feasible.
Coronary Artery Bypass Surgery
Coronary bypass surgery has a 30-year history. For most
patients, the operation requires a median sternotomy inci-
sion and cardiopulmonary bypass. At present, there are
alternative, less invasive forms of bypass surgery under
investigation, and some limited “mini” operations may
acquire the status of standard clinical treatment. However,
at this point, only fairly simple bypass operations are
consistently possible with less invasive techniques, and all
the studies that have documented the long-term effective-
ness of bypass surgery in terms of graft patency, symptom
relief and lower death rate have been carried out involving
patients operated on with standard techniques. With these
standard approaches to bypass surgery, extensive revascular-
ization of complex CAD can be accomplished with relative
safety.
Bypass grafts are constructed with saphenous vein (SVG)
or arterial grafts, most commonly the internal thoracic
(mammary) artery (ITA). One disadvantage of bypass graft-
ing with the saphenous vein is that there is an attrition of
vein grafts with time due to intrinsic changes that may occur
in the grafts. Data from the 1970s showed occlusion rates of
saphenous vein grafts of 10% to 15% within 1 week to 1 year
after operation and 20% to 25% by 5 years after surgery.
Beyond five postoperative years, the development of vein
graft atherosclerosis further compromised grafts so that by
10 postoperative years, '40% of saphenous vein grafts were
occluded, and approximately half of the patent grafts
showed atherosclerotic changes (859–861). Fortunately,
progress has been made in preventing vein graft attrition.
Randomized prospective studies have shown that perioper-
ative and long-term treatment with platelet inhibitors have
significantly decreased the occlusion rate of saphenous vein
grafts at 1 year after surgery to 6% to 11% (862–864), and
long-term occurrence and progression of vein graft athero-
sclerosis appear to be significantly decreased by aggressive
lipid-lowering strategies (865). However, despite these ad-
vances, vein graft atherosclerosis is still the greatest problem
compromising long-term effectiveness of CABG.
Arterial grafts, most notably the ITA, have a much lower
early and late occlusion rate than vein grafts, and in the case
of the left ITA to the LAD bypass graft (LITA-LAD),
.90% of grafts are still functioning .10 years after surgery
(859,866,867). Furthermore, the occurrence of late athero-
sclerosis in patent ITA grafts is extremely rare, and even at
20 postoperative years, the occlusion rate of these grafts is
very low. The use of the LITA-LAD graft has also been
shown to improve long-term clinical outcome in terms of
survival and freedom from reoperation, and this strategy is
now a standard part of bypass surgery at most institutions
(866,868). The right ITA has also been used for bypass
grafts at some centers and excellent long-term results have
been noted, but that strategy has not become widespread.
Other arterial grafts, including the right gastroepiploic
artery, the radial arteries and inferior epigastric arteries have
all shown promise, and excellent early results in terms of
graft patency have been documented. However, the strategy
of extensive arterial revascularization has not become wide-
spread, and long-term outcomes are as yet unknown.
CABG Versus Medical Management
The goals of coronary bypass surgery are to alleviate
symptoms and prolong life expectancy. Early in the history
of CABG, it became clear that successful bypass surgery
relieved angina or lessened symptoms. To investigate the
question of whether bypass surgery prolonged survival, three
large multicenter randomized trials, the Veterans Adminis-
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tration Cooperative Study (VA Study) (869), the European
Coronary Surgery Study (ECSS) (870), and CASS (871),
were undertaken. These trials compared the strategy of
initial bypass surgery with initial medical management with
regard to long-term survival and symptom status for pa-
tients with mild or moderate symptoms. Severely symptom-
atic patients were excluded from the randomized portions of
these trials, and crossover from medical to surgical therapy
was allowed. The lessons learned from these trials concern-
ing survival rate were that the subsets of patients for whom
bypass surgery improved the survival rate the most were
patients who were at high risk of death without surgery. The
characteristics that defined high-risk groups include the
angiographic characteristics of left main coronary artery
stenosis, three-vessel disease with abnormal LV function,
two- or three-vessel disease with a .75% stenosis in the
proximal LAD, and the clinical descriptors of an abnormal
baseline ECG and a markedly positive exercise test.
Recently, a meta-analysis of these three major random-
ized trials of initial surgery versus medical management as
well as other smaller trials has confirmed the survival benefit
achieved by surgery at 10 postoperative years for patients
with three-vessel disease, two-vessel disease, or even one-
vessel disease that included a stenosis of the proximal LAD
(489). The survival rate of these patients was improved by
surgery whether they had normal or abnormal LV function
(489). For patients without a proximal LAD stenosis,
bypass surgery improved the mortality rate only for those
with three-vessel disease or left main stenosis.
It is important to note that the largest and most pertinent
of the trials (ECSS and CASS) contained only patients with
mild or moderate symptoms; severely symptomatic patients
were excluded from randomization. In CASS, these symp-
tomatic patients excluded from randomization were moni-
tored in the CASS registry. Analysis of this prospective but
nonrandomized database showed that initial bypass surgery
dramatically improved the survival rate of severely symp-
tomatic patients with three-vessel disease regardless of
ventricular function and regardless of the presence or
absence of proximal stenoses (872).
Coronary bypass surgery consistently improves the symp-
toms of patients with angina. Observational studies have
noted freedom from angina for approximately 80% of
patients at five postoperative years (72). In the randomized
trials of surgery versus medical therapy, patients receiving
initial surgery experienced superior relief of angina at five
postoperative years. The advantage for the group initially
treated with surgery became less by 10 postoperative years,
in part because during this time many patients initially
assigned to medical therapy crossed over to receive bypass
surgery (873). In the studies included in the meta-analysis
(489), 41% of the patients assigned to the medical treatment
group had crossed over and undergone bypass surgery by 10
postoperative years. This crossover effect is important to
recognize in any study of long-term outcome in which
invasive studies are compared with medical management.
Conversely, patients who underwent initial surgery also had
a progressive increase in the incidence of reoperation with
the passage of time, although less of an incidence than that
of patients crossing over from medical to surgical therapy.
The crossover effect, however, does not totally explain the
observations that the survival advantage and improved
symptoms for patients treated with initial surgery decreased
with time beyond five postoperative years. It is probable that
much of this deterioration was related to late vein graft
failure. It is also important to note that these trials were
carried out in the relatively early years of bypass surgery and
outcomes of the procedure have improved over time. Few
patients received ITA grafts or were treated either with
platelet inhibitors or lipid-lowering agents, strategies that
have all been clearly shown to improve the long-term
outcome of patients undergoing bypass surgery. The im-
provements in short- and long-term survival rates after
bypass surgery that have occurred since the randomized
studies were conducted have been documented by observa-
tional studies (866,868,874), but further CABG-medical
treatment randomized trials have not been conducted.
Another weakness of the randomized trials that must be
kept in mind when interpreting their current implications is
that tremendous advances in imaging techniques have
allowed a more accurate definition of ischemia and thus
allowed identification of patients at “high risk” of events
with medical treatment alone that did not exist during the
years of the randomized trials. The randomized trials were
based on angiographic anatomy and baseline ventricular
function. However, improved imaging techniques have
allowed a more accurate definition of groups that can
potentially benefit from revascularization.
PTCA
Percutaneous transluminal coronary angioplasty (PTCA)
for CAD was introduced in 1977, in this strategy a
catheter-borne balloon was inflated at the point of coronary
stenosis. Alternative mechanical devices for percutaneous
treatments have been developed and have included rotating
blades or burrs designed to remove atheromatous material,
lasers to achieve photoablation of lesions and metal intra-
coronary stents designed to structurally maintain lumen
diameter. The advantages of PTCA for the treatment of
CAD are many and include a low level of procedure-related
morbidity, a low procedure-related mortality rate in prop-
erly selected patients, a short hospital stay, early return to
activity and the feasibility of multiple procedures. The
disadvantages of PTCA are that it is not feasible for many
patients, there is a significant incidence of restenosis in
lesions that are successfully treated, and there is a risk of
acute coronary occlusion during PTCA. The risk of acute
coronary occlusion during PTCA was a serious problem in
the early years of percutaneous treatments, but the advent of
intracoronary stents, improved selection of vessels for treat-
ment and improved pharmacologic therapies have greatly
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decreased the risk of acute occlusion and procedure-related
cardiac morbidity as well as emergency coronary bypass
surgery associated with PTCA. The other disadvantages of
PTCA are that many patients do not have an anatomy
suitable for percutaneous treatment and that restenosis
occurs in 30% to 40% of treated lesions within six months
(875–877).
Despite some disadvantages, the efficacy of PTCA in
producing symptom relief for some patient subsets has
become rapidly apparent, and the number of PTCA proce-
dures performed has grown so rapidly that today PTCA is
performed more commonly than bypass surgery. Initially
used to treat only proximal one-vessel CAD, the concepts of
percutaneous treatment have been extended to more com-
plex situations.
PTCA Versus Medical Treatment
The initial randomized study that compared PTCA with
medical management alone for the treatment of chronic
stable angina was the Veterans Affairs Angioplasty Com-
pared to Medicine (ACME) Trial, which involved patients
with one-vessel disease and exercise-induced ischemia. In a
six-month follow-up, the death rate was expectedly low for
both the PTCA and medically treated groups, and 64% of
the PTCA group were free of angina versus 46% of the
medically treated group (p , 0.01) (878).
A second randomized trial comparing initial PTCA
versus initial medical management (Randomized Interven-
tion Treatment of Angina [RITA-2]) included a majority of
patients with one-vessel disease (60%) and some angina
(only 20% without angina) monitored over a 2.7-year
median follow-up interval. There was a slightly greater risk
of death or MI for the PTCA group (p 5 0.02), although
those risks were low for both groups. The greater risk of MI
in the PTCA group was due to enzyme elevations during
the procedure. The PTCA patients had less angina three
months after randomization, although by two years the
differences between the two groups were small (7.6% more
medically treated patients had angina). Some of that nar-
rowing of the difference in symptom status was due to the
crossover of medically treated patients to PTCA or bypass
surgery. By one year, 15% of the medically treated group
had crossed over to PTCA or CABG and 14.9% of the
initial PTCA group had undergone repeat PTCA or
CABG. Thus, compared with medically treated patients,
the PTCA group had improved symptoms, although rein-
tervention was often needed to maintain that symptomatic
improvement (879).
Both of these randomized studies of PTCA versus
medical management have involved patients who were at a
low risk of mortality even with medical management. The
use of PTCA to treat patients with chronic stable angina
and characteristics that define a high risk of mortality has
not been tested.
Medical Management Versus PTCA or CABG
The most current study of medical management versus
revascularization is the Asymptomatic Cardiac Ischemia
Pilot (ACIP) study. This study included patients with CAD
who were either free of angina or had symptoms that were
well controlled with medical management but $1 episode
of asymptomatic ischemia documented during 48-h ambu-
latory ECG monitoring. The three arms of the study were
medical management guided by angina, medical manage-
ment conducted by ambulatory ECG monitoring and re-
vascularization (either CABG or PTCA, depending on the
judgment of the investigators). At a two-year follow-up, the
170 patients randomized to revascularization (PTCA in 92
patients, CABG in 78) had a significantly lower death rate
(p , 0.005) than those in either of the medically managed
groups. Furthermore, 29% of the patients randomized to
medical management underwent nonprotocol (crossover)
revascularization during the two-year follow-up. Patients
with a $50% LAD stenosis appeared to derive the most
benefit from revascularization (880). Patients with ischemia
on ambulatory ECG monitoring frequently had multivessel
disease, severe proximal stenoses and complex plaque (881).
Use of PTCA Versus Medical Management Versus
CABG
One randomized three-arm trial (the Medicine, Angio-
plasty or Surgery Study [MASS]) (882) compared PTCA,
medical treatment and CABG (LITA-LAD) for the treat-
ment of isolated, severe, proximal LAD stenosis in patients
with lesions ideal for treatment with PTCA. With 214
patients randomized and monitored for three years, there
was no difference in mortality or MI rate among the three
groups. Both revascularization strategies resulted in more
asymptomatic patients (CABG, 98%; PTCA, 82%) when
compared with medical treatment (32%) (p , 0.01), but no
patient in any treatment group had severe angina at follow-
up. Patients assigned to PTCA and medicine had more
revascularization procedures during the follow-up period
than did the patients assigned to surgery. The primary end
point of the study was the combined incidence of cardiac
death, MI or refractory angina requiring revascularization.
That combined end point occurred more often for patients
assigned to PTCA (17 [24%]) and medical therapy (12
[17%]) than for those assigned to bypass surgery (2 [3%],
p , 0.006).
Use of PTCA Versus Use of CABG
Multiple trials have compared the strategy of initial
PTCA with initial CABG for treatment of multivessel
CAD. In general, the goal of these trials has been to try to
answer the question of whether or not there are subsets of
patients that pay a penalty in terms of survival for initial
treatment with PTCA. The two U.S. trials of PTCA versus
CABG are the multicenter Bypass Angioplasty Revascular-
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ization Investigation (BARI) Trial (883) and the one-center
Emory Angioplasty Surgery Trial (EAST) (884).
Both trials included patients with both stable and unsta-
ble angina who were considered suitable candidates for
either PTCA or CABG. There are no PTCA versus CABG
trials of patients with only chronic stable angina, and the
results of the trials that were conducted did not appear to
vary according to whether the patients had stable or unstable
angina. Therefore, in trying to understand the invasive
treatment of patients with chronic stable angina, these trials
represent the best data available. It is important to note that
because of the requirement that the patients be good
candidates for PTCA, the PTCA versus surgery trials
included a minority of the total spectrum of patients with
multivessel disease that are considered for revascularization.
For example, in the EAST trial, 16% of the patients who
were screened were considered eligible for inclusion, and in
the BARI trial, 60% of the patients considered possible
clinical and angiographic candidates were thought to be
anatomically unsuitable for PTCA when subjected to care-
ful angiographic review (885). In both trials, a majority of
patients had two- rather than three-vessel disease and
normal LV function (ejection fraction .50%); a history of
CHF was rare (,10%). In the BARI trial, 37% of patients had
a proximal LAD lesion. In the EAST trial, .70% of patients
had proximal LAD lesions, but the definition of an LAD
lesion allowed more distal stenoses to be considered. There-
fore, these trials did not include large numbers of patients who
are at high risk for death without revascularization.
The results of both these trials at an '5-year follow-up
interval have shown that early and late survival rates have
been equivalent for the PTCA and CABG groups. In the
BARI trial, the subgroup of patients with treated diabetes
had a significantly better survival rate with CABG. That
survival advantage for CABG was focused in the group of
diabetic patients with multiple severe lesions (886). In the
EAST trial, persons with diabetes had an equivalent survival
rate with CABG or PTCA at three years. Longer-term
follow-up data from the BARI and EAST trials have not
yet been published.
In both trials, the biggest differences in late outcomes
were the need for repeat revascularization procedures and
symptom status. In both BARI and EAST, 54% of PTCA
patients underwent subsequent revascularization procedures
during the five-year follow-up versus 8% of the BARI CABG
group and 13% of the EAST CABG group. In addition, the
rate of freedom from angina was better in the CABG group in
both EAST and BARI, and fewer patients in the CABG
group needed to take antianginal medications.
These and other randomized trials have provided impor-
tant insights into the choice of interventional therapy for
some patient subgroups, but there are also some clear
limitations of these trials in terms of current recommenda-
tions for treatment of a broad spectrum of patients with
multivessel CAD. First, because the patients included in the
trials were a select minority of acceptable-risk patients with
multivessel disease who were good angiographic candidates
for PTCA, the long-term outcome benefit of PTCA in the
treatment of subsets of high-risk patients, particularly those
in whom CABG has been shown to prolong survival most,
has not been definitely established. Second, the results of
these trials should not be applied to patients who are not
good angiographic candidates for PTCA. Third, few pa-
tients in the PTCA-CABG randomized trials received
intracoronary stents, a change in percutaneous technique
that has decreased the rate of emergency bypass surgery and
may decrease the incidence of restenosis but has not yet
been subjected to long-term scrutiny. Fourth, the follow-up
period of the PTCA-CABG studies extends only five years
at this writing, a point at which the adverse effect of vein
graft atherosclerosis has not yet become apparent. Fifth,
although most of the patients in the surgical groups received
LITA-LAD grafts, few patients underwent extensive arte-
rial revascularization. All these changes in technique may
conceivably change the relative benefit ratios of CABG and
PTCA for some patient subgroups. Sixth, none of these
trials used aggressive lipid-lowering therapy.
Finally, it is critical to understand that important patient
subgroups, elderly patients, women and patients with pre-
vious bypass surgery were either not represented or were
underrepresented in the randomized trials discussed. None
of these trials have included patients with previous bypass
surgery. The trials of initial medical versus initial surgical
management excluded patients .65 years old and contained
very few women. In the trials of PTCA versus surgery,
women were included and reasonably well represented, but
few patients .70 years old and none .80 were included.
The committee thought that patients with significant
CAD who have survived sudden cardiac death or sustained
ventricular tachycardia are best treated with CABG rather
than PTCA. This subject is discussed in detail elsewhere
(887). Use of CABG reduces sudden cardiac death com-
pared with medical therapy (888) and appears to be bene-
ficial in uncontrolled series of patients with prior cardiac
arrest (889). There are few available data on this issue for
PTCA. The risk of sudden death or ventricular arrhythmias
recurring is likely to be greater with PTCA than CABG
because of the known risk of restenosis after PTCA.
Recommendations for Revascularization in Patients
With Native-Vessel CAD
Advances have been made in medical therapy that reduce
MI and death and decrease the rate of progression of
coronary stenoses. However, there is still no evidence that
medical treatment alone sufficiently improves the life ex-
pectancy of the high-risk subgroups that were defined by the
trials of medical treatment versus bypass surgery.
The randomized trials of initial medical treatment versus
initial surgery showed that the patients with left main
stenoses $70% and those with multivessel CAD with a
proximal LAD stenosis $70% and abnormal LV function
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have a better late survival rate if they have coronary bypass
surgery. Because the randomized trials of PTCA versus
bypass surgery included an inadequate number of patients in
these high-risk subsets, it cannot be assumed that the
alternative strategy of PTCA produces equivalent late sur-
vival in such patients.
Meta-analysis (489) of the randomized trials of medical
management versus CABG has further indicated that pa-
tients without severe symptoms but with a proximal LAD
lesion have a better survival rate with surgery, even if they
have normal LV function and only one-vessel disease. For
these patients, data from the PTCA versus CABG trials
appear to show that, at least for the first five years, the
alternative revascularization strategy of PTCA does not
compromise survival for patients with normal LV function
who are good angiographic candidates for PTCA.
Severely symptomatic patients with three-vessel disease
have a better survival rate with surgery than medical manage-
ment even in the absence of a proximal LAD lesion and the
presence of good LV function. Severely symptomatic patients
with abnormal LV function should have surgery. For good
angiographic candidates who have normal LV function,
PTCA may be considered an alternative to CABG if the
patient is a favorable angiographic candidate for PTCA.
Caution should be used in the treatment of diabetic
patients with PTCA, particularly in the setting of multives-
sel, multilesion, severe CAD, because the BARI trial
showed that patients with diabetes had a better survival rate
with CABG than PTCA (886).
Most patients with chronic angina have not been shown
to have an increased survival rate with invasive treatment
but may require invasive treatment for control of their
symptoms. For patients with two-vessel disease, PTCA and
surgery are both acceptable, and patients and physicians can
select therapies based on an analysis of the advantages and
disadvantages of the two forms of treatment. For patients
with multivessel disease who are candidates for both surgery
and PTCA, the current advantages and disadvantages of
both procedures have been defined by the randomized trials.
Both procedures had a low initial mortality rate (1% to
1.5%), but PTCA involved less initial morbidity cost and a
lower hospital stay. On the other hand, recurrent angina and
repeat procedures (either CABG or PTCA) were much
more common after PTCA. By five postoperative years, the
total cost of both procedures appeared to be equivalent.
Most patients with symptoms and ischemia based on
one-vessel disease can be effectively treated with PTCA. For
symptomatic patients with lesions unfavorable for PTCA or
who wish to decrease the risk of undergoing subsequent
procedures, CABG is an acceptable alternative and pro-
duces excellent long-term outcomes.
An important observation of the EAST trial was that the
patients in the EAST registry (those deemed appropriate for
randomization but not randomized and whose therapy was
determined by patient-physician choice) appeared to have
slightly better outcomes than either of the randomized
groups (890). In particular, the PTCA registry patients had
better long-term outcome than the randomized PTCA pa-
tients did. These observations appear to suggest that even
within a group of patients with similar baseline clinical and
angiographic characteristics, the judgments of experienced
interventional cardiologists and surgeons as to the best therapy
may produce better outcomes than therapy by protocol or
random choice. Furthermore, those judgments often appear to
be based on the angiographic characteristics that influence the
likelihood of a successful outcome with PTCA.
Patients With Previous Bypass Surgery
The previous sections apply only to patients with native-
vessel CAD. The randomized studies of invasive therapy for
chronic angina have all excluded patients who developed
recurrent angina after previous bypass surgery. Patients with
previous bypass surgery differ in many ways from those who
have never had the surgery. First, their pathology is differ-
ent. For patients with previous surgery, myocardial ischemia
and jeopardy may be produced by progression of native-
vessel CAD but also stenoses in vein grafts produced by
intimal fibroplasia or vein graft atherosclerosis, pathologies
that are distinct from native-vessel CAD. Few existing data
define outcomes for risk-stratified groups of patients who
develop recurrent angina after bypass surgery. Those that do
indicate that patients with ischemia produced by late ath-
erosclerotic stenoses in vein grafts are at higher risk with
medical treatment alone than those with ischemia produced
by native-vessel disease (510). Second, the risks of coronary
reoperation are increased relative to the risks of primary
coronary bypass procedures. Third, the risks of percutaneous
treatment of vein graft stenoses are also increased, and
long-term outcome is not as good as that documented for
treatment of native-vessel lesions. Only one observational
study contains data comparing medical and surgical treat-
ments of risk-stratified groups of patients with previous
bypass surgery. That study shows that patients with late (.5
years after operation) stenoses in saphenous vein grafts had
a better survival rate with reoperation than initial medical
management, particularly if a stenotic vein graft supplied
the LAD (509). Patients with early (,5 years after opera-
tion) stenoses in vein grafts did not appear to have a better
survival rate with reoperation, although their symptom
status improved.
The heterogeneity of patients with previous bypass sur-
gery makes treatment protocols difficult to establish. Pa-
tients with multiple vein grafts with late stenoses or late
stenoses in an LAD vein graft should have reoperation in
the absence of major contraindications to surgery. Despite
improvement in the procedure-related complications of
PTCA for vein graft stenoses by the use of coronary stents,
stenting has not significantly decreased the incidence of
restenosis in vein grafts (511) and is not an equivalent form
of revascularization for patients with late vein graft stenoses.
However, many symptomatic patients whose angina is
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caused by native-vessel stenoses or focal and early (,5 years
after operation) stenoses in saphenous vein grafts can be
successfully treated with percutaneous techniques.
These guidelines are only general principles for patients
with previous bypass surgery, and there are many gray areas.
As indicated in Section III.D, a low threshold for angio-
graphic evaluation is indicated for patients who develop
chronic stable angina .5 years after surgery, especially when
ischemia is documented noninvasively (473–475). Deci-
sions about further therapy should be made with experi-
enced invasive cardiologists and cardiac surgeons.
V. PATIENT FOLLOW-UP: MONITORING OF
SYMPTOMS AND ANTIANGINAL THERAPY
Recommendations for Echocardiography, Treadmill
Exercise Testing, Stress Imaging Studies and Coronary
Angiography During Patient Follow-up
Class I
1. Chest X-ray for patients with evidence of new or
worsening CHF. (Level of Evidence: C)
2. Assessment of LV ejection fraction and segmental
wall motion in patients with new or worsening
CHF or evidence of intervening MI by history or
ECG. (Level of Evidence: C)
3. Echocardiography for evidence of new or worsening
valvular heart disease. (Level of Evidence: C)
4. Treadmill exercise test for patients without prior
revascularization who have a significant change in
clinical status, are able to exercise and do not have
any of the ECG abnormalities listed below in
number 5. (Level of Evidence: C)
5. Stress imaging procedures for patients without
prior revascularization who have a significant
change in clinical status and are unable to exercise
or have one of the following ECG abnormalities:
a. Pre-excitation (Wolff-Parkinson-White)
syndrome. (Level of Evidence: C)
b. Electronically paced ventricular rhythm.
(Level of Evidence: C)
c. More than 1 mm of rest ST depression.
(Level of Evidence: C)
d. Complete left bundle-branch block. (Level
of Evidence: C)
6. Stress imaging procedures for patients who have a
significant change in clinical status and required a
stress imaging procedure on their initial evaluation
because of equivocal or intermediate-risk treadmill
results. (Level of Evidence: C)
7. Stress imaging procedures for patients with prior
revascularization who have a significant change in
clinical status. (Level of Evidence: C)
8. Coronary angiography in patients with marked
limitation of ordinary activity (CCS class III) de-
spite maximal medical therapy. (Level of Evidence:
C)
Class IIb
Annual treadmill exercise testing in patients who have
no change in clinical status, can exercise, have none of
the ECG abnormalities listed in number 5 and have an
estimated annual mortality rate >1%. (Level of Evi-
dence: C)
Class III
1. Echocardiography or radionuclide imaging for as-
sessment of LV ejection fraction and segmental wall
motion in patients with a normal ECG, no history
of MI and no evidence of CHF. (Level of Evidence:
C)
2. Repeat treadmill exercise testing in <3 years in
patients who have no change in clinical status and
an estimated annual mortality rate <1% on their
initial evaluation, as demonstrated by one of the
following:
a. Low-risk Duke treadmill score (without
imaging). (Level of Evidence: C)
b. Low-risk Duke treadmill score with neg-
ative imaging. (Level of Evidence: C)
c. Normal LV function and a normal coro-
nary angiogram. (Level of Evidence: C)
d. Normal LV function and insignificant
CAD. (Level of Evidence: C)
3. Stress imaging procedures for patients who have no
change in clinical status and a normal rest ECG,
are not taking digoxin, are able to exercise and did
not require a stress imaging procedure on their
initial evaluation because of equivocal or
intermediate-risk treadmill results. (Level of Evi-
dence: C)
4. Repeat coronary angiography in patients with no
change in clinical status, no change on repeat
exercise testing or stress imaging and insignificant
CAD on initial evaluation. (Level of Evidence: C)
Patients Not Addressed by This Section of the Guidelines and
Level of Evidence for Recommendations for Follow-up
Patients Not Addressed in This Section of the
Guidelines
Follow-up of patients in the following categories is not
addressed by this section of the guidelines:
● Patients who have had an MI without subsequent symp-
toms. These patients should be evaluated according to the
acute MI guidelines (1).
● Patients who have had an acute MI and develop chest
pain within 30 days of the acute MI should be evaluated
according to the acute MI guidelines (1).
● Patients who have had an MI who develop stable angina
.30 days after infarction. These patients should have the
initial assessment and therapy recommended for all pa-
tients.
● Patients who have had revascularization with angioplasty
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or CABG without subsequent symptoms. These patients
should be monitored according to guidelines provided
elsewhere (18,19).
● Patients who have had angioplasty or CABG and develop
angina within six months of revascularization should be
monitored according to the PTCA and CABG guidelines
(18,19).
Level of Evidence for Recommendations on Follow-up of
Patients With Chronic Stable Angina
Although evidence of the influence of antiplatelet therapy,
anti-ischemic therapy, revascularization, and risk factor
reduction on health status outcome in patients with chronic
stable angina exists, published evidence of the efficacy of
specific strategies for the follow-up of patients with chronic
stable angina on patient outcome does not. The recommen-
dations in this section of the guidelines are therefore based
on the consensus of the committee rather than published
evidence.
Questions to Be Addressed in Follow-up of Patients With
Chronic Stable Angina
There are five questions that must be answered regularly
during the follow-up of the patient who is receiving treat-
ment for chronic stable angina:
1. Has the patient decreased his or her level of physical
activity since the last visit?
2. Have the patient’s anginal symptoms increased in fre-
quency and become more severe since the last visit? If the
symptoms have worsened or the patient has decreased his
or her physical activity to avoid precipitating angina,
then he or she should be evaluated and treated appro-
priately according to either the unstable angina (2) or
chronic stable angina guideline.
3. How well is the patient tolerating therapy?
4. How successful has the patient been in modifying risk
factors and improving knowledge about ischemic heart
disease?
5. Has the patient developed any new comorbid illnesses or
has the severity or treatment of known comorbid illnesses
worsened the patient’s angina?
Follow-up: Frequency and Methods
The committee believes that the patient with successfully
treated chronic stable angina should have a follow-up
evaluation every 4 to 12 months. A more precise interval
cannot be recommended because many factors influence the
length of the follow-up period. During the first year of
therapy, evaluations every four to six months are recom-
mended. After the first year of therapy, annual evaluations
are recommended if the patient is stable and reliable enough
to call or make an appointment when anginal symptoms
become worse or other symptoms occur. Patients who are
comanaged by their primary-care physician and cardiolo-
gists may alternate these visits, provided that communica-
tion among physicians is excellent and all appropriate issues
are addressed at each visit. Annual office visits can be
supplemented by telephone or other types of contact be-
tween the patient and the physicians caring for him or her.
Patients who cannot reliably identify and report changes in
their status or who need more support with their treatment
or risk factor reduction should be seen more frequently.
Focused Follow-up Visit: History
General Status and New Concerns
The open-ended question “How are you doing?” is
recommended because it reveals many important issues. A
general assessment of the patient’s functional status and
health-related quality of life may reveal additional issues
that affect angina. For example, loss of weight may indicate
depression or hyperthyroidism. Angina may be exacerbated
by a personal financial crisis that prevents the patient from
refilling prescriptions for medications. Open-ended ques-
tions should be followed by specific questions about the
frequency, severity and quality of angina. Symptoms that
have worsened should prompt reevaluation as outlined in
these guidelines. A detailed history of the patient’s level of
activity is critical, because anginal symptoms may remain
stable only because stressful activities have been eliminated.
If the patient’s account is not reliable, the assessment of a
spouse, other family members, or friends needs to be
included.
Anginal Symptoms and Antianginal and Antiplatelet
Therapy
A careful history of the characteristics of the patient’s
angina, including exacerbating and alleviating conditions
(outlined in Section II.A), must be repeated at each visit.
Detailed questions should be asked about common drug
side effects. An assessment should be made of the patient’s
adherence to the treatment program. Special emphasis
should be given to aspirin because of its effectiveness, low
cost, and minimal side effects. Providing a written prescrip-
tion may help patients follow the recommendation for
aspirin therapy.
Modifiable Risk Factors
Each patient should be asked specific questions about his
or her modifiable risk factors (Section IV.C).
Review of Existing Comorbid Illnesses That May Influence
Chronic Stable Angina
Specific questions should be asked about exacerbating
illnesses and conditions (Section II.B). The elderly deserve
extra attention, especially with regard to a drug’s side effects
and the impact of polypharmacy.
Focused Follow-up Visit: Physical Examination
The physical examination should be determined by the
patient’s history. Every patient should have weight, blood
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pressure and pulse noted. Jugular venous pressure and wave
form, carotid pulse magnitude and upstroke and the pres-
ence or absence of carotid bruits should be noted. Pulmo-
nary examination, with special attention to rales, rhonchi,
wheezing and decreased breath sounds is required. The
cardiac examination should note the presence of gallops, a new
or changed murmur, the location of the apical impulse, and any
change from previous examinations. The vascular exam should
identify any change in peripheral pulses and new bruits. The
abdominal exam should identify hepatomegaly, hepatojugular
reflux and the presence of any pulsatile masses suggestive of
abdominal aortic aneurysm. The presence of new or worsening
peripheral edema should be noted.
Laboratory Examination on Follow-up Visits
Glucose
The committee supports the current American Diabetes
Association recommendation to screen patients not known
to have diabetes with a fasting blood glucose measurement
every three years and annual measurement of glycosylated
hemoglobin for persons with established diabetes (740).
Cholesterol
The committee supports the National Cholesterol Edu-
cation Program Adult Treatment Panel II guidelines, which
recommend follow-up fasting blood work six to eight weeks
after initiating lipid-lowering drug therapy, including liver
function testing and assessment of the cholesterol profile,
and then every 8 to 12 weeks during the first year of therapy.
Subsequent cholesterol measurements at four- to six-month
intervals are recommended. Long-term studies (up to seven
years) demonstrate sustained benefit from continued therapy.
Laboratory Assessment for Noncardiac Comorbid
Conditions
Routine measurement of hemoglobin, thyroid function,
serum electrolytes, renal function or oxygen saturation is not
recommended. These tests should be obtained when re-
quired by the patient’s history, physical examination or
clinical course.
ECG and Follow-up Stress Testing
The ECG can be repeated when medications affecting
cardiac conduction are initiated or changed. A repeat ECG
is indicated for a change in the anginal pattern, symptoms or
findings suggestive of a dysrhythmia or conduction abnor-
mality and near or frank syncope. There is no clear evidence
showing that routine, periodic ECGs are useful in the
absence of a change in history or physical examination.
Despite widespread use of follow-up stress testing in
patients with stable angina, there are very few published
data establishing its utility. The natural history of various
patient cohorts with stable angina is well documented, and
using the rationale described above, the committee formu-
lated the following guidelines by expert consensus. On the
basis of the clinical, noninvasive and invasive data acquired
during the initial evaluation, the clinician should be able to
formulate an estimate of the patient’s cardiovascular risk
over the next three years. In the absence of a change in
clinical status, low-risk patients with an estimated annual
mortality rate of ,1% over each year of the interval do not
require repeat stress testing for three years after the initial
evaluation. Examples of such patients are those with low-
risk Duke treadmill scores either without imaging or with
negative imaging (four-year cardiovascular survival rate,
99%), those with normal LV function and normal coronary
angiograms, and those with normal LV function and insig-
nificant CAD. The first group includes patients with chest
pain .6 months after coronary angioplasty who have
undergone complete revascularization and do not have
significant restenosis as demonstrated by angiography. An-
nual follow-up testing in the absence of a change in
symptoms has not been adequately studied; it might be
useful in high-risk patients with an estimated annual mor-
tality rate .3%. Examples of such patients include those
with an ejection fraction ,50% and significant CAD in $1
major vessel and those with treated diabetes and multivessel
CAD who have not undergone CABG. Follow-up testing
should be performed in a stable high-risk patient only if the
initial decision not to proceed with revascularization may
change if the patient’s estimated risk worsens. Patients with
an intermediate-risk ($1% and #3%) annual mortality rate
are more problematic on the basis of the limited data
available. They may merit testing at an interval of one to
three years, depending on their individual circumstances.
The choice of stress test to be used in patient follow-up
testing should be dictated by considerations similar to those
outlined earlier for the initial evaluation of the patient. In
patients with interpretable exercise ECGs who are capable
of exercise, treadmill exercise testing remains the first
choice. Whenever possible, follow-up testing should be
done using the same stress and imaging techniques to
permit the most valid comparison with the original study.
When different modes of stress and imaging are used, it is
much more difficult to judge whether an apparent change in
results is due to differences in the modality or a change in
the patient’s underlying status. In a patient who was able to
exercise on the initial evaluation, the inability to exercise for
follow-up testing is in and of itself a worrisome feature that
suggests a definite change in functional and clinical status.
In interpreting the results of follow-up testing, the physician
must recognize that there is inherent variability in the tests
that does not necessarily reflect a change in the patient’s
prognosis. For example, in one placebo-controlled trial that
used serial exercise thallium testing, the treadmill time on
repeat testing in the placebo group had a standard deviation
of 1.3 min and the measured thallium perfusion defect of
the left ventricle a standard deviation of about 5% (891).
Both estimates suggest that even one standard deviation
(67% confidence limits) on repeat testing includes a consid-
erable range of results.
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Hypoxemia, angina from, 2105
I
IMAGE (International Multicenter Angina Exercise
Study), 2140, 2142
Increasing angina, 2099, 2102t
Information, patient’s desire for, 2147
Intermediate probability, for exercise testing, 2109
Intermediate risk patients, features of, 2103t
Internal thoracic artery grafts. See Mammary artery
grafts
International Multicenter Angina Exercise Study. See
IMAGE
Intrinsic sympathomimetic activity, of beta blockers,
2137, 2138
Invasive testing. See Angiography
Ischemic chest pain, in exercise testing, 2108
“Ischemic equivalents,” 2094
Ischemic heart disease, 2093. See also Myocardial isch-
emia
chronic stable angina in, 2095
complications, 2148
exercise-induced, 2126
pathology and pathophysiology, 2148
risk factors for, 2102, 2148
transmural, 2110
Isosorbide dinitrate, properties, 2143t
Isosorbide mononitrate, properties, 2143t
Isradipine, 2141t
J
“Jeopardy score,” 2134
Journal of the American College of Cardiology, 2093
K
Kawasaki disease, angiography for, 2119
Ketanserin, 2143
L
Labetalol, 2138t, 2143
Laboratory examination
in follow-up visit, 2168–2169
initial, for diagnosis, 2104–2105
Lead selection, in exercise testing, ST-segment
interpretation and, 2109
Life style modification, for hypertension, 2152
Lipid
effect of exercise training on, 2156
management, 2150t
Lipid panel, fasting, 2104
Lipid-lowering therapy, 2136. See also specific agent
to prevent MI and death, 2137
Lipoprotein
high-density, 2156
decline in, coronary artery disease and, 2154
low-density, 2154, 2156
lowering of, 2151–2152
Lipoprotein(a) (Lp[a]), 2159
LITA-LAD grafts, 2162
Logistic regression equation, 2103
Low-risk patients
evaluation of, 2100
features of, 2103t
M
Magnetic resonance imaging, 2134
Mammary artery (internal thoracic artery) grafts, 2162
occlusion, 2162
Mediastinum, enlargement of, 2106
Medical management, versus PTCA and CABG,
2163–2164
Medical system, contacting of, instructions to patients,
2148
Medicare
DRGs, 2096
fees and volumes of diagnostic procedures for
chronic stable angina, 2096, 2097t
Medication
compliance with, improvement of, 2147
concomitant use with stress cardiac imaging, 2116–
2117
myocardial perfusion imaging and, 2129
Men
amlodipine effects on, 2142
angiography in, 2120f
MI risk in, 2153
Metabolic agents, 2143
Metabolic control, in diabetes, 2154
Metoprolol, 2138t
combined with nifedipine, 2139, 2142
combined with verapamil, 2139
patient outcomes, 2139
METs
in elderly, 2110
of exercise, 2107
Mibefradil, mechanism of action, 2141
Misdiagnosis, cost of, 2102
Mitral regurgitation, ischemic, echocardiography in,
2110
Mitral valve prolapse, 2110
Models, applicability to primary care physicians, 2104
Moderate-risk patients, evaluation of, 2100
Molsidomine, 2143
Morbidity rates, in chronic chest pain syndromes,
2095
Mortality rates
diabetes-related, 2154
due to cardiovascular diseases and cancer, 2096t
effect of exercise training on, 2157
exercise testing-related, 2107
ischemic heart disease-related, 2095
plaque rupture-related, 2100
PTCA-related, 2164
Murmur, systolic, 2110
Myocardial infarction (MI), 2094, 2095
exercise testing-related, 2107
exercise training after, 2156
follow-up visits for, 2167
history of, left ventricular wall motion abnormalities
in, echocardiography for, 2110
infarct size, echocardiographically derived, 2124
nifedipine in, 2142
nonfatal
prognosis of coronary artery disease for, 2121
short term risk of, in unstable angina patients,
2099, 2103t
prevention, recommendations for pharmacologic
therapy for, 2135–2143. See also
Pharmacologic therapy
prior, risk related to, 2122
rates for, effect of exercise training on, 2157
risk of, smoking cessation and, 2150, 2151
risk stratification for, by exercise testing, 2124–
2126
Myocardial ischemia
angiography for, 2119
causes of, 2104, 2105t
ECG manifestations of, 2107
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stress echocardiography of, 2116
Myocardial perfusion imaging
in bundle branch block, 2117
compared with echocardiography, 2117–2118
diagnostic accuracy of, 2114, 2114t, 2115t
exercise, 2112
for risk stratification of patients with chronic
stable angina who are able to exercise, 2127
stress imaging for risk stratification for patients
with chronic stable angina who are unable to
exercise, 2127–2128
prognostic value of, 2129, 2130t
recent developments in, 2118
for risk stratification, 2128
application to specific patient subsets, 2129–
2130
for nonfatal myocardial infarction, 2133
Myocardial viability, stress imaging for, 2113
Myocardial wall motion. See also Ventricular wall
motion
risk stratification with, 2128
N
Nadolol, 2138t
National Ambulatory Medical Care Survey, 2146
National Cholesterol Education Program, 2154, 2160
Adult Treatment Panel II, 2159, 2169
National Heart, Lung and Blood Institute (NHLBI),
2094, 2095t
National High Blood Pressure Education Program
Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High
Blood Pressure, 2152
Negative predictive value, of exercise test, 2108
Negative test results, 2102
of exercise test, 2108
New onset angina, 2102t
Nicardipine, 2140t
Nifedipine
combined with atenolol, 2139
combined with metoprolol, 2139, 2142
mechanism of action, 2140, 2141t, 2140–2141
patient outcomes, 2139, 2142
Nisoldipine, patient outcome, 2142
Nitrate tolerance, 2143
Nitroglycerin and nitrates, 2136, 2145
clinical effectiveness, 2143
combined with beta-blockers, 2138
contraindications, 2144
mechanism of action, 2142
properties of, 2144
side effects, 2143t
Nocturnal angina, 2146
Nonanginal chest pain, 2094
Noncardiac chest pain, 2099
Non-cardiac conditions, angina in, 2098
Noninvasive testing. See also specific procedure
accuracy of, factors affecting, 2113–2114, 2114t,
2115t
ECG, chest x-ray, 2105–2106
echocardiography (rest), 2111–2112
exercise ECG, 2106–2111
risk stratification by, 2123–2124
stress imaging studies, echocardiographic and
nuclear, 2112–2118
O
Obesity
coronary artery disease and, treatment of, 2154
stress echocardiography in, 2131
stress imaging in, 2117
Occupation
angiography and, 2119
stress imaging and, 2117
Oxidative stress, 2159
Oxygen demand
decreased, causes of, 2104
myocardial
effect of calcium antagonists on, 2140
effect of nitroglycerin and nitrates on, 2142
Oxygen supply, myocardial, conditions reducing, 2105
P
P waves, 2110
Pain, anginal, quality of, 2099
Pain type, likelihood of coronary artery disease and,
2102, 2103
Patient education, 2146–2147
information for patients, 2148–2149
principles of, 2147–2148
Patient management, use of exercise testing results in,
2126–2127
Pediatric patients, 2094
Pentaerythritol tetranitrate, properties, 2144t
Perfusion imaging. See Myocardial perfusion imaging
Pericardial disease, 2101
Peripheral vascular disease, 2144
risk stratification by, 2122
Pharmacologic modalities, used in stress imaging,
2113
Pharmacologic stress testing, for risk stratification,
2128
Pharmacologic therapy
choice of, in chronic stable angina, 2143–2144
recommendations to prevent MI and death and
reduce symptoms, 2135–2136
antianginal and anti-ischemic therapy, 2137–
2143
antiplatelet agents, 2136–2137
antithrombotic therapy, 2137
lipid-lowering agents, 2137
special clinical situations, 2144–2145
Physical activity. See Exercise
Physical examination
in follow-up visit, 2168
in patients with stable angina, 2101–2102
risk stratification by, 2121
Physical inactivity, 2154–2155. See also Exercise
training
Physicians’ Health Study, 2136, 2153
Pindolol, 2138t
Plaque
effect of lipid lowering therapy on, 2137
rupture, 2100, 2121, 2122
“significant,” 2121
Platelet hyperaggregability, 2153
Pleural disease, 2101
Positive test results, 2102
Positron emission tomography, 2117
Potassium channel activators, 2143
Practice guidelines, function of, 2093
Predictive models, 2103
generalizability of, 2103–2104
Predictive values, of exercise test, 2108
Pre-excitation (Wolff-Parkinson-White syndrome),
2107
Pretest probability
exercise test, 2109
of exercise test, 2108
Primary care practitioners, applicability of models to,
2104
Prinzmetal angina. See Vasospastic angina
Probability estimate, developing of, 2102–2103
Probucol, 2159
Prognosis
advising patient of, 2148
uncertainty about, 2145
Propranolol, 2138t
Psychiatric conditions, chest pain from, 2105t
Psychological factors, link to coronary artery disease,
2158
Psychosocial risk factors, 2158–2160
PTCA. See Angioplasty, percutaneous transluminal
coronary
Pulmonary disease, chest pain from, 2105t
Pulmonary venous congestion, 2123
Q
Q wave, 2106, 2122
left ventricular wall motion abnormalities and,
echocardiography for, 2110
QRS score, 2122
QS pattern, 2106
Quality of life, chronic chest pain syndromes and,
2095, 2096
Quality-adjusted life years (QALY), myocardial
perfusion imaging compared with
echocardiography, 2118
Quantitative techniques, in stress imaging, 2115
Questions, in follow-up visit, 2168
R
R wave, 2122
in exercise test, 2110
Radiation-induced coronary vasculopathy, angiography
for, 2119
Radionuclide imaging, diagnostic accuracy of, 2114
Randomized Intervention Treatment of Angina. See
RITA-2
Ranolazine, 2143
Reimbursement, for patient education, 2147
Relaxation training, 2158
Reliability, of exercise test, 2109
Repolarization abnormality, causes, 2109
Reports, compiling and reviewing of, 2093
Resources, professionally prepared, for patient
education, 2147
Rest angina, 2099, 2102t, 2146
Restenosis, PTCA versus CABG, 2165
Resuscitation, from ventricular fibrillation and
sustained ventricular tachycardia, coronary
angiography in patients following, 2121
Revascularization, 2112. See also Surgery, coronary
artery bypass, Angioplasty, percutaneous
transluminal coronary
chest pain after, exercise testing for patients with,
2127
planning of
stress echocardiography for, 2131, 2132
use of myocardial perfusion imaging for, 2129
quality of life after, 2095
recommendations for, 2161–2162
repeat, PTCA versus CABG, 2165
stress echocardiography after, 2133
use of myocardial perfusion imaging after, 2130
Risk factors
categorization of, 2149
risk factors associated with increased risk but
which cannot be modified or the modification
would not be likely to change incidence of
coronary disease events, 2160
risk factors for which interventions are likely to
reduced incidence of coronary disease events,
2153–2158
risk factors for which interventions have been
shown to reduce incidence of coronary disease
events, 2149–2153
risk factors for which interventions might reduce
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incidence of coronary disease events 2158–
2160
for coronary artery disease, determination of, 2101
reduction, advising patient of, 2148
treatment of, recommendations for, 2149
Risk stratification
clinical assessment
prognosis of CAD for death or nonfatal MI,
2121
risk stratification with clinical parameters, 2121–
2122
ECG, chest x-ray, 2122–2123
exercise testing for, 2124–2127
noninvasive testing, 2123–2124, 2134t
stress imaging studies (radionuclide and
echocardiography), 2127–2135
RITA-2 (Randomized Intervention Treatment of
Angina), 2164
Rub, 2101
S
SAPAT (Swedish Angina Pectoris Aspirin Trial),
2137
Saphenous vein graft, 2162
lesions, 2135
occlusion, 2162
Scandinavian Simvastatin Survival Study, 2137
Scintigraphy
exercise, 2114t
planar, indications for, 2117
Sensitivity
of exercise test, 2108–2109
myocardial perfusion imaging compared with
echocardiography, 2117–2118
of stress imaging, 2114, 2114t, 2115t
Serotonin antagonists, 2143
Sestamibi. See Technetium-99m sestamibi
Severe new-onset angina, 2099
Sildenafil, interaction with nitroglycerin and nitrates,
2143
“Silent ischemia,” 2094
Simvastatin, 2152
Single-photon emission computed tomography. See
Computed tomography
Sinus tachycardia, 2106
Smoking, 2146
cessation, 2149, 2152t, 2151–2152
Spasm, coronary artery
angiography for, 2119
angiography in, 2120
provocative testing in, 2120
Specificity
of exercise test, 2108–2109
myocardial perfusion imaging compared with
echocardiography, 2117–2118
of stress imaging, 2114, 2114t, 2115t
SPECT. See Computed tomography, single-photon
emission
ST segment
depression
exercise test and, 2109–2110
stress imaging and, 2113, 2126
effect of nitrates on, 2143
exercise-induced ischemia and, 2126
exercise test and, 2109–2110
ischemia and, 2106
ST-T wave
abnormalities, after revascularization, use of
myocardial perfusion imaging after, 2130
angina pectoris and, 2106
ischemia and, 2106
risk stratification by, 2122–2123
Stable angina, 2119. See also Chronic stable angina
risk stratification in, 2122
Stenosis. See also Aortic stenosis
angiographic, ultrafast computed tomography in,
2106
coronary artery, 2128
survival rate, 2134
coronary artery disease definition and, 2098
Stents, 2165
Stress, oxidative, 2159
Stress, psychological
link to coronary artery disease, 2158
reduction, 2158
Stress imaging (radionuclide and echocardiography),
2112–2113
comparison of myocardial perfusion imaging and
echocardiography, 2117–2118
diagnostic accuracy of, 2114–2116
exercise and pharmacological modalities used in,
2113
exercise stress scintigraphy, 2114t
Factors affecting accuracy of noninvasive testing,
2113–2114
follow-up, 2169
for patient follow-up, 2166–2167
for risk stratification
compared with exercise ECG, 2125
for patients with chronic stable angina who are
able to exercise, 2127
for patients with chronic stable angina who are
unable to exercise, 2127–2135, 2128
special issues related to, 2116–2117
timing for, 2113
Stunning, 2124
Sulfhydryl (SH) radicals, 2143
Surgery, coronary artery bypass (CABG), 2136, 2161,
2162
cigarette smoking after, 2151
exercise testing after, 2127
medical management versus, 2164
mortality rates related to, 2133
for native vessel CAD, 2165–2166
previous, patients with, angiography in, 2135
PTCA versus, 2161, 2162, 2164–2165
PTCA versus medical management versus, 2164
Swedish Angina Pectoris Aspirin Trial. See SAPAT
Sympathomimetic toxicity, decreased oxygen demand
from, 2104, 2105
Symptom
anginal, history of, in follow-up visit, 2168
effect of exercise training on, 2155–2158
reduction of, recommendations for pharmacologic
therapy for, 2135–2143. See also
Pharmacologic therapy
Symptom complex, description of, in history taking,
2099
Symptom history, 2097
Symptomatic patients, 2094
Syndrome X, 2110
Systolic function, left ventricular, 2123
echocardiography in, 2110
T
T-channel blocker, 2141
T waves, 2110
Tachycardia, oxygen demand in, 2105
Technetium-99m (99mTC), for risk stratification,
2128
Technetium-99m (99mTC) sestamibi, 2114, 2130
diagnostic accuracy of, 2116
SPECT imaging, breast artifacts in, 2117
Technetium-99m (99mTC) tetrofosmin, 2114
Technetium-99m (99mTC) tracer, 2123
Tests, choice of, 2093
Tetrofosmin. See Technetium-99m tetrofosmin
Thallium-201 (201Tl), 2114, 2129
limitations of, 2117
lung uptake of, 2128
negative, 2130
perfusion defects, 2124
planar scintigraphy
diagnostic accuracy of, 2115
for risk stratification, 2128, 2129
SPECT, diagnostic accuracy of, 2115, 2116
Thrombogenic risk factors, 2153
Thrombosis
coronary artery, 2153
left ventricular, 2124
TIBBS, 2140
TIBET (Total Ischemic Burden European Trial),
2139, 2139t, 2142
Ticlodipine, antiplatelet activity, 2136–2137
Timolol, 2138t
Tissue harmonic imaging, 2110
Tomography. See Computed tomography; Positron
emission tomography
Total Ischemic Burden European Trial. See TIBET
Trapidil, 2143
Treadmill exercise testing
cost and availability of, 2108
ECG, false-positive rate, gender differences, 2120
follow-up, 2169
limitations of, 2117
for patient follow-up, 2166–2167
for risk stratification, compared with stress
echocardiography, 2130
stress echocardiography and, 2133
uses of, 2107
in patient management, 2126
Treatment
advising patient of, 2148
choice of, 2093
definition of successful treatment of chronic stable
angina, 2145–2146
diet, 2160
education of patients with chronic stable angina,
2146–2149. See also Patient education
fish consumption, 2160
garlic therapy, 2160
initial, 2146
pharmacologic therapy, 2135–2145. See also
Pharmacologic therapy
revascularization for chronic stable angina, 2161–
2162. See also Angioplasty; Revascularization;
Surgery, coronary artery bypass
for risk factors, 2149–2160. See also Risk factors
Treatment plan, development, with patient, 2147
Triglycerides, 2154, 2156
high, management of, 2159
Trimetazidine, 2143
Typical angina, 2102t
U
Ultrasound. See Echocardiography
Understanding, patient’s, assessing of, 2147
Unstable angina, 2094
nifedipine in, 2142
principal presentations of, 2099, 2102t
short-term risk of death and nonfatal myocardial
infarction in, 2099, 2103t
V
Valvular heart disease, exercise test specificity in, 2109
Vasodilation, in bundle branch block, 2117
Vasodilators
influence on exercise test performance, 2109
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stress imaging with, 2113
Vasospasm. See Spasm
Vasospastic angina (Prinzmetal angina)
calcium antagonists in, 2141–2142
use of beta-blockers for, 2138
Vein graft disease, angiography in, 2135
Ventricular dysfunction, left
chronic stable angina and, 2133
effect on survival, 2134
identification on angiography, 2134
induced by exercise, 2126
Ventricular fibrillation, resuscitation from, coronary
angiography after, 2121
Ventricular function
left, measurement, in chronic stable angina, 2123–
2124
Ventricular mass, left, echocardiography of, 2123
Ventricular rhythm, electronically paced, 2107
Ventricular tachycardia, resuscitation from, coronary
angiography after, 2121
Ventricular wall motion. See also Myocardial wall
motion
left, abnormalities
assessment of, 2124
echocardiography in, 2110
Ventriculography, left, 2134
for risk stratification, 2132–2135
Verapamil, 2153
combined with atenolol, 2139
combined with beta-blockers, 2138
mechanism of action, 2140, 2141t, 2141
patient outcomes, 2142
Veterans Affairs Angioplasty Compared to Medicine
trial. See ACME trial
Veterans Affairs Cooperative studies (VA Study),
2152, 2162
Viability. See Myocardial viability
Visual analysis, in stress imaging, 2115
Vitamins
antioxidant, 2159
E, 2159
W
Warfarin, 2136, 2137
Web sites, for patient education, 2147
Weight loss, 2154
Well-being, psychological
effect of exercise training on, 2155–2158
treatment directed at, 2158
Women
angiography in, 2119–2120
exercise testing in, 2110
myocardial perfusion imaging in, 2129
postmenopausal, coronary artery disease in, estrogen
replacement effects on, 2157–2158
stress imaging in, 2117, 2131
Workup verification, 2108. See also Bias
Writing groups, 2093
Writing panel, conflict of interest, 2093
X
X-ray. See Chest x-ray
Z
Zatebradin, 2143
Zutphen Study, 2160
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